Program Hivr4p2018

HIVR4P 2018,
HIV Research for Prevention 2018,

Madrid, Spain,
21 - 25 October 2018
Download Program (PDF)
Sunday, 21 October 2018
Satellites
08:30 - 13:00 Dresden & Stuttgart
SA01 Advocates' Pre-Conference Workshop

Hosted by: IRMA, AVAC and others This full day pre-conference workshop will provide an overview of the field and
amplify certain topics to contextualize the themes and issues that will be presented at HIVR4P; will connect research
and advocacy priorities and explore common goals; and build the capacity of advocates and trial staff to better
engage with emerging issues in the field. This workshop is especially designed for advocates, scholarship recipients,
new investigators, first time attendees, community liaison officers at trials and other interested stakeholders to what
HIVR4P.
Chairs:
Jim Pickett (AIDS Foundation of Chicago, United States)
Satellites
08:45 - 12:00 Estrasburgo
SA02 New Pieces to the HIV-1 Vaccine Puzzle: Germline Targeting Strategies and
Immunization Protocols to Elicit Anti-HIV-1 bNAbs
Hosted by: The Rockefeller University It is becoming evident that the design of a vaccine that elicits broadly
protective antibodies against HIV-1 will require a meticulous engineering process to generate suitable germline
targeting strategies that activate bNAb precursors and subsequently support antibody maturation in germinal
centers. Encouraging results were obtained in a bNAb knock-in mouse model in which PGT121-like antibodies were
elicited by step-wise immunization. Despite multiple efforts, these results have not been fully reproduced in wild type
(wt) animal models with a polyclonal B cell repertoire. One of the hurdles to overcome in wt animals is the activation
of bNAb precursors that are present in low frequencies. Recent studies have shown that high-affinity immunogens are
necessary to efficiently activate and expand low-frequency bNAb precursors. An additional barrier for vaccine design
in a wt system is the polyclonal nature of the antibody response. It is believed that immunogen refinement is
necessary in order to focus the antibody response towards neutralizing epitopes and avoid distracting responses to
non-neutralizing epitopes that could frustrate bNAb maturation by competition in the germinal centers. In this
session, we will present progress achieved in the design of strategies to specifically activate and increase the
frequency of bNAb precursors, as well as the results of immunization experiments aiming to elicit anti-HIV-1 bNAbs in
wt animal models. 8:45 am Eliciting broadly neutralizing responses to the exposed N- terminal residues of the
fusion peptide - Peter Kwong 9:00 am Discussion 9:05 am Induction of glycan-reactive bnAb B cell lineages – Kevin
Saunders 9:20 am Discussion 9:25 am Sequential immunization strategies to elicit bnAbs in animal models with a
polyclonal B cell repertoire – Amelia Escolano 9:40 am Discussion 9:45 am Design of germline targeting immunogens
to elicit antibodies targeting the CD4-binding site and V3-N332 epitopes on Env – Harry Gristick 10:00 am Discussion
10:05 am Dissecting neutralizing antibodies to guide rational HIV vaccine design – Marit van Gils 10:20 am
Discussion 10:25 am Nanoparticle-display of native-like envelope trimers - Kwinten Sliepen 10:40 am Discussion
10:45 am Anti-idiotypic antibodies as a strategy to prime bnAb precursors - Andrew McGuire 11:00 am Discussion
11:05 pm Structural basis for germline VRC01 antibody recognition of a glycosylated HIV-1 envelope CD4-binding
site – Marie Pancera 11:20 am Discussion 11:25 am HIV-1 MPER Germline Targeting – Torben Schiffner 11:40 am
Discussion 11:45 am Sequential Immunization with Different Repaired and Stabilized HIV-1 Envelope Trimers
Induces broad Tier2 neutralization in Rabbits - Johannes P.M. Langedijk 11:55 pm Discussion
Chairs:
Amelia Escolano (The Rockefeller University, United States)
Marit van Gils (Amsterdam AMC, University of Amsterdam, Netherlands)
Page 1 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Satellites
SA03 Progress in Inducing HIV Broad Neutralizing Antibodies

Hosted by: The Scripps Research Institute and Duke University This session will explore the progress made in
inducing HIV broad neutralizing antibodies. 12:30 pm Overview of the bnAb Problem- Barton Haynes 12:40 pm V2
apex as a target - Raiees Andrabi 12:55 pm Discussion 1:00 pm Polyclonal Ab response mapping by EM - Andrew
Ward 1:15 pm Discussion 1:20 pm Mouse models of bnAb germ line targeting immunogens - Facundo Batista
1:35 pm Discussion 1:40 pm Host control of bnAbs - Todd Bradley 1:55 pm Discussion 2:00 pm
Overcoming roadblocks of improbable mutations in bnAb B cell lineages - Kevin Wiehe 2:15 pm Discussion 2:20
pm The impact of antibody isotype on neutralization - Penny Moore 2:35 pm Discussion 2:40pm
Structural Diversity of antibody recognition at the V3-glycan epitope - Priyamvada Acharya 2:55 pm Discussion
3:00 pm SHIV infected Rhesus macaques as a model for bnAb development - George Shaw 3:15 pm Discussion
3:20 pm BnAbs - The way forward- Dennis Burton
Chairs:
Dennis Burton (The Scripps Research Institute, United States)
Barton Haynes (Duke University, United States)
Satellites
12:30 - 14:30 Marsella
SA06 Social Sciences in Vaccine Trials: A Booster to Recruit Volunteers

Hosted by: ANRS and Vaccine Research Institute The recruitment of healthy, HIV-seronegative patients to HIV
preventive vaccine trials has fluctuated since the early days of their implementation. There are numerous reasons for
this, including the normalization of the epidemic, the displacement of HIV community action towards other causes,
the transformation of disease management, and the lack of direct benefits. Vaccination is being increasingly rejected.
At a time when scientific advances offer hope for the development of preventive HIV vaccine strategies, the
recruitment of volunteers to future clinical trials may well become a stumbling block. This symposium aims to
highlight the contribution that social science research has made to this complex process by both addressing the
particular nature of HIV infection and placing the topic in a more global context of recruitment to preventive vaccine
trials. 15 minutes Welcome
François Dabis, Director of the ANRS, France Yves Lévy, Director of VRI and CEO of Inserm, France
5 minutes Recruitment of healthy volunteers for HIV vaccine trials: a stumbling block?
Jean-Daniel Lelièvre, Vaccine Research Institute, France
15 minutes Volunteers/Participants Recruitment/Enrolment in Africa
Morenike Folayan, Obafemi Awolowo University, Nigeria
15 minutes Exceptional Risk: US Healthy Volunteers’ Perceptions of HIV/AIDS Clinical Trials.
Marci Cottingham, University of Amsterdam, The Netherlands
15 minutes Participant Recruitment in an Outbreak Context: The Ebola vaccine trials in Sierra Leone
Luisa Enria, University of Bath, UK
45 minutes General discussion and Round Table:
What Kind of Social Science Research to support Clinicians Issues?
Giulio Maria Corbelli, ECAB/EATG, Italy
Frédéric Le Marcis, ENS Lyon, France
Warren Mitchell, AVAC, USA
Caroline Ollivier-Yaniv, Université Paris-Est Créteil, France
10 minutes Conclusion
Guillaume Lachenal and Jean-Daniel Lelièvre
A snack will be served to all participants after the Symposium from 14:30 to 15:00
Chairs:
Guillaume Lachenal (Université Paris-Diderot, France)
Jean-Daniel Lelièvre (Vaccine Research Institute/VRI, Hôpital Henri Mondor, France)
Welcome 12:30 - 12:45

François Dabis (ANRS, France)
Page 2 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Recruitment of healthy volunteers for HIV vaccine trials: a stumbling 12:45 - 12:50
block?
Volunteers/Participants Recruitment/Enrolment in Africa 12:50 - 13:05

Morenike Ukpong-Folayan (Obafemi Awolowo University, Nigeria)
Exceptional Risk: US Healthy Volunteers’ Perceptions of HIV/AIDS Clinical 13:05 - 13:20

Trials
Marci Cottingham (University of Amsterdam, Netherlands)
Participant Recruitment in an Outbreak Context: The Ebola vaccine trials 13:20 - 13:35
in Sierra Leone
Luisa Enria (University of Bath, United Kingdom)
General discussion and Round Table: What Kind of Social Science 13:35 - 14:20
Research to support Clinicians Issues?
Giulio Maria Corbelli (ECAB/EATG, Italy)
Frédéric Le Marcis (ENS Lyon, France)
Mitchell Warren (AVAC, United States)
Caroline Ollivier-Yaniv (University Paris-Est, France)
Conclusion 14:20 - 14:30

Guillaume Lachenal (Université Paris-Diderot, France)
Satellites
14:00 - 17:00 Burdeos
SA05 Planning for Success: Next Steps for Dapivirine Ring

Hosted by: OPTIONS and IPM Researchers, implementers, advocates, policy makers and dapivirine ring users will
share research and experience to refine and coalesce on practical next steps for introduction.
Chairs:
Elizabeth Gardiner (AVAC, United States)
Nadia Sutton (Johnson & Johnson, Global Public Health, United States)
Page 3 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Satellites
15:00 - 18:00 Marsella
SA07 Engagement of African MSM in HIV Prevention Research: Effective

Recruitment and Retention
Hosted by: International AIDS Vaccine Initiative (IAVI) and the US Military HIV Research Program (MHRP) The purpose
of this meeting is to convene researchers and other stakeholders to discuss how African MSM can be successfully
engaged in planned HIV biomedical prevention trials, discuss various recruitment and retention strategies from Africa
and develop best practices and tools to inform future research in Africa and other regions.
•Overview: HIV Prevalence, HIV Incidence, and Retention from Key African Studies of MSM – Joshua Kimani,
University of Manitoba Kenya office •Plenary: Including African MSM in HIV biomedical prevention research –
opportunities, challenges – Anatoli Kamali, IAVI •Lessons learned in recruitment and retention of African MSM
•Frederick Otieno, ‎Nyanza Reproductive Health Society •Elizabeth Wahome, KEMRI •Zahra Parker, Research
Manager, U.S. Military HIV Research Program-Nigeria •Hannah Kibuuka, Research Physician, Makerere
University Walter Reed Project •Victor Akelo, KEMRI/CDC Senior Research Officer, Kisumu, Kenya •Travis
Sanchez, Emory University
•Strategic community engagement
•Sylvia Adebajo, Population Council, Nigeria •Jeffrey Walimbwa, ISHTAR, Kenya
•Moderated Panel Q & A Discussion •Closing remarks – Merlin Robb, U.S. Military HIV Research Program
Chairs:
Kenneth H. Mayer (Fenway Health, United States)
Sylvia Adebajo (Population Council, Nigeria)
Satellites
SA04 State of the Art of HIV bNAbs for Prevention of HIV Infection
Hosted by: HIV Vaccine Trials Network and HIV Prevention Trials Network In April 2016, the HIV Vaccine Trials Network
(HVTN) and the HIV Prevention Trials Network (HPTN) launched the precedent-setting AMP studies to determine if the
broadly neutralizing antibody called VRC01 can prevent HIV infection in people. Broadly neutralizing antibodies
(bnAbs) can be detected in an estimated 25% of persons with untreated HIV infection. Attracting the most attention
are bnAbs with the greatest breadth — those that demonstrate the ability to neutralize the largest number of HIV
strains — or those that have the greatest potency. Such bnAbs offer considerable opportunities for treatment and
prevention of HIV infection. This session will have some of the major figures in the field cover current topics on the
discovery and clinical development of bnAbs to prevent HIV infection.
Chairs:
Larry Corey (Fred Hutchinson Cancer Research Center, United States)
Myron Cohen (University of North Carolina, United States)
Page 4 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Monday, 22 October 2018
Satellites
08:30 - 11:30 Bristol
SA16 Current State of Play: PrEP Implementation Update and Challenges

Hosted by: ICAP at Columbia University, World Health Organization (WHO), AVAC, CHAI and HIV Prevention Trials
Network (HPTN) For more details, please click on this link: https://ghve.box.com/s/vngwv4hrihnctg3vvz7uc3qzll1fgfrd
This session will provide participants with an update on where we are with PrEP and future products, current
understanding of the different approaches to oral PrEP implementation in low- and middle-income countries, the
challenges faced and solutions found in efforts to scale-up programs. Panel discussions will elicit the perspectives
from key experts and include debate on current controversies when considering and prioritizing PrEP implementation.
Chairs:
Wafaa El-Sadr (Mailman School of Public Health, Columbia University, United States)
Rachel Baggaley (World Health Organization, Switzerland)
Satellites
08:30 - 11:30 Oxford
SA18 A Treasure Trove of Clinical Specimens and Data: Mining Research

Opportunities with the HIV Vaccine Trials Network (HVTN)
Hosted by: HIV Vaccine Trials Network (HVTN) The HVTN has conducted more than 75 clinical trials across four
continents, evaluating the safety, tolerability and immunogenicity of numerous study products, delivery methods and
regimens. During the conducting of all HVTN studies, participant data and specimens are collected at multiple time
points to evaluate immunogenicity and generate data across several cellular and humoral research platforms. In
addition, extra samples are collected and stored for use in other studies potentially related to vaccinology,
immunology and HIV. The HVTN maintains comprehensive metadata for all specimens, and has collected more than
one million pages of case report form data from study participants to date. The HVTN is committed to making the
specimens and data collected in HVTN studies available to investigators around the world to foster the development
of diverse, hypothesis-driven research projects to advance HIV vaccine science. This session will provide a brief
overview of the types of specimens, data and resources available to investigators to formulate research hypotheses,
as well as steps to approach collaborating with the HVTN. This overview will be followed by a showcase of several,
ongoing research projects initiated by investigators in collaboration with the HVTN and utilizing HVTN specimens
and/or data.
Chairs:
James Kublin (Fred Hutchinson Cancer Research Center, United States)
Ashley Clayton
Page 5 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Satellites
SA08 Catalyzing Translational Research to Advance HIV Vaccine and Immune-based

Cure Research in Africa: Cross-cutting Translational Research and Capacity
Strengthening in Africa
Hosted by: IAVI and University of KwaZulu Natal This satellite will showcase early and mid-level career African
scientists supported by a 15-year IAVI-led USAID-funded capacity program and from the SANTHE consortium, part of
the DELTAS Africa Initiative, an independent funding scheme of the African Academy of Sciences’ (AAS's) Alliance for
Accelerating Excellence in Science in Africa (AESA). This satellite workshop will aim to provide evidence of the impact
that these investments have created in translational biomedical research in Africa. This session will also host a
moderated panel discussion by African investigators to share personal career pathways, experiences and
perspectives on how research capacity and research outputs could be further strengthened and improved on the
continent.
Chairs:
Daniel Ochiel (IAVI, Kenya)
Thumbi Ndung’u (University of KwaZulu-Natal, South Africa)
Satellites
SA10 Immunological Mechanisms of Inducing HIV Immunity in Infants

Hosted by: Division of AIDS, NIAID, NIH The session aims to better understand: (i) how the unique tolerogenic nature
of the human fetal immune system and developing immune-tolerance in infants provide a unique setting for B-cell
maturation pathways and development of early and broad immunity to HIV; and (ii) how to prioritize HIV candidate
vaccines and target populations for assessment of infant HIV immunization.
Chairs:
Mary Marovich (Division of AIDS, NIAID, NIH, United States)
Sallie Permar (Duke University Medical Center)
Anjali Singh (Division of AIDS, NIAID, NIH)
Satellites
08:30 - 11:30 Burdeos
SA12 Voices in the Long-acting PrEP Movement: Fostering Dialog Between End-
users and Product Developers During the Product Development Process
Hosted by: RTI International, Desmond Tutu HIV Research Foundation, AVAC and IAVI This satellite session aims to
demonstrate and discuss strategies to foster open and iterative dialog between end-users and product developers of
long-acting HIV prevention products. The objective of hosting this satellite is directly in line with the theme of this
year’s HIVR4P Conference, From Research to Impact. Satellite presenters, those working both in product development
and those interfacing with target populations of young women in Southern Africa, aim to achieve synergistic solutions
for the development of long-acting HIV PrEP products that are safe, effective, acceptable and appropriate for their
target end-users, a goal that will ultimately achieve the greatest public health impact.
Chairs:
Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South Africa)
Page 6 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Satellites
08:30 - 11:30 Marsella
SA14 GPP@10 -- Setting New Standards for Clinical Trial Engagement Globally
Hosted by: AVAC, Amsterdam Institute for Global Health and Infectious Diseases Through presentations and
moderated discussions, the session will articulate evolved the Good Participatory Practices (GPP) after 10 years of
implementation, debate challenges and questions around GPP, and explore consensus on GPP as a standard in clinical
trials.
Chairs:
Stacey Hannah (AVAC, United States)
Catherine Hankins (Amsterdam Institute for Global Health and Development, Netherlands)
Satellites
11:30 - 15:00 Burdeos
SA13 It Only Hurts a Little: Long-acting Injectables for HIV Prevention and
Treatment
Hosted by: Center for HIV Identification, Prevention, and Treatment Services and the Center for AIDS Research at the
University of California, Los Angeles, HIV Prevention Trials Network and the AIDS Clinical Trials Group For more
information on the program, please visit: http://chipts.ucla.edu/features/upcoming-hiv-r4p-satellite-session-on-long-
acting-injectables-for-hiv-prevention-and-treatment/ To RSVP to the satellite session, please visit: goo.gl/RQYe1u
Ongoing clinical trials of long-acting injectable antiretroviral medications are being studied currently as both HIV
prevention and maintenance of virologic suppression in HIV treatment. If safe and effective, long-acting agents have
the potential to significantly impact the HIV epidemic by eliminating the requirement for daily oral dosing of
antiretrovirals. This may have significant benefits for individuals living with or at risk for HIV, particularly among those
who also have co-morbidities that complicate daily routinization of medication dosing, such as mental health and
substance use disorders. Such individuals also commonly face structural issues, including housing instability and food
insecurity, which can interfere with their capacity for daily oral medication adherence and persistence. With the first
regulatory approvals of long-acting injectable antiretrovirals imminent, this interactive satellite session aims to
facilitate efforts to mobilize, prepare and plan for culturally responsive, equitable and sustainable scale-up of long-
acting injectable prevention and treatment agents for key populations in high-, middle- and low-income countries. The
session will engage multidisciplinary stakeholders, including academic experts, policy researchers and civic society
members, in a dialogue to articulate the challenges for implementation and uptake and, in particular, how
acceptability and/or barriers may differ from those applicable to daily oral tablet formulations. The session will
convene two moderated panels to discuss clinical, behavioral, policy and community considerations associated with
the implementation of long-acting injectable antiretrovirals for prevention and treatment in the context of different
international resource settings and key populations (for example, MSM, transgender women, pregnant and parenting
cisgender women, youth).
Chairs:
Steven Shoptaw (UCLA Medical Center, Santa Monica, United States)
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)
Lunch and Registration 11:30 - 12:00
Welcome 12:00 - 12:10
Opening Remarks 12:10 - 12:20

Page 7 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Panel 1: Preparing for Long Acting Injectable for Prevention 12:20 - 13:30
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United
States)
Beatriz Grinsztejn (Fundação Oswaldo Cruz, Brazil)
Nyaradzo Mgodi (University of Zimbabwe Collaborative Research Program,
Zimbabwe)
Le Minh Giang (Hanoi Medical University, Viet Nam)
Break 13:30 - 13:40
Panel 2: Preparing for Long Acting Injectable for Treatment 13:40 - 14:50
Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South
Africa)
Santiago Moreno (University of Alcala de Henares, Spain)
Omar Sued (Fundacion Huesped, Argentina)
Ntando Yola (Desmond Tutu HIV Foundation, South Africa)
Closing Remarks 14:50 - 15:00
Adjourn
Satellites
12:00 - 15:00 Bristol
SA17 Love, Power and PrEP: Addressing Relationship Dynamics and Intimate
Partner Violence to Promote Successful HIV Prevention for Women and Girls
Hosted by: FHI 360, RTI International, Population Council and Wits Reproductive Health and HIV Institute For more
details, please click on this link: https://mailchi.mp/3af389e4ecc5/reminder-love-power-prep-r4p-satellite-
session-325431 To successfully empower women and girls to protect themselves against HIV, researchers, policy
makers, funders, advocates and programmers need a nuanced understanding of how relationship dynamics affect HIV
prevention and interventions that jointly address these issues. This satellite session will summarize the state of the
evidence on the effect of gender inequality on the HIV risk of women and girls and their use of HIV prevention
methods, including pre-exposure prophylaxis (PrEP). New evidence will be presented from adolescent girls, young
women, key populations and male partners in Kenya, Ghana and Tanzania on their HIV prevention needs and
preferences, including their views on PrEP and how intimate partner violence (IPV) could affect PrEP access and use. A
panel of experts will present new evidence from clinic- and community-based interventions (CHARISMA, EMPOWER
and Project SOAR) implemented in South Africa and Tanzania, jointly addressing relationship dynamics, IPV, HIV
prevention and PrEP.
Chairs:
Kawango Agot (Impact Research & Development Organization, Kenya)
Jared Baeten (University of Washington, United States)
Page 8 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Satellites
12:00 - 15:00 Oxford
SA19 Whose Desire? Whose Choice? A Debate on the Future of HIV Prevention
Hosted by: AVAC and IRMA Lively, moderated discussion and debate featuring speakers from funding agencies,
research networks and sites, product developers and the advocacy community. Panelists will unpack the evolving HIV
prevention research priorities and product development agendas, and share thoughts on what is necessary to
develop prevention products that people desire and what we mean by giving people "choices."
Chairs:
Helen Rees (Wits Reproductive Health and HIV Institute, South Africa)
Satellites
SA09 Fc-mediated Antibody Functions Impacting HIV Prevention

Hosted by: NIH/NIAID/Division of AIDS Objectives for the Meeting •To review NHP and clinical data on Fc-mediated
functions in the context of HIV/SIV infection and vaccine design. •To futher discuss the biological relevance and
limitations of different assays for measuring Fc-mediated functions. •To provide insights into immunogen design to
maximize the induction of antibodies with Fc-mediated functions. Fc-mediated antibody functions, including antibody-
dependent cell cytotoxicity (ADCC), are potential mechanisms that the immune system can resource to prevent the
establishment of HIV infection by eliminating HIV and/or HIV-infected cells. This session will bring together
investigators to review NHP and clinical data on Fc-mediated antibody functions in the context of HIV/SIV infection
and vaccine design, to discuss the biological relevance and limitations of different assays and to provide insights into
immunogen design strategies to maximize the induction of antibodies with Fc-mediated functions that could impact
HIV infection and persistence.
Chairs:
Christiane Moog (INSERM U1109, FMTS, Université de Strasbourg, France)
Stephen Kent (University of Melbourne, Australia)
Welcome and Opening Remarks 12:00 - 12:05

Higher Antibody Fc Effector Functions Significantly Impact HIV‐1 12:05 - 12:20

Infection Risk in a Human Efficacy Trial
Georgia Tomaras (Duke University, United States)
Epitopes For C1/C2 ADCC Antibodies Induced in HIV Infection and in 12:20 - 12:35
Response to the RV144 and RV305 Vaccine Trials
Marzena Pazgier (Institute of Human Virology of University of Maryland, United
States)
Impact of HIV‐1 Env Conformation on ADCC 12:35 - 12:50

Andres Finzi (CRCHUM / Université de Montréal, Canada)
Knowns and Unknowns: Antibody Fc‐Mediated Anti‐Viral Activity in 12:50 - 13:05

Passive and Active Immunization
Ann Hessell (Oregon Health and Science University, United States)
Role of Non‐Neutralizing Effector Mechanisms in Sterilizing Immunity 13:05 - 13:15

Conferred by Passive Immunization in NHPs
Klaus Überla (Universitätsklinikum Erlangen, Germany)
Page 9 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
PGT121 Sterilely Protects Macaques from Vaginal Challenge with 13:15 - 13:25
SHIVSF163P3 in an FcγR‐ Independent Manner
David Beauparlant (The Scripps Research Institute, USA, United States)
The Link Between Fc Effector Function and Neutralization 13:25 - 13:35

Simone Irene Richardson (Centre for HIV & STIs, National Institute for
Communicable Diseases, South Africa)
The immunomodulatory role of serum IgA upon Fc effector functions 13:35 - 13:50
Amy Chung (Australia)
Time‐dependent susceptibility of HIV‐1‐infected cells to ADCC 13:50 - 13:55

Wen Shi Lee (University of Melbourne, at the Peter Doherty Institute for Infection
and Immunity, Australia)
Contribution of Fc‐Mediated Antibody Activities to HIV Control 13:55 - 14:00

Jéromine Klingler (UMR S_1109, France)
High Rate of anti‐V1V2 Responses Induced by HIV‐DNA Followed by 14:00 - 14:05

HIV‐MVA with or without CN54rgp140/GLA‐AF in Healthy Volunteers
Frank Msafiri (Muhimbili University of Health and Allied Sciences, Tanzania, United
Republic of)
Circulating levels of HIV‐1‐specific IgG differentially affect 14:05 - 14:10

antibody‐dependent cellular cytotoxic and phagocytic responses in HIV‐1
infected individuals.
Ntando G. Phaahla (National Institute for Communicable Diseases of the National
Health Laboratory Service, Center for HIV and STIs, South Africa)
Good things come in threes: mAb combinations for killing infected cells 14:10 - 14:15
Marina Tuyishime (Duke University Medical Center, United States)
Discussion moderated by Dr. Moog and Dr. Kent 14:15 - 15:00
Satellites
SA11 Accelerating a Labor of Love: Time to Transform HIV Prevention for Pregnant
and Breastfeeding Women
Hosted by: Jhpiego, MTN, PHASES, AVAC A growing body evidence supports the need to expand biomedical HIV
prevention options during pregnancy and breastfeeding, periods known to have increased risk for HIV acquisition for
both women and their infants. While the large majority of biomedical HIV prevention trials have excluded pregnant
and breastfeeding women, this trend is starting to change. HIV pre-exposure prophylaxis (PrEP) programs are starting
to serve pregnant and breastfeeding women, and the conversation around equitable access for these populations is
evolving. The proposed session would highlight the growing body of evidence, action, advocacy, and ethics around
increasing access for pregnant and breastfeeding women to safe and effective biomedical HIV prevention options.
Chairs:
Sharon Hillier (University of Pittsburgh, United States)
Kelly Curran
Page 10 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Satellites
12:00 - 15:00 Marsella
SA15 Human Centric Vaccine Discovery

Hosted by: EAVI2020 To view the agenda, please click on this link:
https://ghve.box.com/s/suoa2aow4o4qpsvvgbdcry0u8neo5uev For more details, please click on this link:
https://ghve.box.com/s/9b8uki8p4ep8veinb3notr8tjbyqtgoz This session will highlight the importance of discovery-
phase clinical vaccine trials.
Chairs:
Robin Shattock (Imperial College, United Kingdom)
Opening Plenary
16:00 - 18:00 Auditorium
PL01 Planning for Success (and the Challenges Ahead)

Plenary 1 opens HIVR4P 2018 with a broad statement of our goals, a look at the major challenges facing the field as
we convene and a tribute to some of the researchers and advocates who are taking it forward and keeping us
focused.
Chairs:
Jose Alcamí (Instituto de Salud Carlos III, Spain)
Susan Buchbinder (San Francisco Department of Public Health, United States)
Mike Chirenje (University of Zimbabwe, Zimbabwe)
Welcome to HIVR4P 2018 16:00 - 16:10

Desmond Tutu Award for HIV Prevention and Human Rights 16:10 - 16:17
PL01.01 HIV Vaccines: Where Are We and What Next? 16:17 - 16:47
Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South
Africa)
PL01.02 Novel Trial Designs for a Complex Environment 16:47 - 17:17

Sheena McCormack (MRC Clinical Trials Unit at UCL, United Kingdom)
PL01.03 Ending the HIV/AIDS Pandemic: The Critical Role of HIV Prevention 17:17 - 17:47
Science
Anthony Fauci (National Institute of Allergy and Infectious Diseases, NIH, United
States)
The Omololu Falobi Award for Excellence in HIV Prevention Research 17:47 - 17:55
Community Advocacy
Manju Chatani-Gada (AVAC, United States)
HIVR4P 2018 Scholars 17:55 - 18:00

Page 11 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Welcome Reception
18:00 - 20:00 Atrium Bar and England-France Gallery
Welcome Reception
Page 12 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Tuesday, 23 October 2018
Plenary
PL02 What Happens First: Understanding Susceptibility, Transmission and Early

Infection
Plenary 2 dives deep into some of the most fundamental and challenging questions about the earliest moments of
infection, when HIV enters the complex mucosal microenvironment, and how untangling the mysteries of
susceptibility and infection can lead to smarter, more targeted prevention approaches.
Chairs:
Felipe Garcia (IDIBAPS, Spain)
Julie McElrath (Fred Hutchinson Cancer Research Center, United States)
PL02.01 Visualizing HIV Transmission and Prevention 08:30 - 09:00

Thomas Hope (Northwestern University, United States)
PL02.02 First Responders: What Early Infection Teaches About Prevention and 09:00 - 09:30
Functional Cure Strategies
PL02.03 Untangling Hormonal Impacts on the Vaginal Microbiome and HIV 09:30 - 10:00
Acquisition Risk
Sharon Achilles (University of Pittsburgh, United States)
Oral
10:30 - 12:00 Londres
OA01 Location, Location, Location: Mucosal Mediators of Risk

Chairs:
Doug Kwon (Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital and Harvard Medical School,
United States)
Lindi Masson (University of Cape Town, South Africa)
OA01.01 Role of Epithelial Cells and Fibroblasts From the Female Reproductive 10:30 - 10:45
Tract in TFV and TAF Protection of CD4+ T Cells from HIV Infection
Charles Wira (Geisel School of Medicine at Dartmouth, United States)
OA01.02 Optical Tissue Imaging and Spectroscopic Measurement of 10:45 - 11:00

Spatiotemporal Tenofovir Distribution, Partitioning and Diffusivity in
Vaginal and Rectal Mucosa
Oranat Chuchuen (Khon Kaen University, Faculty of Engineering, Thailand)
OA01.03 Transplanted Human Vaginal Microbiomes Alter HIV-1 Infection and 11:00 - 11:15
Tenofovir Efficacy in Colonized Vaginal Epithelial Multilayer Cultures
Richard Pyles (University of Texas Medical Branch, United States)
OA01.06 Reducing Inflammation as a Novel HIV Prevention Approach: Aspirin 11:15 - 11:30
Reduces Inflammation and HIV Target Cells at the Female Genital Tract
Keith R Fowke (University of Manitoba, Canada)
Page 13 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA01.05 Hormonal Contraception Induced Changes to the Female Genital 11:30 - 11:45
Microbiota in South African Adolescents: A Randomized, Crossover Trial
Christina Balle (University of Cape Town, Institute of Infectious Disease and
Molecular Medicine & Division of Immunology, South Africa)
OA01.04 Impact of Vaginal Bacteria Communities on Antiretroviral-based PrEP 11:45 - 12:00

Drug Metabolism
Ryan Cheu (University of Washington, United States)
Oral
10:30 - 12:00 Bristol
OA02 Immunity in Human Vaccine Trials

Chairs:
Laura Richert (Vaccine Research Institute/VRI, France)
Gabriella Scarlatti (San Raffaele Scientific Institute, Italy)
OA02.01 T-cell and Transcriptomic Responses to Prime-boost Strategies of 3 HIV 10:30 - 10:45
Vaccines (MVA HIV-B; LIPO-5; GTU-MultiHIV B) - ANRS/INSERM VRI01 Trial
OA02.02 Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C 10:45 - 11:00
Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial
Gregory Wilson (Vanderbilt University Medical Center, United States)
OA02.03 V1V2 IgG and Antibody Fc Effector Functions in a Subtype C ALVAC-HIV 11:00 - 11:15
and Bivalent Subtype C gp120/MF59 HIV-1 Vaccine Trial in South Africa
Xiaoying Shen (Duke Human Vaccine Institute, United States)
OA02.04LB DNA-prime Induces Higher Magnitude Humoral Responses Than ALVAC- 11:15 - 11:30
prime in HIV Vaccine Regimens With the Same Protein Boost
Zoe Moodie (Fred Hutchinson Cancer Research Center, United States)
OA02.05LB Vaccine-induced Gene Signature Correlates With Protection Against 11:30 - 11:45
Acquisition in Three Independent Vaccine Efficacy Trials Including RV144
Rasmi Thomas (US Military HIV Research Program (MHRP), Walter Reed Army
Institute of Research, United States)
OA02.06LB Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess 11:45 - 12:00
Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV
Vaccine Regimens
Daniel J. Stieh (Janssen Vaccines & Prevention B.V., Netherlands)
Oral
10:30 - 12:00 Oxford
OA03 Structure and Maturation of bNAbs

Chairs:
Alejandro Balazs (Ragon Institute of MGH, MIT and Harvard, United States)
Page 14 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA03.01 Induction and Maturation of HIV-1 Fusion Peptide-directed Broadly 10:30 - 10:45
Neutralizing Antibodies in Rhesus Macaques by Vaccination
Peter D. Kwong (Vaccine Research Center, United States)
OA03.02 Identification of Near Pan-neutralizing Antibodies Against HIV-1 by 10:45 - 11:00

Deconvolution of Plasma Humoral Responses
Mohammad Sajadi (Institute of Human Virology, School of Medicine, University of
Maryland, United States)
OA03.03 Structural Basis for Germline VRC01 Antibody Recognition of a 11:00 - 11:15
Glycosylated HIV-1 Envelope CD4-binding Site
Marie Pancera (Fred Hutchinson Cancer Research Center, United States)
OA03.04 Fast and Focused Maturation of VH1-2-restricted HIV-env CD4-binding 11:15 - 11:30
Site Targeting bNAbs
Elise Landais (International AIDS Vaccine Initiative (IAVI), United States)
OA03.05 Somatic hypermutation to counter a rare viral immunotype drove off- 11:30 - 11:45
track antibodies in the CAP256-VRC26 V2-directed bNAb lineage
David Sacks (National Institute for Communicable Diseases, National Health
Laboratory Service, South Africa)
OA03.06 New SHIV Models of bNAb Elicitation and Env-Ab Coevolution 11:45 - 12:00
Hui Li (University of Pennsylvania, United States)
Oral
10:30 - 12:00 Marsella, Burdeos & Estrasburgo
OA04 Entry Into the PrEP Continuum

Chairs:
Sybil Hosek (Stroger Hospital of Cook County, United States)
Rupa Patel (Washington University in St. Louis, United States)
OA04.01 Tracking Global Oral PrEP Provision: The Who, What, Where of Oral PrEP 10:30 - 10:45
Laura Fitch (AVAC, United States)
OA04.02 Sexual Health Goal Congruence and PrEP Adoption Among Gay and 10:45 - 11:00
Bisexual Men in Primary Partnerships
Kristi Gamarel (University of Michigan School of Public Health, United States)
OA04.03 Characterization of Early Adopters in a National Oral Pre-exposure 11:00 - 11:15

Prophylaxis (PrEP) Scale-up Program in Kenya
Daniel Were (Jhpiego, Kenya)
OA04.04 “So That I Don’t Get Infected Even If I Have Sex With Someone Who Is 11:15 - 11:30
Positive:” Factors Influencing PrEP Uptake Among Young Women in
Kenya
Nicholas Thuo (Partners in Health Research and Development, Kenya)
OA04.05 HIV-related Risks and Interest in Pre-exposure Prophylaxis (PrEP) Among 11:30 - 11:45
Transgender Respondents of the Community-based Survey Flash! PrEP in
Europe
Rosemary M. Delabre (Coalition PLUS, Community-based Research Laboratory,
France)
Page 15 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA04.06 Substantial Gaps in the PrEP Continuum Among Transwomen Compared 11:45 - 12:00
With MSM in San Francisco
Albert Liu (San Francisco Department of Public Health, United States)
Meet the Experts Lunch

12:00 - 13:00 Toulouse & Lyon
ME01 Meet the Experts Lunch

Daily meet the experts lunches provide early-career investigators and community advocates with valuable
opportunities for informal, in-depth exchange with experts representing a cross-section of research issues,
implementation challenges, and HIV-affected communities.
Chairs:
Eric Arts (University of Western Ontario, Canada)
Emily Bass (AVAC, United States)
Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South Africa)
Marta Boffito (Chelsea and Westminster NHS Trust, United Kingdom)
Zhiwei Chen (The University of Hong Kong AIDS Institute, China)
Charles Dobard (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch,
United States)
Deborah Donnell (Fred Hutchinson Cancer Research Center, United States)
Andrew Harman (The Westmead Institute, University of Sydney, Australia)
Walid Heneine (CDC, United States)
Thomas Hope (Northwestern University, United States)
Luciana Kamel (Fiocruz, Brazil)
Sheena McCormack (MRC Clinical Trials Unit at UCL, United Kingdom)
Lynn Morris (National Institute for Communicable Diseases of the NHLS, South Africa)
Irene Mukui (National AIDS & STI Control Program, Kenya)
Jeffrey Murray (FDA, United States)
Manish Sagar (Boston University, United States)
Kevin Saunders (Duke Human Vaccine Institute, United States)
William Schief (The Scripps Research Institute and IAVI, United States)
Alexandra Schuetz (MHRP Thailand, Thailand)
Gertrude Nanyonjo (UVRI-IAVI HIV Vaccine Program, Uganda)
Eloisa Yuste (Instituto de Salud Carlos III, Spain)
Meet the Experts Lunch 12:00 - 13:00
Oral
13:00 - 14:30 Londres
OA05 If I Choose, Will I Use? Products, People and Preferences

Chairs:
Mary Aikenhead (Bill and Melinda Gates Foundation, United States)
Mina Hosseinipour (University of North Carolina at Chapel Hill, Malawi)
OA05.01 Acceptability of Long-acting Injectable Cabotegravir (CAB LA) in HIV- 13:00 - 13:15
uninfected Individuals: HPTN 077
Elizabeth (Betsy) Tolley (FHI 360, United States)
Page 16 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA05.02 Partners, Peers and Rumours as Influencers of Use and Attitudes 13:15 - 13:30
Towards the Dapivirine Vaginal Ring: Qualitative Data From The Ring
Study (IPM 027)
Cecilia Milford (MatCH Research Unit (MRU), University of the Witwatersrand,
South Africa)
OA05.03 Testing Objective Markers of Placebo Vaginal Product Adherence in the 13:30 - 13:45
Field
Andrea Ries Thurman (CONRAD Eastern Virginia Medical School, United States)
OA05.04 Preference and Choice of Four Vaginal HIV Prevention Placebo Dosage 13:45 - 14:00
Forms Among Young African Women: Results of the Quatro Randomized
Crossover Trial
Elizabeth Montgomery (RTI International, United States)
OA05.05 Attribute Preferences for Long-acting Pre-exposure Prophylaxis (PrEP): 14:00 - 14:15
Results of a Discrete Choice Experiment With South African Youth
Alexandra Minnis (RTI International, United States)
OA05.06LB UChoose: An Adolescent Study of HIV Prevention Choice in Cape Town, 14:15 - 14:30
South Africa
Katherine Gill (Desmond Tutu HIV Foundation, South Africa)
Oral
13:00 - 14:30 Bristol
OA06 Mucosal Models of Prevention

Chairs:
Carolina Herrera (Imperial College London, United Kingdom)
Thandi Onami (Bill & Melinda Gates Foundation, United States)
OA06.01 Combination of MUC5AC and MUC2 Enhances Antibody Neutralization 13:00 - 13:15
Potency Against HIV-1 Infection
Arangassery Rosemary Bastian (Northwestern University, United States)
OA06.02 Neutrophil Extracellular Traps Represent a Novel Mechanism for HIV 13:15 - 13:30
Prevention in the Female Genital Tract
Marta Rodriguez-Garcia (Geisel School of Medicine at Dartmouth, United States)
OA06.03 Select V2 Loop Antibodies Inhibit gp120 Binding to Integrin 13:30 - 13:45
α4β7
Sakaorat Lertjuthaporn (Faculty of Medicine Siriraj Hospital, Thailand)
OA06.04 Investigating the Interactions Between HIV and a New Epithelial Target 13:45 - 14:00
Cell in Human Genital Tissue
Jake Rhodes (Westmead Institute for Medical Research, Australia)
OA06.05 Live Imaging of HIV-1 Transfer Across T-cell Virological Synapse to 14:00 - 14:15
Epithelial Cells That Promotes Stromal Macrophage Infection
Morgane Bomsel (Institut Cochin CNRS UMR8104, France)
OA06.06 Fcα-receptor I Expression by Stratified Squamous Epithelia: Implications 14:15 - 14:30

for IgA-associated Immune Function in the Human Lower Genital Tract
Kadryn Kadasia (Boston University School of Medicine, United States)
Page 17 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Oral
13:00 - 14:30 Oxford
OA07 Understanding Protection Against HIV From the T Cell Perspective

Chairs:
Marcus Altfeld (Heinrich Pette Institute, Germany)
Richard Koup (Vaccine Research Center, United States)
OA07.01 Increased Breadth of T-cell Responses After Mosaic HIV Vaccination in 13:00 - 13:15
Humans (HVTN 106)
Nicole Frahm (Fred Hutchinson Cancer Research Center, United States)
OA07.02 Gag and Env Conserved Element DNA Vaccines Elicit Cytotoxic Responses 13:15 - 13:30
Targeting Subdominant Epitopes Able to Recognize Infected Cells in
Macaques
Barbara K. Felber (National Cancer Institute at Frederick, United States)
OA07.03 Utilizing Computational Machine Learning Tools to Understand 13:30 - 13:45

Immunogenic Breadth of HIV in the Context of a CD8 T-cell Mediated HIV
Response
Jonathan Hare (International AIDS Vaccine Initiative (IAVI), United Kingdom)
OA07.04 Structure-based Network Analysis of HIV-1 Defines Protective CD8+ T 13:45 - 14:00
Cell Epitopes Across Diverse HLA: Implications for Global Immunogen
Design
Gaurav Gaiha (Ragon Institute of MGH, MIT & Harvard, United States)
OA07.05 CD8+ T Cells Do Not Control SIV Replication During ART or Viral Relapse 14:00 - 14:15
After ART Withdrawal
Afam Okoye (Oregon Health & Science University, United States)
OA07.06 CD8 T Cells Responding to Adapted Epitopes Are Enriched in Chronic HIV 14:15 - 14:30
Infection and Induce Dendritic Cell Maturation with Enhanced CD4
Infection
Kai Qin (University of Alabama at Birmingham, United States)
Oral
OA08 bNAbs for Prevention

Chairs:
Boris Juelg (Ragon Institute of MGH, MIT and Harvard, United States)
Alexandra Trkola (University of Zurich, Switzerland)
OA08.01 Combination of HIV-1 Antibodies 3BNC117 and 10-1074 Delays Viral 13:00 - 13:15
Rebound During Treatment Interruption
Pilar Mendoza (Rockefeller University, United States)
OA08.02 SHIV162P3 Transmission by Semen Leukocytes Is Efficiently Inhibited by 13:15 - 13:30

a Combination of Broad Neutralizing Antibodies
Karunasinee Suphaphiphat (CEA, France)
OA08.03 Broadly Neutralizing Antibodies Provide Potent Dose-dependent 13:30 - 13:45

Protection to Rhesus Macaques Against Mucosal SHIV Challenge
Amarendra Pegu (Vaccine Research Center, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, United States)
Page 18 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA08.04 VRC01 Pharmacokinetics at Mucosal Sites in HIV-infected and Healthy 13:45 - 14:00
Adults
Madhu SP Prabhakaran (Vaccine Research Center, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, United States)
OA08.05 Safety and Pharmacokinetics of Multiple Doses of a Potent Anti-HIV 14:00 - 14:15
Monoclonal Antibody, VRC01, in HIV-exposed Newborns
Coleen Cunningham (Duke, United States)
OA08.06 Imaging the Distribution of I.V.-injected VRC01 and VRC01-LS in the In 14:15 - 14:30
Vivo Rhesus Macaque Model
Ann M. Carias (Northwestern University, United States)
Symposium
15:00 - 16:30 Londres
SY01 We Want bNAbs: Passively Infused and Induced by Vaccines

This session will look at state-of-the-art passive infusion designs, including optimal combinations to achieve maximum
breadth, coverage, potency and durability. In addition, multiple vaccine concepts designed to induce bNAbs will be
presented, from the stage of basic concept up to the clinical trials pipeline.
Chairs:
Marina Caskey (The Rockefeller University, United States)
Quentin Sattentau (Sir William Dunn School of Pathology, United Kingdom)
SY01.01 Engineered Tandem Bispecific Neutralising Antibody for HIV-1 Prevention 15:00 - 15:18
and Immunotherapy
Zhiwei Chen (The University of Hong Kong AIDS Institute, China)
SY01.02 Antibody Mediated Protection (AMP): Where Are We? Which Antibodies 15:18 - 15:36
to Use and How Will We Know If It´s Working?
Lynn Morris (National Institute for Communicable Diseases of the NHLS, South
Africa)
SY01.03 Generation of Immunogens Based on HIV-1 Envelopes From Patients With 15:36 - 15:54
Broadly Neutralizing Responses Within the First 6 Months of Infection
Eloisa Yuste (Instituto de Salud Carlos III, Spain)
SY01.04 HIV-1 Vaccine Design for the Elicitation of V3-glycan Broadly Neutralizing 15:54 - 16:12
Antibodies
Kevin Saunders (Duke Human Vaccine Institute, United States)
SY01.05 Progress in Germline-targeting Vaccine Design for HIV 16:12 - 16:30

William Schief (The Scripps Research Institute and IAVI, United States)
Page 19 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Symposium
15:00 - 16:30 Bristol
SY02 Early Invaders: Establishment of HIV Infection

This session addresses virus-host interaction at the mucosal border where transmission occurs and where cells
involved in early immune responses are both viral targets and defense mechanisms.
Chairs:
Cecilia Cabrera (IrsiCaixa AIDS Research Institute, Spain)
Penny Moore (University of the Witwatersrand, South Africa)
SY02.01 Selection of Transmitted Founder Viruses During Sexual HIV-1 15:00 - 15:22
Acquisition
Manish Sagar (Boston University, United States)
SY02.02 Identification of a New HIV Transmitting Target Cell in Human Genital 15:22 - 15:44
Tissue
Andrew Harman (The Westmead Institute, University of Sydney, Australia)
SY02.03 Characteristics Leading to HIV Trapping in the Female Genital Tract and 15:44 - 16:06
Systemic Primary Infection During Transmission
Eric Arts (University of Western Ontario, Canada)
SY02.04 Mucosal Immunology in the Context of Acute HIV Infection and HIV 16:06 - 16:28
Remission Studies
Symposium
15:00 - 16:30 Oxford
SY03 Beyond Placebo: Designing and Implementing Next Generation HIV

Prevention Trials
This session will explore challenges in designing and conducting the next generation of HIV prevention trials. Topics
discussed will include regulatory perspectives, novel trial designs, ethical considerations in provision of standard of
prevention, and active community engagement in the design and successful implementation of complex trials in an
era of proven HIV prevention tools (including voluntary medical male circumcision and oral PrEP).
Chairs:
Peter Godfrey-Faussett (UNAIDS, Switzerland)
Catherine Hankins (Amsterdam Institute for Global Health and Development, Netherlands)
SY03.01 Regulatory Perspectives for Streamlining HIV Prevention Trials 15:00 - 15:18
Jeffrey Murray (FDA, United States)
SY03.02 Novel Trial Design in the Era of Successful HIV Prevention Interventions 15:18 - 15:36
Deborah Donnell (Fred Hutchinson Cancer Research Center, United States)
SY03.03 The Landscape is Changing… [It's] Quite a Complicated Issue" : 15:36 - 15:54
Perspectives on the Standard of Prevention in South African HIV Vaccine
Trials
Zaynab Essack (Human Sciences Research Council, South Africa)
SY03.04A Strengthen Community Expertise on the Important Aspects of Clinical 15:54 - 16:03
Trial Design
Luciana Kamel (Fiocruz, Brazil)
Page 20 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
SY03.04B Community Engagement in the Design and Implementation of HIV 16:03 - 16:12
Prevention Trials: Uganda Virus Research Institute-International AIDS
Vaccine Initiative
Discussion 16:12 - 16:30
Symposium
SY04 ARVs for Prevention: Extrapolating from Data to Clinical Practice

Data on mechanisms for PrEP efficacy are somewhat limited, and interpretation varies in creating policy about timing
of starting and stopping PrEP for protection. This session will explore the PK, PD and clinical trials, and discuss
implications of what is currently known for developing policy on PrEP.
Chairs:
Lara Coelho (Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Brazil)
Clemensia Nakabiito (MUJHU Research Collaboration, Uganda)
SY04.01 Pharmacokinetics of PrEP Agents: Where Do Drugs Go? How Long Do 15:00 - 15:22
They Last?
Marta Boffito (Chelsea and Westminster NHS Trust, United Kingdom)
SY04.02 Lessons Learned from Pre-clinical Animal Models on Pharmacokinetics 15:22 - 15:44
and Pharmacodynamics of ARVs for PrEP
Charles Dobard (Centers for Disease Control and Prevention, Division of HIV/AIDS
Prevention, Laboratory Branch, United States)
SY04.03 Understanding PrEP Effectiveness in Different Populations in the Context 15:44 - 16:06
of Public Health Programs
Irene Mukui (National AIDS & STI Control Program, Kenya)
SY04.04 The PrEP Paradigm for Prevention, Advocacy and Implementation in sub- 16:06 - 16:28
Saharan Africa: Strong Starts, Short Cuts, and the Use (and Abuse?) of
Data
Emily Bass (AVAC, United States)
Poster Discussion
16:45 - 17:30 Londres
PD01 Revealing Targets for Prevention and Cure

Chairs:
Damian Purcell (Doherty Institute, University of Melbourne, Australia)
Jesus Salazar-Gonzalez (Mrc/uvri And Lshtm Uganda Research Unit, Uganda)
PD01.01 V3 Reactive, Broadly Neutralizing DARPins Reveal Efficiently Targetable 16:45 - 16:54
V3 Exposure During Entry and Provide Insight on Native HIV-1 Env
Stability
Matthias Glögl (University of Zurich, Switzerland)
Page 21 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
PD01.02 Memory CD4+CD45RO+SAMHD1low Cells Exhibit Distinct Genes Profile 16:54 - 17:03
and Contain the Highest Level of HIV-1 DNA With Segregated HIV-1
Populations
Lylia Hani (INSERM, U955, Equipe 16, France)
PD01.03 Killing a Moving Target: ADCC Against HIV-1-infected Cells in the Process 17:03 - 17:12
of CD4-downregulation
Wen Shi Lee (University of Melbourne, at the Peter Doherty Institute for Infection
and Immunity, Australia)
PD01.04 Transmitted/Founder Virus-like Variants Are Archived in the Reservoir 17:12 - 17:21
Kelsie Brooks (Emory University, United States)
Poster Discussion
16:45 - 17:30 Bristol
PD02 MEN-ding the Gaps

Chairs:
Kennedy Mupeli (Center for Youth of Hope (CEYOHO), Botswana)
Michelle Rodolph (WHO, Switzerland)
PD02.01 “If She Tests Negative, It Means I Am Also Negative”: Men’s Construction 16:45 - 16:54
of HIV Testing in South Africa
Oluwafemi Adeagbo (Africa Health Research Institute, South Africa)
PD02.02 Awareness, Willingness and Barriers to HIV Self-testing (HIVST) Among 16:54 - 17:03
Men Who Have Sex With Men (MSM) in Brazil: A Cross-sectional Online
Study
Thiago Silva Torres (Fundação Oswaldo Cruz, Brazil)
PD02.03 Increased Trust and Reduced Blaming Characterize Age-disparate 17:03 - 17:12
Heterosexual Relationships in KwaZulu-Natal, South Africa
Alastair van Heerden (Human Sciences Research Council, South Africa)
PD02.04 Profile of the Uncircumcised Zambian Male After Seven Years of 17:12 - 17:21
Circumcision Programs for HIV Prevention
Omega Chituwo (Centers for Disease Control and Prevention, Zambia)
PD02.05LB Reaching Men and Under Tested Populations in South Africa Using the 17:21 - 17:30
STAR Wits RHI HIV Self-screening Test Kits Distribution Models
Mohammed Majam (University of the Witwatersrand, South Africa)
Poster Discussion
16:45 - 17:30 Oxford
PD03 Insights From Vaccines for Improved Breadth, Potency and Durability
Chairs:
Anatoli Kamali (International AIDS Vaccine Initiative, Kenya)
Hanneke Schuitemaker (Janssen Vaccine and Prevention, Netherlands)
PD03.01 Impact of Vaccine Regimen on Vaccine-induced Antibody Durability 16:45 - 16:54

Kelly Seaton (Duke Human Vaccine Institute, United States)
Page 22 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
PD03.02 Delayed and Repetitive Boosting of RV144 Vaccinees Improves Antiviral 16:54 - 17:03
Immunity Associated With Correlates of HIV-1 Infection Risk
La Tonya Williams (Duke University/Duke Human Vaccine Institute, United States)
PD03.03 AIDSVAX (R) B/E gp120 Late Boost Increases HIV-1 Neutralizing 17:03 - 17:12
Antibodies to the Highest Levels in RV144/RV305 Participants Boosted
With ALVAC-HIV Alone
Lindsay Wieczorek (U.S. Military HIV Research Program, United States)
PD03.04 Elicitation of Fusion Peptide-directed Neutralizing Activity Through Three 17:12 - 17:21
Distinct Vaccination Regimens in Rhesus Macaques
Alexander J. Jafari (Vaccine Research Center (VRC), National Institute of Allergy
and Infectious Disease (NIAID), National Institutes of Health (NIH), United States)
PD03.05LB Increase in Env-specific Binding Antibody and CD4+ T Cell-responses 17:21 - 17:30
After Month 30 Boost of gp120/MF59 Delivered Alone or With ALVAC-HIV
Kristen Cohen (Fred Hutchinson Cancer Research Center, United States)
Poster Discussion
PD04 PrEP: Doing It Right at Delivery

Chairs:
Joshua Kimani (University of Nairobi, Kenya)
Benny Kottiri (USAID, United States)
PD04.01 Unmet PrEP Demand and Factors Associated With PrEP Interest Among 16:45 - 16:54
Men Who Have Sex With Men in the United States
Hyman Scott (San Francisco Department of Public Health, United States)
PD04.03 Towards the Development of a Behaviorally Congruent HIV-prevention 16:54 - 17:03

Rectal Microbicide Douche - The DREAM Study
Alex Carballo-Diéguez (Columbia University, HIV Center for Clinical and Behavioral
Studies at New York State Psychiatric Institute and Columbia University, United
States)
PD04.04 "What About the Boys?" Community Perceptions of Girl-centered HIV 17:03 - 17:12
Programming in Nairobi Informal Settlements: Experiences From DREAMS
Implementation
Jane Osindo (Africa Population and Health Research Center, Kenya)
PD04.05 Experiences of Accessing PrEP in Public HIV Clinics: A Case of Kenyan HIV- 17:12 - 17:21
uninfected People in Serodiscordant Relationships
Fernandos Ongolly (Kenya Medical Research Institute, Kenya)
Poster Discussion
PD05 Microbiome: When Microorganisms and the Immune System Meet

Chairs:
Sinaye Ngcapu (Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa)
Sergio Serrano-Villar (Hospital Universitario Ramón y Cajal, Spain)
Page 23 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
PD05.01 Bacterial Vaginosis Is Associated With Elevated Genital Inflammation and 16:45 - 16:54
Cellular Activation in Young African Women at High Risk for HIV infection
Smritee Dabee (University of Cape Town, South Africa)
PD05.02 Immunoregulatory Properties of Clinical Lactobacillus Isolates From 16:54 - 17:03

South African Women at High Risk of HIV Acquisition
Monalisa T. Manhanzva (University of Cape Town, Institute of Infectious Diseases
and Molecular Medicine (IDM), South Africa)
PD05.03 Chlamydia Infection Skews Mucosal CD4+ T-helper Subsets in the Genital 17:03 - 17:12
Tract of HIV-uninfected At-risk Women
Seth Bloom (Massachusetts General Hospital, United States)
PD05.04 Exosomal Proteomics Offers a Biological Basis for Increased 17:12 - 17:21
Susceptibility to HIV in Trichomonas Vaginalis Infection
Yashini Govender (Brigham & Women's Hospital, Harvard Medical School, United
States)
PD05.05LB Human Gut Microbiota Are Associated With HIV-reactive Immunoglobulin 17:21 - 17:30
at Baseline and Following HIV Vaccination
James Kublin (Fred Hutchinson Cancer Research Center, United States)
Poster
17:30 - 19:30 Poster Hall
P01 Antibody Functions (Neutralizing and Non-neutralizing)

P01.03 Prevalence of Broadly Neutralizing Antibody Responses in HIV-1-infected Injecting Drug
Users
P01.05 Elicitation of Moderate Neutralization Response Associated With Polyclonal Antibodies

Among HIV-1 Subtype C Infected Individuals From Southern India
Paneerselvam Nandagopal (YRG Center for AIDS Research and Education, India)
P01.07 Germline-targeting and Reverse Engineering to Elicit CH235.12 Lineage bNAbs

Shay Behrens (Duke University Medical Center, United States)
P01.09 Association of Circulatory Tfh-like Cells With Neutralizing Antibody Responses Among
Chronic HIV-1 Subtype C Infected LTNP and Progressors
Chinnambedu Ravichandran Swathirajan (Y.R. Gaitonde Centre for AIDS Research and Education, India)
P01.11 Immune Responses in HIV-1 Cross-infection and Epidemiologically Linked Superinfection

Ralf Duerr (New York University - School of Medicine, United States)
P01.13 Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA With or Without
CN54rgp140/GLA-AF in Healthy Tanzanian and Mozambican Volunteers
Frank Msafiri (Muhimbili University of Health and Allied Sciences, Tanzania, United Republic of)
P01.15 HIV Infection Leads to the Development of Neutralization-interfering Antibodies that

Hamper the Function of Neutralizing Antibodies
Maria Luisa Rodriguez de la Concepción (IrsiCaixa AIDS Research Institute, Spain)
P01.17 HIV-1 Subtype G Variants Have Similar Sensitivity to Broadly Neutralizing Monoclonal
Antibodies, but Sensitivity to Inhibitors of Viral Entry Varies
Essomba René Ghislain (Catholic University of Central Africa, Cameroon)
Page 24 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P01.19 Monitoring the Sensitivity to Broadly Neutralizing Antibodies of Early (T/F) HIV-1 Variants of
Clade CRF02_AG
Karl Stefic (Université de Tours, France)
P01.21 Inhibition of Robust Antibody-dependent Cellular Cytotoxicity in Elite Controllers by

Elevated HIV-1 Specific gp120 Antibodies
Ntando G. Phaahla (National Institute for Communicable Diseases of the National Health Laboratory
Service, Center for HIV and STIs, South Africa)
P01.23 A Novel Anti-CD4-binding Site Broadly Neutralizing Monoclonal Single Chain Variable
Fragment (scFv) From HIV-1 Clade-C Chronically Infected Children
Sanjeev Kumar (All India Institute of Medical Sciences (AIIMS), India)
P01.25 Recognition and Elimination of HIV-1-infected Cells by ADCC-mediating mAbs for Prevention
and Treatment of HIV-1 Infection
Marina Tuyishime (Duke University Medical Center, United States)
P01.27 Prolonged Intervals Between Boosts Induces High Magnitude Transient V2-specific
Functional Antibodies That Inhibit the Binding of V2 to α4β7 Integrin
Kristina Peachman (U.S. Military HIV Research Program, Henry M. Jackson Foundation for the
Advancement of Military Medicine, United States)
P01.29 Divergent Members of a HIV-1 Broadly Neutralizing Antibody Lineage That Share a Common
Mode of Recognition Within the N332-glycan Supersite
Dale Kitchin (National Institute for Communicable Diseases of the National Health Laboratory Service,
Center for HIV and STIs, South Africa)
P01.31 Bridging Vaccine-induced Antibody Responses in Rabbit and Rhesus Macaque Animal
Models
Justin Pollara (Duke University School of Medicine, United States)
P01.33 HIV-1 Env Trimers Eliciting Antibody With Neutralising and Cellular-dependent Functions in
Vaccinated Cows
P01.37LB A Newly Developed B Cell Immunoglobulin Phenotyping Panel to Facilitate More Efficient
HIV-1 Antibody Discovery
Rosemarie Mason (Vaccine Research Center, NIAID, NIH, United States)
Poster
P02 Antiretroviral Resistance and Impact on Prevention

P02.01 HIV-positive Sex Workers´ Economic Empowerment to Achieve 90-90-90
Simon Mwangi (Bar Hostess Empowerment and Support Program, Kenya)
P02.03 Ultra-deep Sequencing for HIV-1 Minority Drug Resistance Testing Has a Limited Impact on
Virological Outcomes
Bin Su (Beijing You'an Hospital, Capital Medical University, China)
P02.05 Machine Learning-based Classifier Predicts Clinical HIV-1 Isolate Neutralization

Susceptibility to Neutralizing Antibodies With High Accuracy
Chen-Hsiang Shen (Vaccine Research Center, NIAID, NIH, United States)
Page 25 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Poster
P04 Cellular Immunity

P04.01 Genetic Variation in CD101 Alters Immune Signatures and Risk of HIV Acquisition
Jairam Lingappa (University of Washington, United States)
P04.03 Efficacy of Novel Broadly Bispecific CAR-T Against HIV-1 Infection in Humanized Mice
Xilin Wu (Nanjing University, China)
P04.05 Anatomic Site of Origin Affects the Immune-cell Composition of Bone Marrow in Rhesus
Macaques
Thomas Musich (AFRIMS, Thailand)
P04.07 Broad Recognition of Circulating HIV-1 by HIV-1-specific CTLs With Strong Ability to
Suppress HIV-1 Replication
Nozomi Kuse (Kumamoto University, Japan)
P04.09 Control of HIV-1 by CD8+ T Cells Specific for Epitopes of Conserved Mosaic Vaccine
Immunogens
Hayato Murakoshi (Center for AIDS Research, Kumamoto University, Japan)
P04.11 Identification of HIV-1 Epitopes Presented by the Protective HLA-C*12:02 Allele Using Mass
Spectrometry Analysis of Single-allele Transfectants
Takayuki Chikata (Kumamoto University, Japan)
P04.13 Vaccine-encoded Adapted Epitopes Infrequently Induce CD8 T Cell Responses

Sushma Boppana (University of Alabama at Birmingham, United States)
P04.15 Evaluating the Role of Early HIV-1 Specific T-follicular Helper and B Cells on the Subsequent
Antibody Function in HIV-1 Infection
Ian Oyaro (KEMRI-Wellcome Trust Research Programme, Kenya)
P04.17 Correlating HIV RNA Levels, Viral Replicative Capacity and Immune Control Within an Assay
to Measure CD8 T Cell Mediated HIV-1 Inhibition In Vitro
Catherine Kibirige (Imperial College London, United Kingdom)
P04.19 Low HIV-specific CD8+ T-cell Cytotoxic Capacity in Ad5/HIV Vaccinees Is Associated With
Impaired Degranulation of Functionally Intact Lytic Proteins
Stephen Migueles (National Institutes of Health, United States)
Poster
P03 Behavioral and Social Science Research

P03.01 Concordance in Reporting of Sexual Risk Behaviors in the HIV Sero Discordant Couples From
Central Region, Uganda
Charles Brown (Makerere University, Infectious Diseases Institute, Uganda)
P03.03 Behavioral and Social Science Research Supporting Clinical Trials With Broadly Neutralizing
Antibodies Against HIV
Yumeng Wu (The Rockefeller University, United States)
Page 26 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P03.05 Integrating Syndemic and Resiliency Approaches to Assessing YMSM’s Engagement in

Transactional Sex
Steven Meanley (University of Pennsylvania School of Nursing, United States)
P03.07 Psychological and Behavioural Within-participant Predictors of Adherence to Oral HIV Pre-
exposure Prophylaxis (PrEP)
Nneka Nwokolo (Chelsea & Westminster Hospital, United Kingdom)
P03.09 Perceptions of PrEP and HIV Risk in Adolescent Girls and Young Women Declining PrEP
Uptake From a Community Mobile Clinic in Cape Town, South Africa
Elzette Rousseau-Jemwa (Desmond Tutu HIV Foundation, South Africa)
P03.11 Site Approaches to Working With Participant Concerns Regarding Hair Collection: Kampala
Site Experience With Women in MTN025/HOPE
Joselyne Nabisere (Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration,
Uganda)
P03.13 Does the Use of the Dapivirine Vaginal Ring Result in Change in Risk Sexual Behavior?
Sylvia Kusemererwa (MRC/UVRI Uganda Research Unit on AIDS, Uganda)
P03.15 Intimate Partner Violence and Engagement in the HIV Care Continuum Among Women in sub-
Saharan Africa: A Prospective Cohort Study
Sarah T. Roberts (RTI International, United States)
P03.17 Knowledge and Awareness of Acute HIV Infection Among Patients of Primary Care Clinics in
High HIV Prevalence Neighborhoods of New York City
Javier Lopez-Rios (HIV Center for Clinical and Behavioral Studies, United States)
P03.19 HIV Risk and PrEP Beliefs Among Young Kenyan Women
Maria Pyra (University of Washington, United States)
P03.21 Risk Perceptions Before and After Initiating PrEP Among Young Women in Kenya: A
Qualitative Study
Kenneth Ngure (School of Public Health, Jomo Kenyatta University of Agriculture and Technology,
Kenya)
P03.23 Focusing on the Positive to Stay Negative: Oral Pre-exposure Prophylaxis (PrEP) Uptake,
HIV Risk and Vulnerability Among South African Young Women
Shannon O'Rourke (RTI International, United States)
P03.25 Factors Influencing Antiretroviral Therapy Adherence: Voices of Adolescents in Kenya

Millicent Kiruki (LVCT Health, Kenya)
P03.27 Formative Research to Inform Development of PrEP Services for Chinese MSM
Kathrine Meyers (Aaron Diamond AIDS Research Center, United States)
P03.29 HIV Seroadaptation Increased Over Time in iPrEX OLE

Hong-Ha M. Truong (University of California, San Francisco, United States)
P03.31 Acceptability and Uptake of Oral Pre-exposure Prophylaxis Amongst MSM in the
TRANSFORM Study, Johannesburg
Siyanda Tenza (Wits Reproductive Health and HIV Institute, South Africa)
P03.33 How Well Does the Bandason HIV Risk Screening Tool Perform in the Nigerian Setting?
Findings From a Large-scale Field Implementation
Kunle Kakanfo (Family Health International (FHI 360, Nigeria), Nigeria)
Page 27 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P03.35 Participant Adherence Events: Uptake, Outcomes and Modification in a South African HIV
Prevention Trial
Thando Gwetu (MatCH Research Unit, South Africa)
P03.37 Integrating Clinical Trial Participants From a Discontinued Research Center in South Africa:
Start-up Activities
Thando Gwetu (MatCH Research Unit, South Africa)
P03.39 Challenges Faced by Pregnant and Postnatal Adolescents in Uganda Affecting Uptake of
HIV/STI Prevention Services: Observations From the HI-4-TU Study
Miscah Babirye Otim (MUJHU Research Collaboration / MUJHU Care Ltd, Uganda)
P03.41 Interactions Between Young Female Sex Workers and Paying and Nonpaying Sexual
Partners in Western Kenya: Implications for HIV Prevention Interventions
P03.43 “Stigma Is Killing so Many People”: Barriers to HIV Testing Among HIV-negative Adolescent
Girls and Young Women Around Lake Victoria in Western Kenya
Joanne E. Mantell (ICAP at Columbia University, United States)
P03.45 Factors Associated With Interest in Using PrEP Among Men Who Have Sex With Men (MSM)
Respondents to the Community-based Survey Flash! PrEP in Europe
Daniela Rojas Castro (Coalition PLUS, Community-based Research Laboratory, France)
P03.47 Using Photovoice to Understand the Experience and Realities of Female Sex Workers in the
Context of HIV Self-testing in Blantyre, Malawi
Wezzie Lora (Malawi Liverpool Wellcome Trust-Clinical Research Program, Malawi)
P03.49 The Ice Has Been Broken: PrEP Readiness Among Men Who Have Sex With Men (MSM) in
Ukraine
Iana Sazonova (ICF “Alliance for Public Health”, Ukraine)
P03.51 “You Get HIV Because There is No Hope:” Qualitative Assessment of Transgender Women’s
HIV Vulnerabilities in Three South African Cities
Allanise Cloete (Human Sciences Research Council, South Africa)
P03.53 Acceptability and Feasibility of CHARISMA: Results of a Pilot Study Addressing Relationship
Dynamics, Intimate Partner Violence and Microbicide Use
Elizabeth Montgomery (RTI International, United States)
P03.55 HIV Testing Patterns, Acceptability and Barriers to Use of Oral Pre-exposure Prophylaxis
(PrEP) Among Men Who Have Sex With Men (MSM) in Nairobi, Kenya
Rodah Wanjiru (Partners for Health and Development, Kenya)
P03.57 Impact of Childhood Sexual Abuse Among Sub-Saharan African Men who Have Sex with Men
and Transgender Women in HPTN 075
Yamikani Mbilizi (College of Medicine Johns Hopkins Research Project, Malawi)
P03.59LB The Positive and Negative Impact of PrEP Use on the Sexual Well-being of Men Who Have
Sex With Men (MSM) - Qualitative Results
Hanne Zimmermann (Public Health Service of Amsterdam, Netherlands)
P03.63LB Preventing Intimate Partner Violence Among Women in Mwanza, Tanzania: Findings from
the MAISHA Trial and Implications for HIV Prevention
Shelley Lees (LSHTM, United Kingdom)
Page 28 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P03.65LB CashPlus: Adolescent Health, Livelihood and Well-being Intervention as Part of Tanzania’s
Productive Social Safety Network
Lusajo Kajula (UNICEF Office of Research-Innocenti, Tanzania, United Republic of)
Poster
P06 Community Engagement in Prevention Research

P06.01 Attitudes of Church Leaders on HIV Prevention in Mizoram, Northeast India – a Limited-
resource Setting
Lalchhanhima Ralte (Grace Home, Synod Hospital Durtlang, India)
P06.03 Adjusted Criteria for POC HIV-RNA Testing Improved Detection of Acute HIV Infections
Michael Meulbroek (BCN Checkpoint, Spain)
P06.05 High Study Retention and on Time Visit Attendance in a Simulated HIV Vaccine Efficacy Trial
in High-risk Single Zambian Women
Amanda Tichacek (Emory University, United States)
P06.07 Benefits of Prescreening Workshops on Participants’ Understanding of CHOICE, ADHERENCE

and OPEN REPORTING in MTN-025 Study: Kampala Site Experience
Doreen Kemigisha (MU-JHU Research Collaboration/MU-JHU Care Ltd, Uganda)
P06.09 Need for a Multi-purpose Dapivirine Vaginal Ring to Address Sexual and Reproductive
Health Challenges: Lessons Learnt from South Western Uganda
P06.11 Stakeholder Engagement During a Vaccine Demonstration Project in Nigeria: Lessons on

Implementation of the Good Participatory Practice Guidelines
Morenike Ukpong-Folayan (Obafemi Awolowo University, Nigeria)
P06.13 Motivators for Participation in an Open Label Extension Microbicide Trial in South Western
Uganda
P06.15 Voice and Visibility: What Communities Wish Researchers Knew!

Tian Johnson (Vaccine Advocacy Resource Group, South Africa)
P06.17 Effective Interventions at Community Level Positively Impact Study Retention and Product
Adherence
Petina Musara (UZCHS-CTRC, Zimbabwe)
P06.19 Impact of Good Participatory Practices in Engaging Mobile Fishing Communities in Vaccine
Trials in Entebbe, Uganda
P06.21 Community Engagement in HIV Biomedical Prevention Research: Use of Mobile Technologies
and the Asset Based Community Development Approach
Ethel Makila (IAVI-Nairobi, Kenya)
P06.23 Meaningful Engagement of Religious Leaders in Promoting Uptake of HIV Prevention,

Counselling, Testing and Treatment Services in Kenya
Dismas Oketch (Kenya Medical Research Institute, Kenya)
Page 29 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P06.25 Examining the Relationship Between Multiple Sexual Partners and Adherence to the
Dapivirine Vaginal Ring in a Trial in South Western Uganda
P06.27 Community-led Structural Intervention to Address Multidimensional Vulnerabilities Among

Female Sex Workers in India
Bidhubhusan Mahapatra (Population Council, India)
P06.29LB Good Participatory Practice (GPP) Online Training Course: Evaluations and Progress Over
Four Years
Anne Schley (AVAC: Global Advocacy for HIV Prevention, United States)
Poster
P07 Contraception, Pregnancy and HIV Prevention

P07.01 Cost-effectiveness of Integrated HIV Prevention and Family Planning Services for Zambian
Couples
Alexandra Hoagland (Zambia Emory HIV Research Project (ZEHRP), Zambia)
P07.03 The Effect of Depot Medroxyprogesterone Acetate on Stress Hormone Level: Impact on the
Mucosal Immune Response
Julie Lajoie (University of Manitoba, Canada)
P07.05 HIV-1 Infection Is Modulated by Relative Levels and Cross-talk Between the Progesterone
Receptor and the Glucocorticoid Receptor
Kim Enfield (University of Cape Town, South Africa)
P07.07 Differential Biocharacter and Effects on HIV-1 Infection of Synthetic Progestins via the
Glucocorticoid Receptor Ex Vivo
Maleshigo Komane (University of Cape Town, South Africa)
P07.09 Contraception Use and Pregnancy Incidence in Young African Women Using PrEP
Murugi Micheni (Kenya Medical Research Institute, Kenya)
P07.11 Uptake and Use of Reliable Contraceptives and Correlates of Use in Women Participating in
HIV Efficacy Preparatory Trials in Key Populations in Uganda
Andrew Abaasa (MRC/UVRI, Uganda Research Unit on AIDS, Uganda)
P07.13 Pregnancy Incidence and Outcomes Among Women Using Dapivirine Vaginal Ring for HIV
Prevention in a Phase III Clinical Trial in South Western Uganda
P07.15 Voluntary Medical Male Circumcision Uptake Among M-F+ HIV Serodiscordant Couples
Hanzunga Halumamba (Zambia Emory HIV Research Project, Zambia)
P07.17 TDF/FTC Electrospun Nanofibers for Topical Prevention of HIV Transmission

Sarah Bogas (Centro de Física das Universidades do Minho e Porto (CF-UM-UP), Departamento de Física,
Universidade do Minho, Portugal)
P07.19 Maternal and Infant Outcomes of the World Health Organization Option B+ Strategy
Implementation in the Eastern Cape, South Africa
Oladele Vincent Adeniyi (Walter Sisulu University, South Africa)
Page 30 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P07.21 Acceptance of HIV Self-tests for Male Partners Among Pregnant and Postpartum Women in
Maternal Child Health (MCH) Clinics in Kenya
Jillian Pintye (University of Washington, United States)
Poster
P15 Innate Immunity

P15.01 Immunosuppressive Factors Within Seminal Plasma Muzzle Anti-HIV-1 Immune Responses of
Granulocytes and Monocytes
Kevin John Selva (Peter Doherty Institute for Infection and Immunity, Australia)
P15.03 FREM1 Modulates Pro-inflammatory Responses During Vaginal HIV/SIV Infection via
Association With TLR4
Robert Were Omange (University of Manitoba, Canada)
Poster
P09 Delivery Technologies: Novel Approaches, Formulation and Multi-purpose

P09.01 Exploring the Use of Nano-particulate Zera®-induced HIV-1 Env "Protein Bodies" as
Vaccines
Phindile Ximba (Division of Medical Virology, Department of Pathology, University of Cape Town, South
Africa)
P09.03 Lipid-based Nanocarriers for Antiretroviral Drug Delivery: an HIV Topical Prevention
Strategy
Maria Faria (Centro de Física das Universidades do Minho e Porto (CF-UM-UP), Departamento de Fisica,
Universidade do Minho, Portugal)
P09.05 Impact of Intermittent Use on In Vitro Release and Residual Content of 25 mg Dapivirine
Rings
Clare F. McCoy (Queen's University Belfast, United Kingdom)
P09.07 Impact of Particle Size and Release Testing Media on Release of Dapivirine From a Silicone
Elastomer Vaginal Ring
Diarmaid Murphy (School of Pharmacy, Queen's University Belfast, United Kingdom)
P09.09 Embracing Medidata Rave in the 21st Century: Tips for Successful Implementation
Justine Nakyeyune (Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration,
Uganda)
P09.11 Vectorization of Vaccinal mRNA Encoding HIV Antigen Using Biodegradable Poly (Lactic
Acid) Nanoparticles Targeting Dendritic Cells
Anne-Line Coolen (LBTI, UMR 5305, CNRS/UCBL, France)
P09.13 Formulation Development of a Commingled Dapivirine-DS003 Intravaginal Ring for the

Concurrent Delivery of Two Microbicides
Wendy Blanda (International Partnership for Microbicides, United States)
Page 31 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P09.15 Compatibility Screening for Excipients for Delivery of Dapivirine and DS003 Concurrently
From an Intravaginal Ring
P09.17 The Potential of Saquinavir-loaded Nanoparticles for Rectal Microbicide Development

Avelino Ferreira (i3S - Instituto de Investigação e Inovação em Saúde & INEB - Instituto de Engenharia
Biomédica, Universidade do Porto, Porto, Portugal, Portugal)
P09.19 Density Mediated Drug Release From Dapivirine Vaginal Rings Produced by Additive
Manufacturing
Nicole Welsh (Queen's University Belfast, United Kingdom)
P09.23 End-user Opinions About the Future of HIV Prevention: Results From a Global Internet
Survey About Multipurpose Prevention Technologies (MPTs)
Marlena Plagianos (Population Council, United States)
Poster
P10 Discovery and Evaluation of Biomedical Agents

P10.01 Synthesis of a FITC Conjugated Anti-gp120 Aptamer That Can Be Used as a Reagent for the
Detection of HIV-1 by Flow Cytometry
Kanyane Bridgett Malatji (University of the Witwatersrand, Faculty of Health Sciences, South Africa)
Poster
P11 Epidemiology of HIV

P11.01 Risk Factors for HIV-1 Acquisition Among 18-21 Year Old South African Women Participating
in an HIV Prevention Trial
Jennifer Balkus (University of Washington, United States)
P11.03 What Proportion of Female Sex Workers Practice Anal Intercourse and How Frequently? A
Systematic Review and Meta-analysis
Branwen Nia Owen (Imperial College London, United Kingdom)
P11.05 HIV-1 Recombinant Viruses From West Africa Display Higher Replication Capacity Compared
to Recombinants From East Africa
Omotayo Farinre (HIV Pathogenesis Programme, Nelson Mandela School of Medicine, University of
KwaZulu-Natal, South Africa)
P11.07 Significant Reduction in HIV Prevalence Among Men Who Have Sex With Men. Possible
Effect of Antiretroviral Treatment?
Lucia Guzman (Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, UBA-CONICET, Argentina)
P11.09 Factors Associated With Being a First-time HIV Tester Among Clients of Voluntary
Counselling and Testing Centers in Kilifi County, Kenya, 2006-2017
Peter Mugo (Kemri-Wellcome Trust Research Programme, Kenya)
P11.11 HIV Sero-positivity and Associated Risky Sexual Behaviour Among Male Regular Partners of
Female Sex Workers in a Peri-urban Clinic in Kampala, Uganda
Gertrude Namale (MRC/UVRI & LSHTM Uganda Research Unit, Uganda)
Page 32 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P11.13 Hepatitis B and C Prevalence Among Female Sex Workers in Kigali, Rwanda.
Julien Nyombayire Mutagisha (Projet San Francisco, Rwanda Zambia HIV Research Group, Emory
University, Rwanda)
P11.15 Role of Food Security and Disability on HIV Risk Among Caregivers of Orphaned and
Vulnerable Children in Tanzania
Amon Exavery (Pact/Tanzania, Tanzania, United Republic of)
P11.17 High Chlamydia and Gonorrhea Prevalences and Low Performance of Syndromic
Management Among Brazilian Transwomen
Carolina Caracas (Federal University of the State of Rio de Janeiro, Brazil)
P11.19 APOBEC3G/3H Polymorphism Does Not Influence Progression to AIDS in a Mexican

Population
Francisco Lopez Marquez (University Autonomous of Coahuila, Mexico)
P11.21 Prevention and Treatment: Key Groups and Key Areas in EECA Region
Tetiana Saliuk (Alliance for Public Health, Ukraine)
P11.23 Knowledge and Use of HIV Prevention Strategies for Transwomen (TW) in São Paulo, Brazil
Aline Borges Moreira da Rocha (Santa Casa de São Paulo Medical School, Brazil)
Poster
P12 Ethics in HIV Prevention Research

P12.01 Vaccine Education Session for an Upcoming HIV Vaccine Trial: An Ethical Addition to the
Informed Consent Process
Ana-Maria Visoiu (Zambia Emory HIV Research Project, Rwanda Zambia HIV Research Group, Emory
University, Zambia)
P12.03 Engaging Minors in Nationwide At-home HIV Prevention Research in the U.S.: The UNITE
Cohort Study Challenges and Implications for Future Directions
H. Jonathon Rendina (Hunter College of the City University of New York, United States)
Poster
P13 Immunogenetics (Host Immunity and Restriction Factors)

P13.03 The Generation and Validation of Autologous CD8 and CD4 T Cell Lines for Use as Assay
Controls in HIV Viral Inhibition Assays
Natalia Fernandez (Imperial College London, United Kingdom)
P13.05 CCR5 Expression-related Gene Variants and Natural HIV-1 Control in Black South Africans
Gemma Whitney Koor (University of the Witwatersrand, Faculty of Health Sciences, South Africa)
P13.07 KIR3DL1-/Bw4 CD8 T Cells and NK Cell Activation Control HIV-1 Infection
Bin Su (Beijing You'an Hospital, Capital Medical University, China)
P13.09 SERINC Expression Varies Significantly Within CD4 T Cells and Monocytes Among Healthy
Adults
Syna K Gift (U.S. Military HIV Research Program, United States)
Page 33 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P13.11LB Subtype Differences in Nef-mediated SERINC3/5 Antagonism Across Viral Subtypes

Modulates HIV-1 Infectivity
Steven W. Jin (Simon Fraser University, Canada)
Poster
P16 Mathematical Modeling: Impact and Effectiveness

P16.01 Understanding HIV Transmission Dynamics and the Impact of Past HIV Interventions Among
MSM in Baltimore: A Modelling Study for HPTN 078
Romain Silhol (Imperial College London, United Kingdom)
P16.03 Modeling the Impact of Biomedical Interventions to Break the Cycle of HIV Transmission
Katharine Kripke (Avenir Health, Project SOAR, United States)
P16.05 Modulating Effects of Revaccination Rates and Immune Refractoriness on the Projected
Impact of Future HIV Vaccination in South Africa
Simon de Montigny (University of Montreal, Canada)
P16.07 Deducing Mucosal Pharmacokinetics and Pharmacodynamics for Anti-HIV Molecules From
Measurements in Blood
Sachin Govil (Duke University, United States)
P16.09 Evaluating the Potential Impact and Cost-effectiveness of Dapivirine Ring Pre-exposure
Prophylaxis for HIV Prevention
P16.11 Pooling Strategies as a Cost-effective Solution to Acute HIV-1 Infection Detection in High
Risk, Seronegative Individuals in Lusaka and Ndola, Zambia
Etienne Karita (Project San Francisco, Rwanda)
P16.13 Modeling Probability of Infection and Its Alteration by Microbicides by Integrating HIV
Transport and Infection Dynamics With Drug Transport & Action
Daniel Adrianzen (Duke University, United States)
P16.15 Measles, Mumps and Rubella Vaccination to Reduce the Risk of Measles During HIV Vaccine
Trials
Susan Allen (Rwanda Zambia HIV Research Group-Emory University, United States)
Poster
P17 Microbiome & STI: Impact on Prevention

P17.01 High Level of Macrolide Resistance of Mycoplasma Genitalium Found Among MSM at High
Risk for HIV in a Belgian PrEP Demonstration Project
Irith De Baetselier (Institute of Tropical Medicine, Belgium)
P17.03 Lymphogranuloma Venereum Among MSM Using PrEP in Belgium. Time to Test!
Irith De Baetselier (Institute of Tropical Medicine, Belgium)
Page 34 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P17.05 Preparation of Chlamydia Trachomatis Antigens to Evaluate Inflammatory Responses and

Correlates of Protection That May Influence HIV Risk in Women
Rubina Bunjun (University of Cape Town, South Africa)
P17.07 Development of an In Vivo Model to Study the Impact of the Microbiota on Sexually
Transmitted Infection Control and Immune Responses
Cindy Adapen (CEA-Université Paris Sud-Inserm U1184, Immunology of viral infections and autoimmune
diseases/IDMIT Department/DRF/IBFJ, France)
P17.09 Persistent Increase in the Incidence of STIs and Hepatitis C in MSM in Madrid
Oskar Ayerdi (Centro Sanitario Sandoval, IdISSC, Spain)
P17.11 Pathogen Inhibitory Properties of Vaginal Lactobacillus Isolates From South African Women
at High Risk of HIV Infection
Andrea Gillian Abrahams (Institute of Infectious Disease and Molecular Medicine (IDM), University of
Cape Town, South Africa)
P17.13 Alterations in Key Vaginal Bacteria Among Women Initiating DMPA

Bridget M. Whitney (University of Washington, United States)
P17.15 Hepatitis C Seroconversions in a Sexually Transmitted Infections Clinic in Madrid

P17.17 An Algorithm to Reduce Cost of Chlamydia, Gonorrhea and Trichomoniasis Diagnosis in

Lusaka and Ndola, Zambia: Pooled Testing Using GeneXpert
Constance Himukumbwa (Zambia Emory HIV Research Project, Zambia)
P17.19 BV-associated Bacteria Cause Molecular and Physiological Dysfunction of the Vaginal
Epithelium
Alicia Berard (University of Manitoba, Canada)
Poster
P18 Mucosal Immunology

P18.01 Pre-exposure Prophylaxis Differentially Alters Circulating and Mucosal Immune Cell
Activation in HSV-2 Seropositive Women
Jennifer Lund (Fred Hutchinson Cancer Research Center, United States)
P18.03 The Rectal Mucosal Transcriptome of Transgender Women on Cross-sex Hormone Therapy Is
Distinct From Cisgender Men
Colleen Kelley (Emory University School of Medicine, United States)
P18.05 HIV-1 Specific Mucosal IgA Antibodies Detected in Highly Exposed but Persistently IgG
Seronegative (HEPS) Individuals From Southern India
Kailapuri.G. Murugavel (YRG Centre for AIDS Research and Education, India)
P18.07 Identification of HIV-1 Clade C Transmitted Founder Viruses that Replicate Efficiently in
Human Rectal and Vaginal Tissue Explant Cultures
Robert Langat (IAVI Human Immunology,Imperial College London, United Kingdom)
P18.09 C. trachomatis Infection Results in Elevated HIV Target Cell Densities and Differential
Chemokine Expression Between the Inner and Outer Foreskin
Kyle L. O'Hagan (University of Cape Town, South Africa)
Page 35 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P18.11 Vaccination with ALVAC-HIV/AIDSVAX (R) B/E of Non-human Primates (NHPs) Elicits Distinct
Mucosal and Systemic Responses
P18.13 A Regional Mucosal Immunology Approach to Measuring HIV Susceptibility at Barrier Tissue
Sites
Alison Swaims-Kohlmeier (CDC, United States)
P18.15 MAdCAM Signals Through Integrin-α4β7Inducing Cellular

Activation and HIV Replication
Livia Ramos Goes (National Institutes of Health, National Institute of Allergy and Infectious Diseases,
United States)
P18.17 Collection of Secreted IgG in Rectal Secretions Using OriCol Devices

Julie Czartoski (Fred Hutchinson Cancer Research Center, United States)
P18.19 The Effect of DMPA Use on the Human Cervical Epithelium - Mechanisms Revealed by Image
Analysis
Gabriella Edfeldt (Karolinska Institute, Sweden)
P18.21LB Association of Persistent HPV Infection With Immune Activation in the Anorectal Mucosa
Yoojin Choi (University of Toronto, Canada)
Poster
P19 Novel Vaccine and Prevention Approaches

P19.01 Immune Responses Induced by Live-attenuated Zoster Vaccine in Healthy Kenyan Women:
Setting the Stage for a Potential VZV-based HIV Vaccine
Kelly MacDonald (University of Manitoba, Canada)
P19.03 Efficient Induction of T-cell Responses Against Conserved HIV-1 Regions by Mosaic Vaccines
Delivered as Self-amplifying mRNA
Nathifa Moyo (University of Oxford, United Kingdom)
P19.05 Construction and Characterization of Recombinant MTBVAC.HIV, a New Live Attenuated

Vaccine Against HIV and Tuberculosis
Narcís Saubi (Hospital Clinic de Barcelona-IDIBAPS, Spain)
P19.07 Use of Encapsulated TLR7 Ligand for Increasing Germinal Centers and Enhancing HIV
Humoral Responses
Capucine Phelip (Institut de Biologie et Chimie des Protéines, LBTI, UMR 5305 CNRS/Université de Lyon,
France)
P19.09 Broadly Neutralizing Nanobodies From Env-immunized Dromedaries for Prophylactic

Lactobacillus-based Approaches Against HIV-1
Sarah Kalusche (Georg-Speyer-Haus, Germany)
P19.11 Schistosoma mansoni Eggs in the Absence of Live Worms Suppresses Induction of HIV-1 Env-
specific Antibody Responses
Godfrey Dzhivhuho (University of Cape Town, South Africa)
Page 36 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P19.13 DNA and MVA Vaccines Expressing HIV-1 Virus-like Particles Presenting Modified HIV-1 Env
Generate Tier 2 Autologous Neutralising Antibodies
Michiel T. van Diepen (University of Cape Town, Institute of Infectious Disease and Molecular Medicine,
South Africa)
P19.15 Cervicovaginal Inflammatory Cytokine and Chemokine Responses to Two Different SIV
Vaccines in Mauritian Cynomolgus Macaques
Nikki P. L. Toledo (University of Manitoba, Canada)
P19.17 Novel Trimeric HIV-1 Clade C Envelope Vaccine Candidates Exhibit Increased Stability and
Optimal Antigenic Properties In Vitro and In Vivo
Alexandra Hauser (University of Regensburg, Institute of Medical Microbiology and Hygiene, Germany)
P19.19 A Novel Immunogen Selectively Eliciting CD8+ T Cells but Not CD4+ T Cells Targeting Viral
Antigens
Tetsuro Matano (National Institute of Infectious Diseases, Japan)
P19.21 A Clade C Env Obtained From an Elite Neutralizer Induced Potent Autologous Neutralizing
Antibodies Similar to that Elicited in Natural Infection
Rajesh Kumar (Translational Health Science and Technology Institute, India)
P19.23 In Vitro Evaluation of Self-amplifying Alphavirus Replicons Delivered as DNA or RNA

Expressing HIVgp140 as Potential RNA Based Vaccine Candidates
Manel Enric Bargallo Mares (AIDS Research Unit, IDIBAPS, Spain)
P19.25 HIV Neutralizing Antibodies Induced by Native-like Envelope Trimers Incorporated Into a
Rhabdoviral Vector Vaccine
Janine Kimpel (Medical University of Innsbruck, Austria)
P19.27 Mumps and PIV5 Pseudotyped Virus-like Particles for HIV-1 Env Trimer Display
Yoann Aldon (Imperial College London, United Kingdom)
P19.29 Novel gp41 W614A-3S Peptide-conjugated Adjuvanted Vaccine Promote T Follicular Helper
Cells for Broadly Neutralizing Antibodies Against HIV-1
Behazine Combadière (CIMI-Paris, France)
P19.31 Cross-reactivity Between HIV-1 bNAbs and Parasite Glycans

Isabella Huettner (King's College London, United Kingdom)
P19.33 Immunogenicity of HIV-1 gp120 DNA Prime and Env gp145 Protein Boost Vaccine Regimen in
Combination With Novel Adjuvants
Poonam Pegu (U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement
of Military Medicine, United States)
P19.35 A New Envelope Based Antigen Forming Soluble Hexamers Triggers Potent Humoral
Responses Against HIV-1
Suresh Chithathur Raman (Centro Nacional de Biotecnología, Spain)
P19.37 An Escape Mutation in the V2 Region of the HIV Envelope Protein of a T/F Virus Guides
Vaccine Design to Elicit Broadly Reactive V2-directed Antibodies
Swati Jain (The Catholic University of America, United States)
P19.39 Sequential Immunization Strategies to Elicit HIV-1 bNAbs in Animal Models With a
Polyclonal B Cell Repertoire
Page 37 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P19.41 Structural Basis for Neutralization of Diverse HIV-1 Strains by Antibodies Elicited From
Fusion Peptide Immunizations in Rhesus Macaques
Yiran Wang (National Institute of Allergy and Infectious Diseases, United States)
P19.43LB Development and Pre-clinical Immunogenicity of a Formulated saRNA Replicon Vaccine

Expressing Designed Native-like ConSOSL.UFO HIV Env Glycoproteins
Paul F McKay (Imperial College London, United Kingdom)
P19.45LB Comparison of Monoclonal Antibodies Induced by BG505 SOSIP Trimer Immunization and
BG505 SHIV Infection in Non-human Primates
Jelle van Schooten (Amsterdam University Medical Center, University of Amsterdam, Netherlands)
P19.47LB Structure and Immunogenicity of a Stabilized HIV-1 Envelope Trimer Based on a Group M
Consensus Sequence
Kwinten Sliepen (Amsterdam UMC, Netherlands)
P19.49LB Development of a Point of Care Urine Tenofovir Test - A PrEP and ART Adherence Tool
Giffin Daughtridge (Perelman School of Medicine, United States)
P19.51LB Sequential Immunization With Different Repaired and Stabilized HIV-1 Envelope Trimers
Induces Broad Tier2 Neutralization in Rabbits
Johannes Langedijk (Janssen Vaccines & Prevention, Netherlands)
Poster
P20 Passive Immunization

P20.01 An Additional Late Boost of AIDSVAX B/E in RV144 Participants Induced Plasma HIV Env-
specific IgG4 and IgG1 With Enhanced Durability
Siriwat Akapirat (Armed Forces Research Institute of Medical Sciences, Thailand)
P20.03 Limited Impact of Fc-dependent Functions on the Efficacy of the Anti-HIV-1 Broadly
Neutralizing Antibody PGT121 in Macaques
Stephen Kent (University of Melbourne, Australia)
P20.05LB Rectal Biopsies From Men and Women Infused Intravenously With VRC01 mAb Show Partial
Protection That Wanes Over Time in Ex Vivo HIV-1 Challenges
Maria P. Lemos (Fred Hutchinson Cancer Research Center, United States)
Poster
P21 Pharmacology/PK and PD Studies

P21.01 Tenofovir-diphosphate as a Marker of PrEP Use Among East African Men and Women
Maria Pyra (University of Washington, United States)
P21.03 Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir: Increased

Tenofovir Diphosphate in Depot Medroxyprogesterone Acetate Users
P21.05 Pharmacokinetics of Dapivirine Vaginal Ring During Ring Removals and Re-insertions
Neliette Van Niekerk (International Partnership for Microbicides, South Africa)
Page 38 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Poster
P22 Phylogenetics and Viral Diversity

P22.01 Prediction of VRC01 Neutralization Sensitivity by HIV-1 gp160 Sequence Features
Craig A. Magaret (Fred Hutchinson Cancer Research Center, United States)
P22.03 Characterization of HIV-1 Envelope Genes in a Long-term Nonprogressor With Broadly

Neutralizing Activity
Kunxue Hong (National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control
and Prevention, China)
P22.05LB Recent HIV Infection Is a Major Driver of Incident Cluster Growth

Susan Little (University of California, San Diego, United States)
Poster
P23 Policy and Advocacy

P23.01 Policy Recommendation for First-line DTG-based ART in PrEP Seroconverters
Lisa Levy (FHI 360, United States)
P23.03 Engaging Youth to Achieve the 90-90-90 Goal in Uganda Through Community Outreach
Programs: A Young Generation Alive (YGA) Innovation
Stella Nanyonga (Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration,
Uganda)
P23.05 Reservations About and Opportunities for PrEP Introduction: Perspectives of Policymakers
in Tanzania
Nanlesta Pilgrim (Population Council, United States)
P23.07LB Tracking the Impact of the Expanded Mexico City Policy on PEPFAR Implementing Partners
Jennifer Sherwood (amfAR, The Foundation for AIDS Research, United States)
Poster
P24 Pre-clinical Studies for HIV Prevention

P24.01 Comparison of Dissolution Testing Methods for the 25 mg Dapivirine Vaginal Ring
Karl Malcolm (Queen's University Belfast, United Kingdom)
P24.03 The CAVD DataSpace Data Sharing and Discovery Tool Facilitates HIV Immunological Data
Exploration From Pre-clinical and Clinical HIV Vaccine Studies
Bryan Mayer (Fred Hutchinson Cancer Research Center, United States)
P24.05 HIV Env Antibody Can Provide Sterilizing Immunity in the Strictest Sense
Klaus Überla (Universitätsklinikum Erlangen, Germany)
P24.07 Efficacy of a Trimeric Envelope Protein Vaccine From an Indian Clade C HIV-1 Isolate Against
Heterologous Clade C SHIV Isolate Challenges in Macaques
Ranajit Pal (Advanced BioScience Laboratories, Inc., United States)
Page 39 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P24.09 Vaccine that Targets In Vivo HIV-1 Env to Human CD40-expressing Antigen-presenting Cells
Elicits Env-specific IgG+ B Cells and Memory Tfh Cells
Veronique Godot (Université Paris-Est-Créteil, France)
P24.11 Reversible Modulation of the Endocannabinoid System as an Anti-HIV-1 Prevention Strategy

P24.13 Sheep Genital Outcomes After Use of Chemical Irritants: Positive Control for Toxicity
Studies
Kathleen Vincent (University of Texas Medical Branch, United States)
P24.15 Heterologous Combination of VSV and NYVAC Vectors Expressing Trimeric HIV Env Elicits
Higher T and B Cell Responses Compared With Homologous Regimen
Beatriz Perdiguero (Centro Nacional de Biotecnología (CNB-CSIC), Spain)
P24.17 In Vitro-In Vivo and In Vivo-In Vivo Correlations of TAF Release From a Novel Subdermal
Implant
John Moss (Oak Crest Institute of Science, United States)
P24.19 Development of an Extended Release MK-2048 Vaginal Film

Lisa Rohan (University of Pittsburgh, United States)
P24.21 Post-exposure Prophylaxis with Single Doses of Combination EVG/COBI/FTC/TAF Protect

Macaques Against Rectal SHIV Infection
Ivana Massud (Centers for Disease Control and Prevention, United States)
P24.25LB G2-S16 Dendrimer as a New Innovative a Promising Drug Close to a Clinical Trial
Mª Ángeles Muñoz-Fernández (Hospital General Universitario Gregorio Marañon, Sección Immunología,
Laboratorio InmunoBiología Molecular, IiSGM, CIBER-BBN and Spanish HIV-HGM BioBank, Spain)
P24.27LB Novel Protocol to Compare PrEP Drugs, Dosing and Schedule Using Ex Vivo Challenge on
Resected Foreskin Tissue: Protocol for the CHAPS RCT
Poster
P25 Product Acceptability and Adherence

P25.01 PrEP “Can Make You Have Peace”: Perspectives on PrEP Among Young Female Sex Workers
and Their Male Clients in Kisumu, Kenya
P25.03 From Theory to Practice: Implementation of Client Centered Adherence Counselling at the
Kampala Site for the HOPE Study
Aisha Zalwango Sesaazi (MUJHU Care Ltd / MUJHU Research Collaboration, Uganda)
P25.05 Interviewer Adjustment of Smart Pillbox Monitoring Did Not Improve Accuracy in Measuring
Oral PrEP Adherence in HPTN 067
Bonnie J. Dye (FHI 360, United States)
P25.07 Interest in Long-acting Injectable PrEP by One’s History of Oral PrEP Use Among Men Who
Have Sex with Men in Washington, DC
Matthew Levy (George Washington University Milken Institute School of Public Health, United States)
Page 40 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P25.09 PrEP Access and Adherence: Identifying Barriers and Assessing the Utility of Tenofovir Urine
Testing
Travis Hunt (Thomas Jefferson University, United States)
P25.11 Anonymous Internet-aided Urine-based HIV Testing Service for the Patients in Sexually
Transmitted Diseases Clinics and Their Sexual Partners
Xianlong Ren (Beijing Center for Diseases Prevention and Control, China)
P25.13 Acceptance and Adherence to a Vaccination Schedule in a SiVET Among Adults in Fishing
Communities of Lake Victoria, Uganda
Ali Ssetaala (UVRI-IAVI HIV Vaccine Program, Uganda)
P25.15 Adherence and Acceptability of Rectal Microbicides: A Synthesis Review

Omar Bruce (University of Pennsylvania, United States)
P25.17 Challenges With Oral Pre-exposure Prophylaxis (PrEP) Disclosure Among Adolescent Girls
and Young Women (AGYW) in Kenya and South Africa
P25.19 Factors Associated With PrEP Discontinuation Among Men Who Have Sex With Men in
Washington, DC
Anya Agopian (George Washington University Milken Institute of Public Health, United States)
P25.21LB One Year Retention in PrEP Care Outcomes in a Three-site Implementation Science Program
in the United States
Amy Nunn (Brown University School of Public Health, United States)
P25.23LB Quo Vadis HIV Prevention? Marketing Research on the Acceptance of Long-acting PrEP
Among Men Having Sex With Men and Medical Practitioners in the U.S.
Ewa Bryndza Tfaily (Northwestern University Feinberg School of Medicine, United States)
Poster
P26 Systems Immunobiology Approaches & Sequencing Technologies

P26.01 Classification of HIV Controllers in an Acute Infection Cohort to Enable Systems
Investigation of Signatures Associated With Control of Infection
Julia Makinde (Imperial College London, United Kingdom)
P26.03 Systems Analysis of the Innate and Adaptive Immune Responses to the RV144 ALVAC HIV
Vaccine in a South African HIV Uninfected Cohort
Lamar Fleming (Fred Hutchinson Cancer Research Center, United States)
Poster
P27 Therapeutic Vaccine, Viral Latency and Cure

P27.01 Combinations of Maraviroc With Other Latency Reversing Drugs to Reactivate Latent HIV-1
María Rosa López Huertas (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital
Universitario Ramón y Cajal, Spain)
Page 41 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P27.03 Selective miRNAs Inhibition Fails to Activate HIV-1 Replication in In Vitro Latency Models
María Rosa López Huertas (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital
Universitario Ramón y Cajal, Spain)
P27.05 Tandem Bispecific Neutralizing Antibodies Inhibit HIV-1 Infection in Humanized Mice
Mengyue Niu (AIDS Institute and Department of Microbiology, State Key Laboratory of Emerging
Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong)
P27.07 Impact of HCV Coinfection in the Splicing of HIV Proviral DNA

Paula Martínez-Román (Institute of Health Carlos III, National Center of Microbiology, Spain)
P27.09 Vedolizumab-mediated Integrin α4β7 Blockade Enhances HIV-1 SF162 Rebound Following
cART Interruption in Humanized Mice
Lijun Ling (The University of Hong Kong, Hong Kong)
P27.11 HIV-1 Reservoirs Form in Urethral Tissue Macrophages of Patients Under Antiretroviral
Therapy
Morgane Bomsel (Institut Cochin CNRS UMR8104, France)
P27.13 Unique and Expanded Breadth Estimate of CD8 T-cell Responses to Cohort-specific HIV-1
GAG Protein Peptides
Clive Michelo (Zambia Emory HIV Research Project, Zambia)
P27.15LB Mapping Acute Viral Dynamics and Rebound Post ART Interruption in SIV Infected Macaques
Using Total Body ImmunoPET/CT
Mariluz Arainga (University of Louisiana at Lafayette, United States)
Poster
P28 Transmission of HIV

P28.01 Past or Active Schistosome Infection Is Associated With Incident HIV Transmission and
Disease Progression Risk in Men and Women, Zambia
Susan Allen (Rwanda Zambia HIV Research Group-Emory University, United States)
P28.03 Biological Properties of Envelope Glycoproteins for Early and Late HIV-1 Variants Issued
From a Same Transmission Cluster
Maxime Beretta (INSERM U1259, France)
P28.05 Near Full-length Genome Characterization of HIV-1 Subtypes Among Drug Users in Kenya
Thando Zulu (University of KwaZulu-Natal, South Africa)
P28.07 Characterizing Env-specific Monoclonal Antibodies Isolated From U.S. and Malawian HIV-
infected Non-transmitting and Transmitting Women
David R. Martinez (Duke Human Vaccine Institute, United States)
P28.09 Per Act HIV Transmission Risk Through Anal Intercourse: An Updated Systematic Review
and Meta-analysis
Marie-Claude Boily (Imperial College, United Kingdom)
P28.11 Transmission of Unique Intersubtype HIV-1 Recombinants Predominate in Both Single and
Multiple Variant Infections in Uganda
Sheila Nina Balinda (MRC/UVRI & LSHTM Uganda Research Unit, Uganda)
Page 42 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P28.13 Comparison of Genetic Sequences From Donor and Recipient Viruses From Linked Subtype A
Transmission Pairs
Samantha McInally (Emory University, United States)
P28.15 Receptive Anal Intercourse as a Risk Factor of HIV Infection in Women: A Systematic Review
and Meta-analysis
James Stannah (Imperial College London, United Kingdom)
P28.17 Seminal Plasma Enhances SIV Replication in Macaque Colorectal Tissue Explants and
Induces Intraepithelial Recruitment of Antigen Presenting Cells
Mariangela Cavarelli (CEA, France)
P28.19 Pretreatment With an Anti-MAdCAM mAb Increases the Susceptibility of Macaques to

Mucosal Challenge by SIV
Claudia Cicala (National Institute of Allergy and Infectious Diseases, NIH, United States)
P28.21LB Back to the Future: Even in the ART Era, Men Co-infected With HIV and Urethritis Pose a
Potential Transmission Threat
Jane S. Chen (University of North Carolina at Chapel Hill, United States)
P28.23LB Test and Treat in Malawi: HIV Seminal Viral Load Response to ART Initiation Among Men Co-
infected With Urethritis
Mitch Matoga (University of North Carolina Project Lilongwe, Malawi)
P28.25LB Circumcision Increases the Barrier Function of the Glans Epithelium

Gianguido C. Cianci (Feinberg School of Medicine, Northwestern University, United States)
P28.27LB Enhanced Selection for HIV-1 Transmitted/Founder Viruses in BLT Humanized Mice
Following Intravaginal Exposure
Daniel Claiborne (Ragon Institute of MGH, MIT and Harvard, United States)
Poster
P29 Treatment as Prevention

P29.01 Protection Efficacy of the Virucidal Small Peptide C5A Against Vaginal and Rectal HIV
Challenges in Humanized Mice
Philippe Gallay (The Scripps Research Institute, United States)
P29.03 Evaluating Psycho-social Support in Improving Adherence Among HIV-positive Adolescents

Aged 10-19 Years at Gertrude´s Children´s Hospital, Nairobi
Kevin Munene Njue (Gertrude's Children's Hospital, Kenya)
P29.05 Treatment as Prevention and Viral Response in a Cohort of Female Sex Workers in Cotonou,
Benin
Mamadou Diallo (Université Laval, Canada)
P29.07 Real-time Antiretroviral Adherence Monitoring Intervention in Young African American Men
Who Have Sex With Men: Acceptability and Monitoring Results
Mark Dworkin (University of Illinois at Chicago, United States)
P29.09 Test and Treat Care Cascade in General and Key Populations in Coastal Kenya
Elizabeth Wahome (KEMRI-Wellcome Trust Research Programme Centre for Geographic Medicine
Research, Kenya)
Page 43 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P29.11 Late Entry Into HIV Care Is a Threat to Treatment-as-prevention in Ho Chi Minh City,
Vietnam
Thuy Dao (Hanoi Medical University, Viet Nam)
P29.13LB Hypo-osmolar Rectal Douche Delivers Tenofovir to the Rectal Mucosa and Effectively
Protects Macaques Against Repeated SHIV Challenges
Francois Villinger (University of Louisiana at Lafayette, United States)
Poster
P05 Clinical Trial Results

P05.01 Finding MSM who may be Potential Amplified HIV Transmitters: Results from HPTN 078
Theresa Gamble (FHI 360, United States)
P05.03 Characteristics of Women Who Enrolled Into an Open Label Extension Trial of the Dapivirine
Intravaginal Ring for HIV-1 Prevention
Nyaradzo Mgodi (University of Zimbabwe Collaborative Research Program, Zimbabwe)
P05.05 Final Report of ANRS COV1-COHVAC Cohort of Healthy Volunteers From Preventive HIV-1
Vaccine Trials
Christine Durier (INSERM US19, France)
P05.07 HIV Vaccine Trials in Uganda: Barriers and Facilitators

Violet Mirembe (UVRI-IAVI HIV Vaccine Program, Uganda)
P05.09 Potential Causes for Decreased Enrollment of Acutely Infected Participants in the ASPIRE
Trial Compared to VOICE
Edward Livant (Magee-Womens Research Institute, United States)
P05.11 A Phase 1 Trial of AAV1 Vectored Immunoprophylaxis for HIV

Huub C Gelderblom (International AIDS Vaccine Initiative, United States)
P05.13LB HIV, ART, Vedolizumab and Analytical Treatment Interruption (ATI): Rebound Viremia
Kinetics in the Dose-ranging HAVARTI Trial
Michaeline McGuinty (University of Ottawa at The Ottawa Hospital Research Institute, Canada)
P05.15LB Vaccine-induced Seropositivity in Participants of the APPROACH Study (HIV-V-A004)

L. Lavreys (Janssen Pharmaceutica NV, Belgium)
P05.17LB Retention in the Ongoing AMP Trials of VRC01, a Broadly Neutralizing Antibody (bnAb) to
Prevent HIV in Women, MSM & Transgender (TG) People
Philip Andrew (FHI 360, HIV Prevention Trials Network, United States)
P05.19LB Griffithsin Administered Vaginally for 14 Days Is Well-tolerated, With Anti-HIV Activity Up to
8 Hours Post Dose in the First-in-human Trial
Barbara Friedland (Population Council, United States)
Poster
P08 Correlates of Protection and Exposure
Page 44 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P08.01 Older Age at Infection and Nulliparity Are Associated with Long-term Non-progression in
Female Sex Workers Infected with Non-Subtype B HIV-1
Vernon Mochache (National AIDS Control Council, Kenya)
P08.03 Prevalence and Predictors of Violence Against Female Sex Workers in Rwanda
Kalonde Malama (Aix-Marseille University, France)
P08.05 Female Sex Workers in Kigali, Rwanda: A Key Population at Risk of HIV, Sexually
Transmitted Infections and Unplanned Pregnancy
Rosine Ingabire (Project San Francisco, Rwanda)
P08.07 Estrogen, Progesterone and Sex-hormone Binding Globulin in Association With Innate
Immunity Correlates of HIV Risk and Protection
Raina Fichorova (Brigham and Women's Hospital, Harvard Medical School, United States)
Poster
P14 Implementation Science, Including Structural Interventions, PrEP & VMMC

P14.01 Online Survey about Reasons for Stopping PrEP is an Opportunity to Re-engage Inactive
PrEP Clients
Chelsea Shover (University of California, Los Angeles, United States)
P14.03 Acceptability of Infant Circumcision Among Traditionally Circumcising Communities in

Kenya: Views of Traditional Circumcisers and Councils of Elders
P14.05 Adherence to Daily Antiretroviral Pre-exposure Prophylaxis Among Heterosexual

Serodiscordant Partners in the Nigeria PrEP Demonstration Project
Nancin Dadem (Jos University Teaching Hospital, Nigeria)
P14.07 Ensuring Potential Volunteers Are the “Right Fit” for Study Participation: Insights From the
CAPRISA eThekwini Clinical Research Site
Kalendri Naidoo (CAPRISA, South Africa)
P14.09 Correlates of Retention in Care Among HIV Infected Adolescents and Young Adults Enrolled
in an HIV Program in Kenya
Lawrence Mwihaki (Christian Health Association of Kenya (CHAK), Kenya)
P14.11 Correlates of Attrition Among MSM Followed in a HIV-1 Vaccine Feasibility Cohort Study in
Kenya
Elizabeth Wahome (KEMRI-Wellcome Trust Research Programme Centre for Geographic Medicine
Research, Kenya)
P14.13 Fidelity Monitoring to Ensure Accurate Implementation of an Evidence-based Adherence

Counseling Intervention in MTN-025 (the HOPE Study)
Iván Balán (New York State Psychiatric Institute and Columbia University, United States)
P14.15 Frontline PrEP Champions Accelerating Effective Integration of PrEP Delivery for HIV
Serodiscordant Couples in Public Health Facilities in Kenya
Kenneth Mugwanya (University of Washington, United States)
P14.17 Enhanced Adherence Counseling 1, 2, 3: Our Success Story in Achieving Viral Suppression in
HIV Positive Key Population Clients
Maureen Akolo (Kenya AIDS Control Program, Kenya)
Page 45 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P14.19 PrEP Implementation: Retention Challenges Among Female Sex Workers in Nairobi, Kenya
Maureen Akolo (Kenya AIDS Control Program, Kenya)
P14.21 Experiences from PrEP Rollout Among HIV-1 Serodiscordant Couples in Western Kenya
Josephine Odoyo (Kenya Medical Research Institute, Kenya)
P14.23 Association Between Intimate Partner Violence and Uptake of HIV Pre-exposure Prophylaxis
(PrEP) Among Adolescent Girls and Young Women (AGYW) in Kenya
Lina Digolo (LVCT Health, Kenya)
P14.25 Understanding Service Providers’ Knowledge of Oral PrEP and Attitudes Toward Provision to
Populations at Substantial HIV Risk in South Africa
Mercy Murire (Wits Reproductive Health & HIV Institute, South Africa)
P14.27 Health Care Providers’ Knowledge, Attitudes and Practices Towards Provision of PrEP to
Adolescent Girls and Young Women in Kenya: A Descriptive Study
Maryline Mireku (LVCT Health, Kenya)
P14.29 Perspectives of Young Men Who Have Sex With Men on Peer Navigation to Improve
Adherence to PrEP
P14.31 PrEP Delivery Platforms: Are Family Planning Clinics an Option?

Victor Omollo (Kenya Medical Research Institute, Kenya)
P14.33 Measuring HEART: Validity of a HEAlthy Relationships Assessment Tool to Guide Tailored
Counseling in the CHARISMA Pilot Study
Elizabeth (Betsy) Tolley (FHI 360, United States)
P14.35 Low Costs and Opportunities for Efficiency in the First Year of Programmatic PrEP Delivery
in Kenya’s Public Sector
Kathryn Peebles (University of Washington, United States)
P14.37 Increasing Uptake of Pre-exposure Prophylaxis (PrEP) in Cleveland, Ohio, Through

Community- and Provider-focused Interventions
Rustin Zomorodi (Case Western Reserve University, United States)
P14.39 Platforms, Processes and Perceptions of PrEP Delivery Through DREAMS in a Rural Setting
in KwaZulu-Natal, South Africa
Natsayi Chimbindi (Africa Health Research Institute (AHRI), South Africa)
P14.41 How Do We Roll Out PrEP for Adolescent Girls and Young Women (AGYW)? Hearing From
AGYW, Male Partners, Parents, Healthcare Providers and Policymakers
P14.43 Differences by Wave of Respondent-driven Sampling Recruitment Among Gay Men and
Other Men Who Have Sex With Men in 4 U.S. Cities: Results From HPTN 078
Stefan Baral (Johns Hopkins, United States)
P14.45 How Can Men’s Perceptions of PrEP and ART in Lesotho Help Inform Strategies for
Promoting Adherence?
Mathabang Mokoena (JHPIEGO, Lesotho)
P14.47 Attitudes and Knowledge About HIV PrEP Among Infectious Diseases Physicians in Brazil
Natalia Cerqueira (University of Sao Paulo, Brazil)
Page 46 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P14.49 Willingness to Pay and Actual Costs for HIV Pre-exposure Prophylaxis Users in the United
States Private Health System
P14.51LB A Descriptive Analysis of Calls and Text Messaging Communication Between Participants
and Health Care Providers
Harriet Fridah Adhiambo (Kenya Medical Research Institute, Kenya)
P14.53LB Attitudes in Assessing Patients for Pre-exposure Prophylaxis Among Pediatric and Internal
Medicine Residents Training in New York City
Jeremy A.W. Gold (Columbia University Irving Medical Center, United States)
P14.55LB Benefits of Girl-only Club Participation on HIV Risk Reduction: Experiences of Very Young
Out of School Adolescent Girls Aged 10-14 in Rural Malawi
Wanangwa Chimwaza (University of Malawi, Malawi)
P14.57LB Pre-exposure Prophylaxis (PrEP) Uptake Among Predominantly Black and Latina Women at
Risk for HIV Acquisition in New York
Deborah A. Theodore (Columbia University Medical Center, United States)
Poster
Poster Session 01
Odd-numbered abstracts will be presented in Poster Session 01 on Tuesday, 23 October. Even-numbered abstracts
will be presented in Poster Session 02 on Wednesday, 24 October.
Page 47 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Wednesday, 24 October 2018
Plenary
PL03 The Future is Now: Next Steps in Developing New Prevention Options
Plenary 3 answers the question, “What’s new in prevention?” with a look at systemic and topical agents in
development, new approaches to vaccines and new methods of delivery that could transform the future of HIV
prevention.
Chairs:
Julia del Amo (Institutode Salud Carlos III, Spain)
Ian McGowan (Orion Biotechnology, Spain)
PL03.01 Beyond TDF/FTC: The Future of Systemic Pre-exposure Prophylaxis 08:30 - 09:00
States)
PL03.02 On-demand Topical Agents for HIV Pre-exposure Prophylaxis 09:00 - 09:30
Craig Hendrix (Johns Hopkins University, United States)
PL03.03 Vaccine Design 2.0: The Pipeline Novel HIV-1 Envelope Proteins to Induce 09:30 - 10:00
Neutralizing Antibodies
Rogier Sanders (Amsterdam University Medical Centers (Amsterdam UMC),
University of Amsterdam, Netherlands)
Oral
10:30 - 12:00 Londres
OA09 Translating Immunity From Pre-clinical Animal Models to Humans

Chairs:
OA09.01 Co-crystal Structure of SIVmac239 gp120 with rhCD4 and Neutralizing 10:30 - 10:45
Antibody ITS90.03 Reveals Similar Sites of Vulnerability Between HIV-1
and SIV Env
Jason Gorman (NIH/NIAID/VRC, United States)
OA09.02 Native HIV-1 Env Circulating During the Development of Breadth in 10:45 - 11:00
Human Subjects Elicits Tier 2 Heterologous Neutralizing Monoclonal
Antibodies in NHP
OA09.03 Macaque SHIV Induction of 2G12-like Broadly Neutralizing Antibodies 11:00 - 11:15
Wilton Bryan Williams (Duke University, United States)
OA09.04 Tight Control of SHIV BaL.P4 Challenge in Rhesus Macaques Co- 11:15 - 11:30
immunized With DNA and Protein HIV Vaccine Regimen
Miroslaw K. Gorny (New York University School of Medicine, Department of
Pathology, United States)
Page 48 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA09.05 Tracking Cy5‐conjugated VRC01 Following IV Injection in the Rhesus 11:30 - 11:45
Macaque Reveals That Tissue Distribution Can Take 1 Week to Achieve
Steady State
Jeffrey Schneider (Northwestern University, United States)
OA09.06LB A Meta-analysis to Evaluate the Relationship Between Serum Antibody 11:45 - 12:00
Neutralizing Titer and Protection Against SHIV Challenge in Nonhuman
Primates
Ying Huang (Fred Hutchinson Cancer Research Center, United States)
Oral
10:30 - 12:00 Bristol
OA10 Key to the Response: Populations, Partners and Prevention

Chairs:
Valdilea Veloso (Fundação Oswaldo Cruz, Brazil)
OA10.01 Male Partners of Adolescent Girls and Young Women (AGYW) in Durban, 10:30 - 10:45
South Africa: How High Is Their HIV Risk and What Groups Are Most at
Risk?
Julie Pulerwitz (Population Council, United States)
OA10.02 Help-seeking Behavior of Women Reporting Intimate Partner Violence in 10:45 - 11:00
Mwanza, Tanzania, and Its Implications for HIV: Findings From the
MAISHA Study
Sheila Harvey (London School of Hygiene & Tropical Medicine, United Kingdom)
OA10.03 Undercurrents of Sex Work: Characteristics and Experiences of Female 11:00 - 11:15
Sex Workers in Kisumu, Kenya
OA10.04LB HIV Incidence Among Men Who Have Sex With Men and Transgender 11:15 - 11:30
Women in Sub-Saharan Africa: Findings From the Multi-country HPTN 075
Cohort Study
Theo G.M. Sandfort (New York State Psychiatric Institute, United States)
OA10.05 Young Transwomen in Brazil Have High HIV Risk and Low Prevention Use 11:30 - 11:45
Erin C Wilson (San Francisco Department of Public Health, United States)
OA10.06 An Integrated Intervention to Increase ART and MAT Reduces Mortality 11:45 - 12:00
Among PWID: Results From the HPTN 074 Randomized Trial
Kostyantyn Dumchev (Ukrainian Institute on Public Health Policy, Ukraine)
Oral
10:30 - 12:00 Oxford
OA11 Novel Vaccine Strategies

Chairs:
Yoann Aldon (Imperial College London, United Kingdom)
Susan Barnett (Bill and Melinda Gates Foundation, United States)
Page 49 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA11.01 Combined Skin and Muscle DNA Priming Provides Enhanced Humoral 10:30 - 10:45
Responses to an HIV-1 Clade C Envelope Vaccine
Robin Shattock (Imperial College, United Kingdom)
OA11.02 Fusion Peptide-directed Antibodies Elicited in Immunized Rhesus 10:45 - 11:00

Macaques Neutralized 59% of 208 Wildtype HIV-1 Strains
Rui Kong (Vaccine Research Center, NIAID, NIH, United States)
OA11.03 Vaccination of Rabbits and Macaques With V1V2-scaffold Immunogens 11:00 - 11:15
Induces V1V2-specific Antibody Responses With Antiviral Functions
Svenja Weiss (Icahn School of Medicine at Mount Sinai, United States)
OA11.04 Immune Control of SHIV Infection in Rhesus Macaques by PD-1-based 11:15 - 11:30
Vaccine
Yik Chun Wong (AIDS Institute, The University of Hong Kong, Hong Kong)
OA11.05 Vaccine-elicited Cross-neutralizing HIV Antibodies (bNAbs) to Two Env 11:30 - 11:45
Sites of Vulnerability Following Heterologous NFL Trimer Liposome
Prime: Boosting
Richard Wyatt (IAVI Neutralizing Antibody Center at Scripps, United States)
OA11.06LB Immune Responses to PENNVAX-GP (R) HIV DNA Vaccine Plus IL-12 Are 11:45 - 12:00
Equivalent or Superior When Delivered by Intradermal vs. Intramuscular
Electroporation
Srilatha Edupuganti (Emory University, United States)
Symposium
SY11 ARVs for Prevention in Women of Childbearing Age

Chairs:
Gita Ramjee (South African Medical Research Council, South Africa)
SY11.01 No Woman Left Behind: An Ethical Framework for Prevention Studies in 10:30 - 10:52
Reproductive Age Women
Annie Lyerly (University of North Carolina, United States)
SY11.02 Efavirenz and Dolutegravir: A Tale of Two ARVs 10:52 - 11:14

Elaine Abrams (Columbia University, United States)
SY11.03 Studying Periconception Outcomes in Women on ARVs in Brazil 11:14 - 11:36

Adele Benzaken (Ministry of Health, Brazil, Brazil)
SY11.04 Striking a Balance 11:36 - 11:58

Page 50 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018


Daily meet the experts lunches provide early-career investigators and community advocates with valuable
opportunities for informal, in-depth exchange with experts representing a cross-section of research issues,
implementation challenges, and HIV-affected communities.
Chairs:
Elaine Abrams (Columbia University, United States)
Rama Amara (Emory University, United States)
Adele Benzaken (Ministry of Health, Brazil, Brazil)
Martha Brady (PATH, United States)
Wendy Burgers (Institute of Infectious Disease and Molecular Medicine, UCT, South Africa)
Mary Carrington (Frederick National Laboratory for Cancer Research, United States)
Alex Coutinho (Partners in Health, Rwanda)
Anthony Cunningham (The Westmead Institute, The University of Sydney, Australia)
Maria del Rosario Leon (Impacta Salud y Educacion, Peru)
Sarit Golub (Hunter College, United States)
Renee Heffron (University of Washington, United States)
Tony Kelleher (Kirby Institute, UNSW Sydney, Australia)
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)
Maximilian Muenchhoff (Pettenkofer-Institute, Germany)
Zaza Ndhlovu (University of KwaZulu Natal, South Africa)
R. Keith Reeves (Beth Israel Harvard, United States)
Rogier Sanders (Amsterdam University Medical Centers (Amsterdam UMC), University of Amsterdam, Netherlands)
Hasina Subedar (Department of Health, South Africa)
Oral
13:00 - 14:30 Londres
OA12 Contraception and HIV Risk: Still Between a Rock and a Hard Place
Chairs:
Maureen Goodenow (Office of AIDS Research, National Institutes of Health, United States)
Charles Morrison (FHI 360, United States)
OA12.01 MPA, Used in Injectable Contraception, Increases HIV-1 Replication ex 13:00 - 13:15
vivo by a Different Mechanism Compared to Luteal Phase Progesterone
Levels
Chanel Avenant (University of Cape Town, South Africa)
OA12.02LB Safety and Pharmacokinetics of Dapivirine and Levonorgestrel Vaginal 13:15 - 13:30
Rings for Multipurpose Prevention of HIV and Pregnancy
OA12.03 Increased CCR5 Levels Result in Increased R5-HIV Replication by 13:30 - 13:45
Medroxyprogesterone Acetate, Unlike Norethisterone, via the
Glucocorticoid Receptor
Janet Hapgood (University of Cape Town, South Africa)
Page 51 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA12.04 Effect of Depot-medroxyprogesterone Acetate on T Cell Expression of 13:45 - 14:00

Immunosuppressive Markers, PD-1 and CTLA-4 in HIV-negative Women
Taguma. A Matubu (University of Zimbabwe College of Health Sciences Clinical
Trials Research Centre, Zimbabwe)
OA12.05 Successful Use of Safer Conception Strategies Resulting in High 14:00 - 14:15
Pregnancy Rates and no HIV Transmissions Among Kenyan HIV-
discordant Couples
OA12.06 Risk of HIV-1 Acquisition Among South African Women Using a Variety of 14:15 - 14:30
Contraceptive Methods in a Prospective Study
Thesla Palanee-Phillips (Wits Reproductive Health and HIV Institute, South Africa)
Oral
13:00 - 14:30 Bristol
OA13 Virus Control: Therapeutic Interventions

Chairs:
Mariano Esteban (Centro Nacional De Biotecnología, Spain)
Moses Nsubuga (Stigmaless Uganda, Uganda)
OA13.01 Setting the Stage for Meaningful Community Engagement and 13:00 - 13:15
Participation in HIV Cure-related Research: Lessons Learned From the
HIV Prevention Field
Melissa Hermerding (Forum for Collaborative Research, University of California,
Berkeley, School of Public Health, United States)
OA13.02 A Novel Approach to Inhibit CD4 Exhaustion: Results of a Placebo- 13:15 - 13:30
controlled Phase II Study of a gp41 Peptide Vaccine in HIV-1 Patients
Under ART
Behazine Combabière (CIMI-Paris, France)
OA13.03 DNA-GTU/LIPO-5 Vaccine Followed by Supervised Treatment Interruption 13:30 - 13:45

(STI) in a Therapeutic HIV Phase II Randomized Trial: VRI02 ANRS 149
LIGHT
Christine Lacabaratz (Vaccine Research Institute/VRI, France)
OA13.04 Therapeutic Vaccination With a Combination of IDLV-SIV-Gag and IDLV- 13:45 - 14:00
PGT121 Results in Prolonged Virus Control in Chronically SHIV-infected
Macaques
Maria Blasi (Duke University Medical Center, United States)
OA13.05 Long-term Delivery of Anti-HIV Monoclonal Antibodies 14:00 - 14:15

Jose M. Martinez-Navio (University of Miami - Miller School of Medicine, United
States)
OA13.06LB Tissue Viral Seeding Drives SHIV Pathogenesis in Infant Macaques and Is 14:15 - 14:30
Reduced by Early bNAb Therapy
Page 52 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Oral
13:00 - 14:30 Oxford
OA14 Antibody Functions Beyond Neutralization

Chairs:
Cynthia Derdeyn (Emory University, United States)
Christiane Moog (INSERM U1109, FMTS, Université de Strasbourg, France)
OA14.01 HIV gp120 V2 Mimics IgSF Domain 1 of MAdCAM, the Natural Ligand of 13:00 - 13:15
Integrin α4β7
James Arthos (NIAID, NIH, United States)
OA14.02 IgG3 Hinge Length Enhances Neutralization Potency and Fc Effector 13:15 - 13:30
Function of an HIV V2-specific Broadly Neutralizing Antibody
Simone Irene Richardson (Centre for HIV & STIs, National Institute for
Communicable Diseases, South Africa)
OA14.03 Neutralizing and ADCC Activity of Anti-HIV-1 Antibodies Against Acute 13:30 - 13:45
Subtype C Envs: Implications for Prevention and Treatment of HIV-1
Infection
Dieter Mielke (Duke University, United States)
OA14.04 Structural Characterization of Rhesus Macaque Fc Domains of IgG1-4 and 13:45 - 14:00
the FcγRIIIa1-IgG1Fc Complex
William Tolbert (Institute of Human Virology, University of Maryland, School of
Medicine, United States)
OA14.05 IgA Inhibits HIV-specific Antibody-dependent Neutrophil Phagocytosis 14:00 - 14:15

Matthew Worley (The Peter Doherty Institute for Infection and Immunity,
University of Melbourne and Royal Melbourne Hospital, Australia)
OA14.06LB Tight Control of SHIVBaL in Rhesus Macaques Immunized 14:15 - 14:30

With gp160 DNA + gp120 Proteins (Clades E and B) Correlates With V2p
Antibodies
Svenja Weiss (Icahn School of Medicine at Mount Sinai, United States)
Oral
OA15 New ARVs for Prevention

Chairs:
Juan Berenguer (Infectious Diseases at Hospital General Gregorio Marañón, Spain)
Anton Pozniak (Chelsea and Westminster Hospital, United Kingdom)
OA15.01 Pharmacokinetic and Pharmacodynamic Evaluation of the Antiretroviral 13:00 - 13:15

Compound MK-2048 Released From an Intravaginal Ring in Rhesus
Macaques
James Cummins (Division of AIDS, NIAID, NIH, United States)
OA15.02 Efficacy of UAMC01398 Gel Formulation in NHP Model of HIV Vaginal 13:15 - 13:30
Transmission
Delphine Desjardin (CEA Université Paris Sud, Inserm u1184, IDMIT Department,
France)
Page 53 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA15.03 Dose-ranging Pharmacokinetic Assessment of Vaginally Administered 13:30 - 13:45

EVG/TAF Inserts in Macaques for PrEP
Charles Dobard (Centers for Disease Control and Prevention, Division of HIV/AIDS
Prevention, Laboratory Branch, United States)
OA15.04 HIV Prevention in Healthy Women: Safety and Pharmacokinetics of a 13:45 - 14:00
Potential New Tenofovir Alafenamide Fumarate (TAF)-based Oral PrEP
Regimen
Jill Schwartz (CONRAD Eastern Virginia Medical School, United States)
OA15.05 Cabotegravir (CAB) Long-acting (LA) Phase 3 (Ph3) PrEP Dose Selection 14:00 - 14:15
Based on Population Pharmacokinetics (PPK) in Healthy and HIV-infected
Adults
Susan Ford (PAREXEL International, United States)
OA15.06LB Tail-phase Safety, Tolerability and Pharmacokinetics of Long-acting 14:15 - 14:30

Injectable Cabotegravir in HIV-uninfected Individuals: HPTN 077 Final
Results
States)
Symposium
15:00 - 16:30 Londres
SY05 Close Encounters of the Third Kind: Innate and Adaptive Immune Responses
in HIV Dissemination
This session will review host responses to HIV/SIV infection within mucosal and lymphoid tissues in humans and
nonhuman primates. Topics will include the role of molecular pathways implicated in natural immune control, early
host response, novel mucosal innate lymphocyte subsets, and relevant findings from acute HIV infection studies.
Chairs:
Guido Ferrari (Duke University Medical Center, United States)
Hendrik Streeck (Institute for HIV Research, Germany)
SY05.01 Interfering with Interferons: How HIV Subverts the Interferon System to 15:00 - 15:22
Facilitate Sexual HIV Transmission
Anthony Cunningham (The Westmead Institute, The University of Sydney,
Australia)
SY05.02 Fixed Characteristics of HLA Class I Alleles That Impact HIV Disease 15:22 - 15:44
Mary Carrington (Frederick National Laboratory for Cancer Research, United
States)
SY05.03 HIV Persistence and the Immune Microenvironment in Lymph Nodes 15:44 - 16:06
Following Initiation of cART During Hyperacute HIV-1 Infection
Zaza Ndhlovu (University of KwaZulu Natal, South Africa)
SY05.04 The First Line Against HIV/SIV: Innate Immune Effectors at the Virus- 16:06 - 16:28
Mucosae Interface
R. Keith Reeves (Beth Israel Harvard, United States)
Page 54 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Roundtable
15:00 - 16:30 Bristol
RT01 Accelerating Product Introduction for Impact

Millions of new HIV infections occur yearly despite availability of novel and effective HIV prevention products. This
session will explore best practices for introduction of prevention products, and discuss successes and challenges
using lessons learnt from completed demonstration projects. Best practices from sexual and reproductive health
technologies and experiences from non-HIV vaccines will be used as examples of implementation planning for
product introduction.
Chairs:
Nyaradzo Mgodi (University of Zimbabwe Collaborative Research Program, Zimbabwe)
RT01.01 Preparing for Successful Implementation of Prevention Strategies 15:00 - 15:10

Hasina Subedar (Department of Health, South Africa)
RT01.02 Learning From the Past: Planning for Future Success in Implementing 15:10 - 15:20
Biomedical HIV Prevention Products
Alex Coutinho (Partners in Health, Rwanda)
RT01.03 Successes and Shortcomings in Introducing Sexual and Reproductive 15:20 - 15:30
Health Technologies: Insights From End-users, Providers and Policy
Makers
Martha Brady (PATH, United States)
RT01.04 Learning from History: Roll-out of Non-HIV Vaccines 15:30 - 15:40

Swati Gupta (International Aids Vaccine Initiative, United States)
RT01.05 Introduction of New Health Technologies in HIV Prevention and 15:40 - 15:50
Treatment Trials: Best Practices of Community Engagements and
Communication in Peru
Maria del Rosario Leon (Impacta Salud y Educacion, Peru)
Panel Discussion 15:50 - 16:30
Symposium
15:00 - 16:30 Oxford
SY06 Let's Talk T Cells!

There is an urgent need to revisit approaches to elicit cell-mediated immunity for both vaccine prevention and cure
strategies. The session will cover the latest and greatest candidates in pre-clinical and clinical development, as well
as address the need to strike the right balance of T cell immunity.
Chairs:
Paul Goepfert (University of Alabama at Birmingham, United States)
Julia G. Prado (AIDS Research Institute Irsicaixa, Spain)
SY06.01 T Cell Responses in HIV-infected Children: Potential for Prevention or 15:00 - 15:18
Cure?
Maximilian Muenchhoff (Pettenkofer-Institute, Germany)
SY06.02 T Cells in Vaccine Trials 15:18 - 15:36

Wendy Burgers (Institute of Infectious Disease and Molecular Medicine, UCT, South
Africa)
Page 55 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
SY06.03 What Defines an Effective T-cell Response to HIV? 15:36 - 15:54

Christian Brander (IrsiCaixa, Spain)
SY06.04 Role of Tfh in Protective Immunity 15:54 - 16:12

Tony Kelleher (Kirby Institute, UNSW Sydney, Australia)
SY06.05 Vaccine-induced Th1-biased CD4 T Cell Responses: Too Much can be Bad 16:12 - 16:30
Rama Amara (Emory University, United States)
Symposium
SY07 Optimizing PrEP Delivery for PrEP Users

This session will discuss the next phase of PrEP implementation – removing barriers to uptake and persistence
of PrEP. The talks will focus on integrating PrEP with family planning. They will include: discussion of MPTs; discussion
of new PrEP delivery strategies, such as pharmacy- or telemedicine-based delivery; exploration of “positive frame”
methods of describing PrEP to help individuals determine whether they might benefit from PrEP; and discussion of
new technologies for increasing uptake and persistence of PrEP.
Chairs:
Will Nutland (PrEPster, United Kingdom)
Omar Sued (Fundacion Huesped, Argentina)
SY07.01 Integrating PrEP and Reproductive Health Services and Preparing for 15:00 - 15:22
MPT Delivery
SY07.02 New Delivery Approaches: Improving PrEP Uptake and Persistence 15:22 - 15:44
SY07.03 PrEP Messaging: Taking “Risk” Out of the Pitch 15:44 - 16:06
Sarit Golub (Hunter College, United States)
SY07.04 Mobilizing Communities Through Innovations to Improve PrEP Uptake 16:06 - 16:28
Nittaya Phanuphak (Thai Red Cross AIDS Research Centre, Thailand)
Poster Discussion
16:45 - 17:30 Londres
PD06 Mechanisms of Natural Control

Chairs:
Yves Levy (INSERM, France)
Marianne Mureithi (University of Nairobi, Kenya)
PD06.01 Distinct Antibody Profile Associated With HIV Controllers 16:45 - 16:54
Jéromine Klingler (UMR S_1109, France)
PD06.02 Broadly Neutralizing Sera From Long-term Non-progressors 16:54 - 17:03

Predominantly Target Envelope Epitopes Within the V3 Glycan-dependent
Region
Nuria Gonzalez (Instituto de Salud Carlos III, Spain)
Page 56 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
PD06.03LB Single-cell Cloning of HIV-specific Natural Killer Cells in Humans 17:03 - 17:12
Olivier Lucar (Harvard Medical School/Beth Israel Deaconess Medical Center,
United States)
PD06.04 Heightened Inflammatory Response to Acute HIV-1 Infection in Zambian 17:12 - 17:21
Women Compared to Men
Elina El-Badry (Emory University, United States)
PD06.05 Synergistic Interactions Between Microbial RNA and DNA Sensing 17:21 - 17:30
Pathways Lead to Improved HIV-1 Immune Recognition by cDCs in Elite
Controllers
Enrique Martin-Gayo (Ragon Institute of MGH, MIT and Harvard, United States)
Poster Discussion
16:45 - 17:30 Bristol
PD07 Beyond Acronyms: Understanding Young Women’s Dreams, Realities and

Perceptions
Chairs:
Margaret McCluskey (USAID/GH/OHA/RES, United States)
Definate Nhamo (Pangaea Zimbabwe AIDS Trust (PZAT), Zimbabwe)
PD07.01 Quantitative Study for HIV Prevention Reveals a Typology Consisting of 16:45 - 16:54
Six Distinct Types Among South African Adolescent Girls and Young
Women
Kenyon Crowley (University of Maryland, United States)
PD07.02 HIV Risk and Perception Among Adolescent Girls and Young Women 16:54 - 17:03
(AGYW) Accessing Oral Pre-exposure Prophylaxis (PrEP) in Kenya
Daniel Were (Jhpiego, Kenya)
PD07.03 “DREAMS Means Future and Hope.” Perceptions of Young Women Selling 17:03 - 17:12
Sex of How the DREAMS Package Is Affecting Their HIV Risk in Zimbabwe
Phillis Mushati (Centre for Sexual Health HIV and AIDS Research (CeSHHAR),
Zimbabwe)
PD07.04 Population Characteristics and Implications for Prevention Interventions 17:12 - 17:21
for Young Female Sex Workers in Kisumu, Kenya
Julie Franks (ICAP at Columbia University, United States)
PD07.05 How Does Relationship Power Influence HIV Risk Among Adolescent Girls 17:21 - 17:30
and Young Women in Kenya?
Ann Gottert (Population Council, United States)
Poster Discussion
16:45 - 17:30 Oxford
PD08 Trials and Tribulations in Roll Out

Chairs:
Page 57 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
PD08.01 Adaptive Non-inferiority Margins in HIV Prevention Trials 16:45 - 16:54

Brett Hanscom (Fred Hutch Cancer Research Center, United States)
PD08.02 What Do Women Prefer in a Vaginal HIV Prevention Product? Findings 16:54 - 17:03
From a Discrete Choice Experiment in Southern Africa
Erica Browne (RTI International, United States)
PD08.03 No Discontinuations of TDF-based PrEP Use Due to Changes in Renal 17:03 - 17:12
Function in a Longitudinal Clinical Cohort
PD08.04 PrEP Side-effects and Discontinuation in Pregnant and Non-Pregnant 17:12 - 17:21
Women
PD08.05 Project Moxie: A Pilot-study of Video Counseling and Home-based HIV 17:21 - 17:30
Testing for Transgender Youth
Rob Stephenson (University of Michigan Center for Sexuality and Health
Disparities, United States)
Poster Discussion
PD09 Long-acting Prevention Agents in Experimental Models

Chairs:
Stephanie Barrett (Merck & Co., Inc., United States)
PD09.01 Ultra-long-acting Tunable, Biodegradable and Removable Injectable 16:45 - 16:54

Formulation: Sustained Delivery of Dolutegravir in BLT Mice and
Macaques
S. Rahima Benhabour (University of North Carolina, Chapel Hill, United States)
PD09.02 Novel Parenteral Platforms for Tunable Long-acting Administration of 16:54 - 17:03
Hydrophobic HIV Compound
Nima Akhavein (GSK, United States)
PD09.03 Multispecies, In Vivo Evaluation of Subdermal Implants Delivering 17:03 - 17:12

Tenofovir Alafenamide: Of Mice, Dogs and Sheep
Marc M Baum (Oak Crest Institute of Science, United States)
PD09.04 A Subcutaneous Biodegradable Implant for Sustained Delivery of 17:12 - 17:21

Tenofovir Alafenamide (TAF) for HIV Pre-exposure Prophylaxis (PrEP)
Leah Johnson (RTI International, United States)
PD09.05 Novel Vaginal Ring Design for the Controlled Release of the 17:21 - 17:30
Macromolecule Microbicide 5P12-RANTES
John McBride (Queen's University Belfast, United Kingdom)
Page 58 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Poster Discussion
PD10 Roadmaps for bNAb Elicitation

Chairs:
Ralf Wagner (University Of Regensburg, Germany)
PD10.01 Expansion of VH1-2*02 Env-specific B Cells in a Non-neutralizing HIV-1 16:45 - 16:54

Env Vaccine Regimen
Lamar Ballweber Fleming (Fred Hutchinson Cancer Research Center, United
States)
PD10.02 Assessment of the Frequency of VRC01 Class Naïve B Cells in Different 16:54 - 17:03
Populations That Can Potentially Engage an HIV CD4 Binding Site
Immunogen
David Leggat (NIH, VRC, United States)
PD10.03 Mechanistic Insights Into Vaccine Induction of V2 Apex-directed, 17:03 - 17:12

Heterologous Tier 2 Neutralizing Responses in CH103 UCA Knock-in Mice
Laurent Verkoczy (San Diego Biomedical Research Institute, United States)
PD10.04 Epitope Focusing by Priming and Sequential Boosting With Glycan- 17:12 - 17:21
altered Immunogens Induces Immune Responses That Neutralize
Heterologous Viruses
Tongqing Zhou (VRC, United States)
PD10.05LB Dual Maturation Pathways from the Unmutated Common Ancestor of 17:21 - 17:30
HIV-1 Envelope Broadly Neutralizing Antibodies Overcome Glycan
Barriers
Mattia Bonsignori (Duke Human Vaccine Institute, Duke University Medical Center,
United States)
Poster
P01 Antibody Functions (Neutralizing and Non-neutralizing)

P01.02 Glycoengineering HIV-1 Env Creates "Supercharged" and "Hybrid" Glycans to Increase
Neutralizing Antibody Potency, Breadth and Saturation
James Binley (San Diego Biomedical Research Institute, United States)
P01.06 Molecular and Structural Characterization of a Highly Neutralization Resistant Tier 3 HIV-1
Strain
Thandeka Moyo (International Centre for Genetic Engineering and Biotechnology, South Africa)
P01.08 HIV Neutralising Monoclonal Antibodies With Optimised Antibody Effector Functions
P01.10 iMab-CAP256, a Novel, Highly Potent Bi-specific Antibody That Targets HIV-1
Tumelo Moshoette (University of the Witwatersrand, Faculty of Health Sciences, South Africa)
P01.12 Impact of Env Conformation and CD4 Downregulation on ADCC Responses

Page 59 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P01.14 Plasma Antibodies with Broadly Cross-neutralizing Activity Show an Enhanced Ability to
Block HIV-1 Binding to the DC-SIGN Receptor
Kabamba Bankoledi Alexandre (Council for science and industrial research, South Africa)
P01.16 Vaccine Induction of V2 Apex-directed, Cross-reactive Neutralizing Antibodies in CH01 UCA

“HC Only” Knock-in Mice
Raiees Andrabi (The Scripps Research Institute, United States)
P01.18 Immortalization of Murine B Cells After HIV-1 Fusion Peptide Immunization Induces In Vitro
Expansion and Maturation of Antibody Secreting B Cells
Yongping Yang (NIH, United States)
P01.20 Role of Conventional Antibodies in Control of HIV-1 CRF01_AE Viruses

Takeo Kuwata (Kumamoto University, Japan)
P01.22 Pro-inflammatory Cytokine Profiles and HIV-specific Antibody Responses in the Male Genital
Tract
Thevani Pillay (CAPRISA, University of KwaZulu-Natal Nelson Mandela Medical School, South Africa)
P01.24 Higher HIV Neutralization Breadth in Young Children Than in Chronically Infected Adults
Genevieve Fouda (Duke University Medical Center, United States)
P01.26 Structural Comparison of Human Anti-HIV-1 gp120 V3 MAbs of the Same Gene Usage
Induced by Vaccination and Chronic Infection
Xiangpeng Kong (NYU School of Medicine, United States)
P01.28 Initiation and Early Development of Three MPER-directed Neutralizing Antibody Lineages
From a Single HIV-1 Infected Individual
Nicole A. Doria-Rose (National Institutes of Health, United States)
P01.30 Immortalization of HIV-1-specific B Cells for Long-term Culture Facilitates Neutralizing

Antibody Discovery and Characterization
Evan Cale (Vaccine Research Center, NIAID, NIH, United States)
P01.32 Cross-clade ADCC Activities in Human Volunteer Sera Elicited by a Polyvalent DNA Prime-
protein Boost HIV Vaccine DP6-001
Shan Lu (University of Massachusetts Medical School, United States)
P01.34LB Delineating HIV-1 Evolutionary Pathways Associated With Development of a Broadly

Neutralizing Antibody Response
Vinita Joshi (Ragon Institute of MGH, MIT and Harvard, United States)
P01.36LB A Co-receptor-mimicking Antibody Stabilizes the Displaced V1V2 Loops in a Partially Open
sCD4-bound HIV-1 Envelope Complex
Christopher Barnes (California Institute of Technology, United States)
Poster
P02 Antiretroviral Resistance and Impact on Prevention

P02.02 Circulating HIV-1 Drug Resistance Mutations in Dar Es Salaam, Tanzania: Implication for Pre-
exposure Prophylaxis
Godfrey Barabona (Centre for AIDS Research, Kumamoto University, Japan)
Page 60 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P02.04 Emergence of Novel HIV Polymerase Mutations in Non-B Clades Associated with Treatment
Intensification in Cameroon
Ralf Duerr (New York University - School of Medicine, United States)
P02.06LB Fully-phased SMRT HIV-pol Sequencing Unravels the Complexity of Viral Quasispecies
During Treatment Failure
Dario Dilernia (Emory University Rwanda Zambia HIV Research Group, United States)
Poster
P05 Clinical Trial Results

P05.02 Safety and Acceptability of the PrePex™ Device in Contraindicated Adolescent Boys Age
10-12 Years in Kisumu, Kenya
Risper Bosire (Impact Research and Development Organization, Kenya)
P05.04 Post-Exposure Prophylaxis for HIV infection in Sexual Assault Victims.

Alexy Inciarte (Hospital Clinic/IDIBAPS/University of Barcelona, Spain)
P05.06 Sexual Risk and Study Drug Detection in MSM Participants in a Phase II Study of Maraviroc
(MVC) +/- Tenofovir DF (TDF) or FTC versus TDF/FTC for PrEP
P05.08 Safety and Pharmacokinetics of DS003 When Administered to Women as a Vaginal Tablet
Chantél Friend (International Partnership for Microbicides, South Africa)
P05.10 Vaginal Film Administration and Placement Study in Women (FLAG Trial)
Sravan Kumar Patel (University of Pittsburgh, United States)
P05.12 High-risk Single Women as HIV Vaccine Trial Participants: A Suitable Population With High
HIV Incidence and Good Retention
Amanda Tichacek (Emory University, United States)
P05.14LB HVTN114: A Phase 1 Trial to Evaluate Late Boosts With AIDSVAX B/E of Participants
Previously Vaccinated With MVA/HIV62B in DNA/MVA or MVA Regimens
Paul Goepfert (University of Alabama at Birmingham, United States)
P05.16LB DNAVAC: Clinical Optimization of DNA Vaccination for Experimental Medicine Trials of gp140
Immunogens
Hannah M. Cheeseman (Imperial College London, United Kingdom)
P05.18LB Antibody Mediated Prevention: Proof-of-concept, Randomized, Blinded, Placebo-controlled

Trials to Assess Safety and Efficacy of VRC01 to Prevent HIV-1
Srilatha Edupuganti (Emory University, United States)
P05.20LB Tetravalent Janssen Mosaic Ad26/Protein HIV Vaccine Shows Increased Clade C Env-specific
CD4+ T-cell and Antibody Responses Versus Trivalent Vaccine
Nicole Frahm (Fred Hutchinson Cancer Research Center, United States)
Poster
P28 Transmission of HIV
Page 61 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P28.02 Heterosexual Anal Intercourse Practices and Associated HIV Risk in Two Recent Cohort
Studies in Eastern and Southern Africa
Romain Silhol (Imperial College London, United Kingdom)
P28.04 Targeting Viral Infection Frequency but Not Burst Size Is Effective at Extinguishing Initial
Infection in a Model of Suboptimal PrEP
Ana Moyano de las Muelas (Africa Health Research Institute, South Africa)
P28.06 Pol-driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection
Doty Ojwach (HIV Pathogenesis Programme, South Africa)
P28.08 Providing PrEP Navigation to High-risk Populations With Multiple Health Disparities in Los
Angeles, CA, USA: A Comparison of MSM and Trans Women
Cathy Reback (Friends Research Institute, United States)
P28.10 Association of Herpes Simplex Virus Type 2 (HSV-2) and HIV Infection Amongst Men Who
Have Sex With Men (MSM) in the TRANSFORM Study, Johannesburg
Cecilia Mokoena (Wits Reproductive Health and HIV Institute (WRHI), South Africa)
P28.12 Development of a Predictive Algorithm for Transmitted/Founder Phenotype Through In

Silico Identification of HIV-1 Envelope Signatures
Francisco Díez-Fuertes (Instituto de Salud Carlos III, Spain)
P28.14 Induction of Neutralizing Antibodies Against Autologous Viruses in HIV-1 Infected Pregnant
Women Immunized With a gp120/160 Vaccine
Eliza D. Hompe (Duke University School of Medicine, United States)
P28.16 Deciphering HIV-1 Infection Into Mucosal Tissues

P28.18 Exploring the Transmission Dynamic of HIV-1 Epidemic Spread in Serbia Using Birth-death
Skyline Plot
Valentina Cirkovic (Institute of Microbiology and Immunology, University of Belgrade Faculty of
Medicine, Serbia)
P28.20 Quantitative Examination of the Capture of HIV-1 Primary Viruses by Human PBMCs in the
Presence of Broadly Neutralizing Antibodies
Jiae Kim (The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States)
P28.22LB Differential Infection of Cultured Peripheral and CNS Cells by Distinct Transmitted/Founder
HIV-1 Infectious Molecular Clones (IMC)
David Chang (U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research,
United States)
P28.24LB In Vivo Analysis of Penile HIV-1 Acquisition

Martina Kovarova (University of North Carolina at Chapel Hill, United States)
Poster
P14 Implementation Science, Including Structural Interventions, PrEP & VMMC

P14.02 Testing the Testers: Are Young Men Who Have Sex with Men Receiving Adequate HIV
Testing Services?
Jose Bauermeister (University of Pennsylvania, United States)
Page 62 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P14.06 Associations Between Perceived Risk of HIV and PrEP Eligibility, Willingness to Use PrEP,
and Actual PrEP Use Among Young MSM in Washington, DC
Hannah Yellin (George Washington University Milken Institute School of Public Health, United States)
P14.08 Missed Opportunities: Barriers to PrEP Use Among Patients With Recently Acquired HIV
Infection in Northern California
Jonathan Volk (Kaiser Permanente San Francisco Medical Center, United States)
P14.10 Awareness and Uptake of DREAMS Interventions and Packages Among Young Women in
Kenya and South Africa: Analysis of Population-based Surveys
P14.12 Implementing a Patient-centered Peer Counselling Intervention for HIV Treatment in Kenya
Sarah Iguna (Kenya Medical Research Institute, Kenya)
P14.14 Outcomes for PrEP Users in the Southern U.S.: Persistence and STIs
Meredith Clement (Duke University Medical Center, United States)
P14.16 High Incidence of STIs Among MSM in PrEP Without a Significant Increase
P14.18 Using Differentiated HIV Testing Service (HTS) Approaches to Scale up Pediatric HIV
Diagnosis on the Roadmap Towards the 90-90-90 Targets in Uganda
Kiiza Cornelius (AIDS Healthcare Foundation (AHF)-Uganda Cares, Uganda)
P14.20 Training Health Care Providers to Scale Up PrEP for HIV Serodiscordant Couples Attending
Public Health Facilities in Western and Central Kenya
Josephine Odoyo (Kenya Medical Research Institute, Kenya)
P14.22 Providing PrEP for People Who Inject Drugs: Are Syringe Services Programs the Way to Go?
Mehri McKellar (Duke University, United States)
P14.24 Developing an Effective HIV PrEP Program at STD Clinic

Jodie L Suh (Ridgewood High School, United States)
P14.26 Creatively Empowered: The Role of a Creative Concept and IEC Materials in Influencing
Decision-making to Use Oral PrEP
Elmari Briedenhann (Wits Reproductive Health & HIV Institute, South Africa)
P14.28 Health Care Workers’ Knowledge, Attitudes, and Practices About Oral PrEP Provision to
Adolescent Girls and Young Women in Zimbabwe
Definate Nhamo (Pangaea Zimbabwe AIDS Trust (PZAT), Zimbabwe)
P14.30 Successful Recruitment Strategies Used in Pre-exposure Prophylaxis (PrEP) Study at Kisumu
Site, Kenya
Eric Ochieng Sedah (Kenya Medical Research Institute, Kenya)
P14.32 Health Care Provider Experiences Delivering PrEP to HIV Serodiscordant Couples in Public
HIV Clinics in Kenya
Kenneth Ngure (School of Public Health, Jomo Kenyatta University of Agriculture and Technology,
Kenya)
P14.34 Baseline and Early Changes in HIV Risk Behavior Among Key Populations Initiating Pre-
exposure Prophylaxis (PrEP) in Kenya: Lessons From a PrEP Program
Griffins Manguro (International Center for Reproductive Health Kenya, Kenya)
P14.36 Limited Awareness of PrEP Among People Who Inject Drugs in Athens, Greece
Georgios Nikolopoulos (Medical School, University of Cyprus, Cyprus)
Page 63 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P14.38 $1 a Day PrEP: Sustainable Delivery of Pre-exposure Prophylaxis by the PrEP-30 Program in
Bangkok, Thailand
P14.40 Characteristics of Oral Pre-exposure Prophylaxis (PrEP) Users From the General Population
as Part of Kenya’s National PrEP Rollout
Abednego Musau (Jilinde Project, Jhpiego, Kenya)
P14.42 A Mixed Methods Study Assessing Readiness for Oral PrEP in a Rural Area of KwaZulu-Natal,
South Africa
Sarah Nakasone (The University of Chicago, United States)
P14.44 A Model for Mentoring Skills Training in Scientific Writing for HIV Researchers From Low-
and Middle-income Countries
Matthew Price (University of California San Francisco, United States)
P14.46 Risk Assessment Tools and the Identification of Individuals at High-risk of HIV Infection in
the Delivery of Oral PrEP
Megan S. Dunbar (AVAC, United States)
P14.48 Factors Associated With Pre-exposure Prophylaxis Adherence in Black Men Who Have Sex
With Men and Transgender Women in a Community Setting
P14.50 Using Transportability to Understand Differences in PrEP Effectiveness between Men who
Have Sex with Men and Transgender Women in iPrEx
Megha L. Mehrotra (University of California San Francisco, United States)
P14.52LB Do VMMC Strategies Increase HIV Testing and Proportion Positive Among Young Men
Compared to Non-VMMC Strategies in Kisumu County?
Harriet Fridah Adhiambo (Kenya Medical Research Institute, Kenya)
P14.56LB Does Community Distribution of HIV Self-test Kits Increase Uptake of HIV Testing at
Population Level? Results of a Cluster-randomised Trial in Zambia
Melissa Neuman (London School of Hygiene & Tropical Medicine, United Kingdom)
P14.58LB Results From PEPFAR´s DREAMS Partnership: Implications for Prevention Programming for
Adolescent Girls and Young Women
Shannon Allen (USAID, United States)
Poster
P03 Behavioral and Social Science Research

P03.02 Alcohol and Stimulant Use, STIs and Condomless Sex Among HIV-positive Persons With and
Without Partners on Pre-exposure Prophylaxis
J. Carlo Hojilla (University of California, San Francisco, United States)
P03.04 Acceptability of iCON, an Online Life Skills WebApp for Young Men Who Have Sex With Men
and Transgender Women in Metro Detroit
Jose Bauermeister (University of Pennsylvania, United States)
P03.06 Functional Knowledge of PrEP and PrEP Use and Willingness Among Male Couples in South
Africa and Namibia
Rob Stephenson (University of Michigan Center for Sexuality and Health Disparities, United States)
Page 64 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P03.08 HIV Self-test Distribution by Young Women: An Innovative Way to Reach Men in Rural South
Africa
Linda Kimaru (University of North Carolina, Chapel Hill, United States)
P03.10 Social Impact of Participating in a Simulated Vaccine Efficacy Trial on Lake Victoria, Uganda
Emily Keneema (UVRI-IAVI HIV Vaccine Program, Uganda)
P03.12 Perspectives of South African Health Providers on the Design of an HIV Prevention Implant:
Learning From Challenges With Contraceptive Implant Rollout
Emily A. Krogstad (University of Washington, United States)
P03.14 Use of Recreational Drugs for Sex in Recent HIV Seroconverters

P03.16 SMARTtest: User-designed Smartphone App to Facilitate HIV Self and Partner Testing,
Interpretation of Results, and Linkage-to-Care
Iván Balán (New York State Psychiatric Institute and Columbia University, United States)
P03.18 Invisible Even Among the Unseen: A Methodological Review of Inclusion of Transgender
Persons as Participants in HIV Prevention Research
Ana María del Río-González (George Washington University, United States)
P03.20 Perceived Acceptability of Intravenous Infusion of Broadly Neutralizing Antibodies Among

Individuals Residing in NYC High HIV Prevalence Areas
P03.22 What We Talk about When We Talk about Risk: Perceived Sources of HIV Risk Among Young
Female Sex Workers and Their Male Clients in Kisumu, Kenya
P03.24 Understanding Chinese Gay Men’s Sexual Health Needs to Prepare for Implementation of
PrEP in China
Kathrine Meyers (Aaron Diamond AIDS Research Center, United States)
P03.26 Characterization of Behavioral and Clinical Risk Factors for HIV Risk Among Transgender
Women
Tanyaporn Wansom (Armed Forces Research Institute of Medical Sciences, Thailand)
P03.28 Post-exposure Prophylaxis: An Underutilized Biomedical HIV Prevention Method Among

MSM in China
Yumeng Wu (The Rockefeller University, United States)
P03.30 Dose-response Association Between Cocaine Use and Adherence to HIV Pre-exposure
Prophylaxis (PrEP)
J. Carlo Hojilla (University of California, San Francisco, United States)
P03.32 “It Takes Two to Tango”: Negotiating Condom Use Among Female Sex Workers and Their
Male Clients in Kisumu, Kenya
P03.34 “There Is Nothing to Hide”: Disclosure of PrEP Use by Young Women in South Africa and
Tanzania – Findings From a Demonstration Project
Sinead Delany-Moretlwe (University of the Witwatersrand, South Africa)
P03.36 Intimate Partner Violence and Women Testing for HIV: Findings From the MAISHA Study in
North-Western Tanzania
Sheila Harvey (London School of Hygiene & Tropical Medicine, United Kingdom)
Page 65 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P03.38 Characteristics of Male Sexual Partners and Knowledge of Partner’s HIV Status Among
Women Who Sell Sex Enrolled in an Evaluation of DREAMS, Zimbabwe
Phillis Mushati (Centre for Sexual Health HIV and AIDS Research (CeSHHAR), Zimbabwe)
P03.40 High Interest in PrEP and Economic Interventions for HIV Prevention Among Male Sex
Workers in Mexico
Alberto Edeza (Brown University School of Public Health, United States)
P03.42 Empowerment Among Adolescent Girls and Young Women in Korogocho and Viwandani
Slums in Nairobi: Perceptions and Implications for the "E" in DREAMS
P03.44 Exploring Perceptions and Experiences of Adolescent Girls and Young Women Participating
in DREAMS in Rural Northern KwaZulu-Natal, South Africa
Thembelihle Zuma (Africa Health Research Institute (AHRI), Nelson Mandela School of Medicine,
University of KwaZulu-Natal, Durban, South Africa)
P03.46 Stigma, Self-esteem and Depressive Symptoms in HIV-infected Men Who Have Sex With
Men and Transgender Women in Sub-Saharan Africa (HPTN 075)
Erica Hamilton (FHI 360, United States)
P03.50 Testing the Role of Collectivization on Safe Sex Behavior With Occasional Clients Among
Female Sex Workers Using Structural Equation Modelling
Monika Walia (Population Council, India)
P03.52 Intersectionality of HIV Risk Groups: Substance Using Men Who Have Sex With Men in Lower
Socioeconomic Positions
Tomás Delgado Jr. (University of Miami, United States)
P03.54 Never Have I Ever: Factors Associated With Never Testing for HIV and With Testing Positive
for HIV at First HIV Test in Peruvian MSM and TW
P03.56 Stigma and Mobile App Use Among Young Black Men who Have Sex with Men
Anna L. Rosengren-Hovee (University of North Carolina Chapel Hill, United States)
P03.58 Acceptability and Determinants of Uptake of Oral Pre-exposure Prophylaxis (PrEP) among
Fishing Communities in Uganda: A Discrete Choice Experiment
Monica.O. Kuteesa (Medical Research Council/Uganda Virus Research Institute and LSHTM,Uganda
research unit, Uganda)
P03.60LB Which Out-of-school Adolescent Girls and Young Women (AGYW) Should Be Reached With
HIV Programming?
P03.64LB Use of Primary Care Providers to Promote Access to HIV Pre-exposure Prophylaxis (PrEP)
Among Female Patients in Oakland, California, United States
Kimberly Koester (University of California, San Francisco, United States)
P03.66LB Understanding HIV Prevention From the Perspective of Adolescent Girls & Young Women by
Applying Behavioral Economics & Human Centered Design
Anabel Gomez (AVAC, United States)
Page 66 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Poster
P04 Cellular Immunity

P04.02 Antibody-mediated Phagocytosis of HIV Targets by Leukocytes Isolated From Human Breast
Milk
Rebecca Powell (Icahn School of Medicine at Mount Sinai, United States)
P04.04 Regulation of CD8+ T Cell Cytotoxic Activity by TGFβ in the Human Female Reproductive
Tract
Charles Wira (Geisel School of Medicine at Dartmouth, United States)
P04.06 ALVAC-HIV/AIDSVAX (R) B/E Late Boost Strategies (RV306) Increase the Proliferative
Capacity of CD4+ Effector Memory T Cells
P04.08 Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Enhances
Immune Control of HIV-1
Christian Boutwell (Ragon Institute of MGH, MIT and Harvard, United States)
P04.10 Induction and Relationship of HIV Envelope-specific B Cells in the Peripheral Blood and Bone
Marrow Following Vaccination in Humans
James Kobie (University of Rochester, United States)
P04.12 High GILZ Levels in Dendritic Cells From HIV-1+ cART Patients Decrease Their Ability to
Induce Effector T Cells and Prevent Effective Vaccination
Lola Vigouroux (Université Paris-Est-Créteil, France)
P04.14 Betamethasone Reduces HIV Infection Through Modulation of Cytokine Expression

Ross Cromarty (Centre for the AIDS Programme of Research in South Africa, South Africa)
P04.16 Low CCR5 Expression Protects Specific CD4+ T Cells of HIV Controllers From Viral Entry
Lisa A. Chakrabarti (Pasteur Institute, France)
P04.18 The Induction of Follicular-like CD8 T-cells by TGF-beta and IL-23 Is Hampered by PD-1 in
HIV-infected Patients
Maria T. Rugeles (Universidad de Antioquia, Colombia)
Poster
P06 Community Engagement in Prevention Research

P06.02 An Electronic Clinic Flow Chart to Optimize Retention at a Community-based HIV Prevention
Clinical Trial Centre in South Africa
Ayman Osman (Setshaba Research Centre, South Africa)
P06.04 Client-initiated Voluntary Counseling and Testing at an HIV Vaccine Preparedness Rural
Research Clinic in South Western Uganda
Freddie Mukasa Kibengo (MRC/UVRI and LSHTM, Uganda Research Unit, Uganda)
P06.06 Innovative Approaches for Effective Recruitment of Former Trial Participants Into MTN
025/HOPE Open Label Trial; How Kampala Team Did It!”
Sophie Clare Nanziri (Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration,
Uganda)
Page 67 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P06.08 Comparing and Contrasting Evaluation Findings From PrEP and TasP Implementation
Projects in a Community Setting From 2015 to 2017
Gregory Phillips (Northwestern University, United States)
P06.10 Effective Community Engagement in HIV Prevention Trials: Experience from a Microbicide
Trial in South-Western Uganda
Sylvia Masawi (MRC/UVRI Uganda Research Unit on AIDS, Uganda)
P06.12 Catalyzing India-Africa Regional Collaboration on Engaging Key Populations in HIV

Biomedical Research
Nikhil Singla (International AIDS Vaccine Initiative (IAVI), India)
P06.14 Recruitment and Retention of a Highly Mobile Cohort of Fisherfolks At-risk of HIV
Acquisition: Experience From a Rural Research Center in SW Uganda
Freddie Mukasa Kibengo (MRC/UVRI & LSHTM Uganda Research Unit, Uganda)
P06.16 Transformative Partnerships: Perspectives on Implementing Research Best Practice With

Key Populations in Kenya
George Victor Owino (International AIDS Vaccine Initiative (IAVI), Kenya)
P06.18 Preparing Ugandan Fishing Communities for HIV Prevention Efficacy Trials: A Cross-
sectional Survey of Healthcare Use and Barriers to Access
Ali Ssetaala (UVRI-IAVI HIV Vaccine Program, Uganda)
P06.20 Should Good Participatory Practice (GPP) Become a Trial Standard? A Report From the First
Global GPP Think Tank
P06.22 HIV/STI Prevalence and Contraceptive, Reproductive and Sexual Health of High Risk Women
Receiving Services at Two Zambian Research Centers
Constance Himukumbwa (Zambia Emory HIV Research Project, Zambia)
P06.24 Capacity Building of Community Advocates Critical for Achieving UNAIDS 90-90-90 Target
Oluwatosin Alaka (New HIV Vaccine and Microbicide Advocacy Society (NHVMAS), Nigeria)
P06.26 Assessing Strategies and Capacity for Gender Integration in HIV Biomedical Research
Ethel Makila (IAVI-Nairobi, Kenya)
P06.28LB High PrEP Awareness Among Kenyan Young People in High HIV Burden Counties
Poster
P07 Contraception, Pregnancy and HIV Prevention

P07.02 An SMS and Clinic-based Tablet Application to Support Safer Conception Among HIV
Serodiscordant Couples in Kenya: Feasibility and Acceptability Study
Jennifer Velloza (University of Washington, United States)
P07.04 Condom Use Among Young Women Who Sell Sex Enrolled in an Impact Evaluation of
DREAMS in Zimbabwe
Phillis Mushati (Centre for Sexual Health HIV and AIDS Research (CeSHHAR), Zimbabwe)
Page 68 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P07.06 Low Levels of Serum Medroxyprogesterone Acetate (MPA) Are Associated With Increased
HIV Risk
P07.08 One-month PrEP Continuation Among Adolescent Girls and Young Women in Routine
Maternal Child Health and Family Planning Clinics
P07.10 Dapivirine Vaginal Ring Use and Cervical Cytology Abnormalities: Data From the Placebo-
controlled MTN-020/ASPIRE Trial
Krishnaveni Reddy (Wits Reproductive Health and HIV Institute, South Africa)
P07.12 Progestin and ARV Interactions in Cells and Tissues of the Female Reproductive Tract:
Implications for Choice of Combination Therapy
Salndave Bongani Skosana (University of Cape Town, South Africa)
P07.14 Acceptability of Genital Mucosal Sampling Nested Within a Randomized Contraceptive Trial
Among Women in Africa
Caitlin Scoville (University of Washington, United States)
P07.18 “Had I Known Before” – Using Peer Led Interventions to Change HIV/STI Risk Behavior
Among Adolescents: Health Improvement-4-teen Ugandans Study
Juliane Etima (MU-JHU Research Collaboration, Uganda)
P07.20 Implementation of a Safer Conception Program for HIV-affected Men and Women in Uganda
Lynn T. Matthews (Massachusetts General Hospital, United States)
P07.22LB No Association Found Between Prenatal PrEP Use and Adverse Infant Outcomes: Results
From a Large PrEP Implementation Program in Kenya
Julia C. Dettinger (University of Washington, United States)
Poster
P08 Correlates of Protection and Exposure

P08.02 Health Workers Perceived Barriers and Attitudes Towards Identifying and Responding to
Gender-based Violence in Afghanistan
Basant Motawi (University of Maryland, United States)
P08.04 The Interleukin 21 (IL 21)/ microRNA-29 (miR-29) Axis Is Correlated With Natural Resistance
to HIV-1 Infection
Irma Saulle (Università degli studi di Milano, Italy)
P08.06 Comparison of Baseline Characteristics of Female Sex Workers and Single Mothers in
Zambia
William Kilembe (Zambia Emory HIV Research Project, Zambia)
P08.08 Ontogeny of T Regulatory and Th17 Cells in HIV-exposed Uninfected Infants From Birth to
36 Weeks
Sonwabile Dzanibe (University of Cape Town, South Africa)
Page 69 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Poster
P09 Delivery Technologies: Novel Approaches, Formulation and Multi-purpose

P09.02 DAPTA-modified Nanoparticles as Potential Microbicide Drug Carriers for Targeting CCR5+
Cells
Catarina Coutinho (i3S – Instituto de Investigação e Inovação em Saúde & INEB – Instituto de
Engenharia Biomédica, Universidade do Porto, Porto, Portugal, Portugal)
P09.04 Solid State 13C-NMR Spectroscopy Provides Direct Evidence for Reaction Between Ethinyl
Estradiol and a Silicone Elastomer Vaginal Ring
P09.06 Mechanical Testing Protocols for Vaginal Ring Formulations

P09.08 Effect of Exposure of the 25 mg Dapivirine Vaginal Ring to Cleaning Solutions and Personal
Lubricants
P09.10 Microarray Patches (MAPs) for Delivery of Long-acting HIV PrEP and Contraception
Annie Rein-Weston (PATH, United States)
P09.12 Systematic Review of the Performance and Clinical Utility of Point-of-care HIV-1 RNA Tests
for Diagnosis and Care
Clara A Agutu (KEMRI-Wellcome Trust Research Programme, Kenya)
P09.14 Formulation Development of a Segmented Intravaginal Ring for the Concurrent Delivery of
Dapivirine and DS003
P09.16 Compatibility Screening for Excipients for Delivery of Dapivirine and Darunavir Concurrently
From an Intravaginal Ring
P09.18 Targeted Adolescent HIV Testing in Two South African Health Sub-districts
P09.20 Vaginal Ring for Sustained Release of DL-lactide as a Lactic Acid Pro-drug
Vicky-Leigh Young (Queen's University Belfast, United Kingdom)
P09.22 Monoclonal Antibodies Against CD52g, a GPI-anchored Glycoprotein in Semen, Co-

agglutinate Sperm and Capture Semen-exposed HIV
Gabriela Baldeon Vaca (Boston University School of Medicine, United States)
P09.24 Mucus-diffusive Nanoparticles Provide Enhanced Local Pharmacokinetics of Efavirenz

Following Rectal Administration
Rute Nunes (i3S - Instituto de Investigação e Inovação em Saúde & INEB - Instituto de Engenharia
Biomédica, Universidade do Porto, Porto, Portugal, Portugal)
Poster
P10 Discovery and Evaluation of Biomedical Agents
Page 70 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P10.02 A New Humic Substance (HS)-based Potential Microbicide Strongly Active Against HIV
Andrei Siniavin (Gamaleya Center for Epidemiology and Microbiology, Russian Federation)
Poster
P11 Epidemiology of HIV

P11.02 Baseline Socio-demographic Characteristics Associated With HIV Prevalence Rates Among
MSM in the TRANSFORM Study, Johannesburg, South Africa
Thesla Palanee-Phillips (Wits Reproductive Health and HIV Institute, South Africa)
P11.04 Prevalence and Determinants of Anal Intercourse Among Female Sex Workers in Swaziland
Branwen Nia Owen (Imperial College London, United Kingdom)
P11.06 Experience of Violence Is Associated With HIV Prevention Uptake and HIV Infection Among
Young Women Who Self-identify as Sex Workers in Mombasa, Kenya
Michael Pickles (Imperial College London, United Kingdom)
P11.08 Epidemiological Trade-offs: How Much Yield Is Sacrificed When Reaching Men and
Implementing Workplace Services?
Dorian Smith (CareWorks, South Africa)
P11.10 Prevalence and Factors Associated With Recreational Drug Use Among Volunteers in a High-
risk Fisher Folk Community in South Western Uganda
Freddie Mukasa Kibengo (MRC/UVRI & LSHTM Uganda Research Unit, Uganda)
P11.12 A Meta-analysis of Metabolic Syndrome Prevalence in HIV Infected and Uninfected

Populations in Sub-Sahara Africa
Olamide Todowede (University of KwaZulu-Natal, South Africa)
P11.14 High Incidence Rate of HIV Infection Among a MSM Cohort in Tokyo
Daisuke Mizushima (National Center for Global Health and Medicine, Japan)
P11.16 Pooling Strategy to Detect Acute HIV-1 Infection (AHI) Among At-risk Women
P11.18 Common Signs and Symptoms of Sexually Transmitted Infections Among Most at Risk
Populations in the Early Capture Cohort Study in Kampala, Uganda
Douglas Makumbi (Makerere University Walter Reed Project, Uganda)
P11.20 Evidence of Growing HIV Epidemic Among Men Who Have Sex With Men in Ukraine
Tetiana Saliuk (Alliance for Public Health, Ukraine)
P11.22 Sexual Behavior and HIV Incidence Among High Risk Women Cohorts in Two Urban Cities in
Zambia
Ana-Maria Visoiu (Zambia Emory HIV Research Project, Rwanda Zambia HIV Research Group, Emory
University, Zambia)
P11.24 Number of Sexual Partners Does Not Predict HIV Status in a Brazilian STI Clinic
Ricardo Vasconcelos (Medicine School of University of São Paulo, Brazil)
Page 71 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Poster
P12 Ethics in HIV Prevention Research

P12.02 Roll-over: Experience of Switching Participants to Active Treatment Arm During a Phase III
Placebo-controlled Trial
Annalene Nel (International Partnership for Microbicides, South Africa)
P12.04LB Is Parental Consent Needed to Access PrEP? Parents, Adolescents and Providers Weigh In
Poster
P13 Immunogenetics (Host Immunity and Restriction Factors)

P13.02 A Rapid Protocol for Enriching Peptide-specific CD8 T Cell Lines to Determine Their
Contribution to Viral Inhibition
Julia Makinde (Imperial College London, United Kingdom)
P13.04 Polymorphisms in Host Factors Fc-gamma Receptors IIa and IIIa Demonstrate Insignificant
Impact on Heterosexual HIV Acquisition and Disease Progression
Sarah Connolly (Emory Vaccine Center and Yerkes National Primate Research Center, United States)
P13.06 Evaluation of Protective Genetic Variants in HIV-1-infected cART Treated Patients

Elisa Maria Lori (Università degli Studi di Milano, Italy)
P13.08 Possible Effect of Hyperthermia on Accessibility of Cellular and Viral miRNAs to mRNAs
Involved in HIV Replication
Lucia Guzman (Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, UBA-CONICET, Argentina)
P13.10 Development of Neutralizing Antibody Responses in SHIV CH505-infected Adult and Infant
Rhesus Macaques
Ashley N. Nelson (Duke University School of Medicine, United States)
Poster
P15 Innate Immunity

P15.02 Association of Vaginal Microbiota With Mucins in the Cervicovaginal Fluid
Bernard J Moncla (University of Pittsburgh School of Medicine, United States)
Poster
P16 Mathematical Modeling: Impact and Effectiveness

P16.02 Shortened Time to ART Initiation in MSM Reduces Risk of HIV-1 Sexual Transmission
Juan Berenguer (Infectious Diseases at Hospital General Gregorio Marañón, Spain)
Page 72 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P16.04 Oral Pre-exposure Prophylaxis for HIV Prevention in Lesotho: Modeling the Potential Cost-
effectiveness and Impact
Robert Manda (U.S. Agency for International Development, Lesotho)
P16.06 Potential Competition Between PrEP and HIV Vaccines in Seattle, WA

Blythe Adamson (University of Washington, United States)
P16.08 A Compositional Transform Reveals HIV Exposure Induced Shifts in the Fecal Microbiota of
Nigerian Infants
Bryan Brown (Seattle Children’s Research Institute, United States)
P16.10 Modelling the Impact of Prevention and Treatment Interventions on HIV and Hepatitis C
Virus Transmission Among PWID in Nairobi
Jack Stone (University of Bristol, United Kingdom)
P16.12 Impact of Scaling Up Pre-exposure Prophylaxis Among Female Sex Workers in South Africa:
A Modelling Analysis
Jack Stone (University of Bristol, United Kingdom)
P16.14 The Potential Impact of Risk Compensation in Response to an HIV Vaccine: Accelerated
Rates of Viral Adaptation and Reduced Cost-effectiveness
Kathryn Peebles (University of Washington, United States)
P16.16LB Modeling Pharmacokinetics and Pharmacodynamics of Luminally Acting Microbicides

Delivered by Vaginal Inserts: Application to Griffithsin
Alan Sze (Duke University, United States)
Poster
P17 Microbiome & STI: Impact on Prevention

P17.02 Impact of the 25 mg Dapivirine and Placebo Vaginal Rings on the Vaginal Microbiota of
Adolescents, Lactating and Post-menopausal Women
P17.04 Immune Modulatory Effects of Vaginal Microbiota Organic Acid Metabolites on Ectocervical
Epithelial Cells
David Delgado Diaz (Burnet Institute, Australia)
P17.06 Repopulating the Cervicovaginal Microbiome With Beneficial Lactobacillus sp. to Prevent
HIV Acquisition
Laurel Lagenaur (Osel Inc., United States)
P17.08 Metabolomics as a Novel Safety Measure in the Vaginal Delivery of Antiretroviral Drugs
Marc M Baum (Oak Crest Institute of Science, United States)
P17.10 Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using
Placebo, Tenofovir and Tenofovir/Levonorgestrel Vaginal Rings
P17.12 Reducing Genital Inflammation and HIV Risk: Assessing the Role of Point-of-care STI/BV
Testing With Expedited Partner Therapy
Nigel Garrett (CAPRISA, University of KwaZulu-Natal, South Africa)
Page 73 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P17.14 Cost Effective Approach for Detection of HIV1, HIV2, HCV & HBV in Blood Plasma Using
Multiplex PCR & Validating Result by Liquid Hybridization Assay
Priyanka Sharma (Seth Research Foundation, India)
P17.16 Cohort-level Analysis of the Functional Variation of the Vaginal Microbiome

Sarah Mutch (University of Manitoba, Canada)
P17.18 Longitudinal Comparison of Diagnosis of Bacterial Vaginosis Using Nugent Criteria

Compared to cpn60 Microbial Profiling Among African Women
Elinor Shvartsman (University of Manitoba, Canada)
P17.20LB Altered Composition and Elevated Diversity in the Enteric Virome of HIV Exposed Uninfected
South African Infants
Bryan Brown (Seattle Children’s Research Institute, United States)
Poster
P18 Mucosal Immunology

P18.02 Clearance of Sexually Transmitted Infections and the Impact of Genital Inflammation in HIV-
infected Women
Andile Mtshali (Centre for the AIDS Programme of Research in South Africa, South Africa)
P18.04 Neutralization Potency Can Account for the Majority of Antibody-mediated Protection
Observed in ex vivo Vaginal Explant Models of Early HIV Infection
Rena D. Astronomo (Fred Hutchinson Cancer Research Center, United States)
P18.06 Abundant Highly Activated Th17 Cells in the Lower Reproductive Tract of Adolescent Girls at
Risk for HIV Infection
Iyaloo Konstantinus (University of Cape Town, South Africa)
P18.08 Altered CD4+ CCR5+ Expression and Cellular Activation in Mucosal and Lymphoid Tissues of
Transgender Women
Sandhya Vasan (Military HIV Research Program, Henry M. Jackson Foundation, Thailand)
P18.10 Relationship Between Vitamin D Deficiency and Genital Mucosal Immunity in Young South
African Women Related to Risk for HIV and HPV Infections
Ramla F Tanko (University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM),
South Africa)
P18.12 Fibroblasts Protect Against HIV Infection of the Human Female Reproductive Tract
Mickey Patel (Geisel School of Medicine at Dartmouth, United States)
P18.14 Women Recently Exposed to Sexual Violence Have Increased Levels of Plasma C-reactive
Protein, an Inflammatory Marker Associated With HIV Infection
Mimi Ghosh (George Washington University, United States)
P18.16 Liver Bacterial Dysbiosis Persists During Antiretroviral Therapy of SIV+ Macaques
Bridget Fisher (Center for Infectious Disease Research, United States)
P18.18 Metaproteomics Based Methodologies for Large-scale Analysis of Host and Microbial
Function in a Human Cohort
Michelle Perner (University of Manitoba, Canada)
Page 74 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P18.20 Anti-HIV miRNAs Protect CD4+ T Cells from the Human Female Reproductive Tract from HIV
Infection
Mickey Patel (Geisel School of Medicine at Dartmouth, United States)
P18.22LB Exploring the Impact of HIV-1 Infection on Overall and HIV-specific Gut Mucosal B Cells and
Antibody Excretion in a Kenyan Cohort
Xinyan Wang (Department of Immunology, University of Toronto, Canada)
Poster
P19 Novel Vaccine and Prevention Approaches

P19.02 Vector-mediated Delivery of Broadly Neutralizing Antibodies (bNAbs) Targeting the V2 Apex
Nigel Aminake Makoah (National Institute for Communicable Diseases, South Africa)
P19.04 Development of a Scalable Plant-based Expression System for the Production of Soluble
HIV-1 Envelope Protein Trimers
Emmanuel Margolin (Institute of Infectious Diseases and Molecular Medicine, University of Cape Town,
South Africa)
P19.06 Differential Induction of Antibody Responses to V1V2 and V3 of HIV Envelope gp120 by
Immune Complex Vaccines
Catarina Hioe (Icahn School of Medicine at Mount Sinai, United States)
P19.08 Designing an Indian Clade C 4-2.J41 Based Soluble Trimeric Env With Targeted Glycan Holes
to Improve Immune-focusing
Shubbir Ahmed (Translational Health Science and Technology Institute, India)
P19.10 Gene Editing to Solve the Proteolysis Problem in the Production of Env Vaccines Expressed
in CHO Cells
Sophia Li (University of California, Santa Cruz, United States)
P19.12 Scaffold-based Epitope Designing: Reorienting Focus Towards HIV Env Surface
Tripti Shrivastava (Translational Health Science and Technology Institute, India)
P19.14 Differential Regulation of HIV-1 Envelope Protein Intracellular Trafficking by Cytoplasmic

Tail
Sweety Samal (Translational Health Science and Technology Institute, India)
P19.16 Army Liposome Formulations, ALFA and ALFQ, Are Potent Adjuvants
Zoltan Beck (Henry M. Jackson Foundation for the Advancement of Military Medicine, United States)
P19.18 Variants of HIV Envelope Glycoprotein With Enhanced Affinity for Precursors to Broadly
Neutralizing Antibodies Identified Using Yeast Surface Display
Mark Dumont (University of Rochester, United States)
P19.20 Sendai Virus Particles Carrying an HIV Env-Sendai Virus F Chimeric Protein for Induction of
Anti-HIV Antibodies
Hiroshi Ishii (National Institute of Infectious Diseases, Japan)
P19.22 Virus-like Particle (VLP) and Stabilized Trimer (SOSIP) Immunogens Based on HIV-1
Envelopes From Patients With Early Broadly Neutralizing Responses
Carolina Beltrán Pavez (Institute of Health Carlos III, Spain)
Page 75 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P19.24 Anti-PD-1 Antibody Combined With IL15/IL15Rα Improves In Vitro Polyfunctional HIV-1
Specific T-cell Responses to Dendritic Cell-therapeutic Vaccination
Audrey Hubert (Inserm, U955, Equipe 16, France)
P19.26 A New Generation of C-terminally Stabilized Env BG505 SOSIP Trimers: Structural and
Immunogenic Characterization
Guidenn Sulbarán (Univ. Grenoble Alpes, CEA, CNRS, IBS, France)
P19.28 Potent HIV-1-specific CD8 T Cell Responses Induced in Mice After Immunization With a
Heterologous DNA-TMEP Prime/ MVA-B Vaccine Boost Regimen
Carmen Elena Gómez (Centro Nacional de Biotecnología (CNB-CSIC), Spain)
P19.30 Recombinant BCG:tHIVconsvX Prime-ChAdOx:tHIVconsvX Boost Regimen Was Safe, Stable

and Elicited Specific HIV-1 T-cell Immune Responses in BALB/C Mice
Athina Kilpeläinen (Hospital Clínic/IDIBAPS-HIVACAT, Spain)
P19.32 A Heterologous HIV-1/SIV gp140 Prime-boost Regimen Induces Broad HIV-1 Antibody-
dependent Cellular Cytotoxicity Responses
Jeanette Linnea Tingstedt (Statens Serum Institut, Denmark)
P19.34 MVA Vaccine Candidates Expressing Trimeric HIV-1 Clade C Envelopes as Immunogens
Against HIV
Juan García-Arriaza (Centro Nacional de Biotecnología (CNB-CSIC), Spain)
P19.36 gp41 Residues Modulate CD4-induced Conformational Changes in the Env and Evolution of a
Relaxed Conformation of gp120
Carol Weiss (FDA, United States)
P19.38 Optimizing Murine Vaccination Regimens to Elicit HIV-1 Neutralizing Responses Targeting
Diverse Fusion Peptide Sequences
Hui Geng (Vaccine Research Center, NIAID, NIH, United States)
P19.40 Potent Expression of HIV-1 Broadly Neutralizing Antibodies Using DNA Encoded Monoclonal
Antibody Technology
Megan Wise (Inovio Pharmaceuticals, United States)
P19.42 Integrase-defective Strains of HIV Are Transcriptionally Active and Immunogenic in BLT
Humanized Mice
Daniel Claiborne (Ragon Institute of MGH, MIT and Harvard, United States)
P19.44LB IV-1 Lineage Envelope Proteins Based on Viral Sequences From Elite Neutralizers
Anna Schorcht (AMC Amsterdam, Netherlands)
P19.46LB Development of HIV-1 gp120 Core-based Immunogens for Priming CD4 Binding Site bNAbs
Quentin Sattentau (Sir William Dunn School of Pathology, United Kingdom)
P19.48LB HIV-1 Incidence, Adherence to Ring Use and Safety in an Open-label Trial of Dapivirine
Vaginal Ring - DREAM
Annalene Nel (International Partnership for Microbicides, South Africa)
P19.50LB Co-administration of 3 Doses of DNA/Protein Improves Antibody Responses to a Prime-boost

Approach, but Needle-free Injection of DNA Shows No Benefit
Mina Hosseinipour (University of North Carolina at Chapel Hill, Malawi)
Page 76 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Poster
P20 Passive Immunization

P20.02 Pushing the Envelope With Rationally Designed Multi-NAbs
James Steinhardt (Institute for Bioscience and Biotechnology Research, United States)
P20.04 Determinants of Transplacental Transfer of Protective Maternal IgG in HIV-infected Women

P20.06LB Engineering Enhanced HIV Broadly Neutralizing Antibodies (ebnAbs) With Improved Potency
Poster
P21 Pharmacology/PK and PD Studies

P21.02 Pharmacodynamic Activity of DS003, a Novel gp120 Blocker, When Administered to Women
as a Vaginal Tablet
Jeremy Nuttall (International Partnership for Microbicides, United States)
P21.04 Pharmacokinetics (PK) of Dapivirine Vaginal Ring (25 mg) Co-administered With
Clotrimazole
Neliette Van Niekerk (International Partnership for Microbicides, South Africa)
P21.06 Anti-HIV Activity and Drug Concentrations in Tenofovir-based Products: Intravaginal Ring
Versus Oral Tablet
Jill Schwartz (CONRAD Eastern Virginia Medical School, United States)
Poster
P22 Phylogenetics and Viral Diversity

P22.02 Analysis of Vpu-mediated CD4 and Tetherin Downregulation Across Major HIV-1 Group M
Subtypes
Gisele Umviligihozo (Simon Fraser University, Canada)
P22.04 Characterization of HIV-1 Transmission Clusters Actively Expanding in Spain

Elena Delgado (Instituto de Salud Carlos III, Spain)
P22.06LB Tracing HIV-1 Evolution in a Dually Infected Subject Developing a Broadly Neutralizing
Antibody Response
Ruchi M. Newman (Ragon Institute of MGH, MIT and Harvard, United States)
Poster
P23 Policy and Advocacy
Page 77 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P23.02 Evolution in the Adoption of National Policies on PMTCT in Relation to WHO Guidelines: A
Policy Review From South Africa, Tanzania and Malawi 2013-2017
Mosa Moshabela (Africa Health Research Institute, South Africa)
P23.04 Planning for Dapivirine Ring Introduction: Summarizing Lessons Learned from Like-product
Experiences
P23.06 Civil Society Role in HIV Vaccine Research: A Report From the Vaccine Advocacy Resource
Group (VARG)
P23.08LB HIV Prevention Research & Development Funding Trends 2016-2017: Investing to End the
Epidemic as a Public Health Threat
Fatima Riaz (AVAC, United States)
Poster
P24 Pre-clinical Studies for HIV Prevention

P24.02 Combination of Griffithsin and Broadly Neutralizing Antibodies Results in Antiviral Synergy
Against HIV-1
José A. Fernández Romero (Borough of Manhattan Community College, United States)
P24.04 Exploring the Causes of Attrition in HIV Vaccine Clinical Trials Among Men Who Have Sex
With Men (MSM)
Hellen Babu (Partners for Health and Development in Africa, Kenya)
P24.06 Pharmacokinetic Comparison of DS003, a Novel gp120 Blocker, Delivered by Vaginal Tablet
or Vaginal Ring in Pigtailed Macaques
Jeremy Nuttall (International Partnership for Microbicides, United States)
P24.08 Investigation of the South African Medicinal Plant Lobostemon Trigonus as a Potential HIV-1
Microbicide
Phindiwe Felicia Chawuke (Council for Scientific and Industrial Research, South Africa)
P24.10 Env-2dCD4S60C Complexes Elicit Potent, Broadly Neutralizing Antibodies Against Clinically
Relevant Viruses in Chinese Origin Rhesus Macaques
Roberto Carlos Rebelo Pereira (University of the Witwatersrand, Faculty of Health Sciences, South
Africa)
P24.12 Comparison of p24 and Spliced RNA to Quantify Viral Growth and Drug Response in
Cervicovaginal Explants
Lindsey Brewers (University of Minnesota, United States)
P24.14 Analysis of the Genital Tract Metaproteome in South African Women: From Bacterial
Vaginosis Biomarkers to HIV Prevention
Arghavan Alisoltani (University of Cape Town, South Africa)
P24.16 Ovine Vaginal Microbiome and Cytokine Profiles as Safety Markers for Vaginal Drug Delivery
Studies
Richard Pyles (University of Texas Medical Branch, United States)
Page 78 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P24.18 Comparison of Droplet Digital PCR Techniques to Characterize HIV-1 Replication in Explant
Models
Rhonda M. Brand (University of Pittsburgh School of Medicine, United States)
P24.20 Preclinical Progressive Selection of a Tenofovir Prodrug Enema for HIV Pre-exposure
Prophylaxis
Thuy Hoang (Johns Hopkins School of Medicine, United States)
P24.22 Mucosal Elicitation of Anti-V2, a4b7-site-targeted Antibodies

Timothy Cardozo (New York University School of Medicine, United States)
P24.26LB Assessing Immunogenicity of Novel Envelope Components for Ad26/gp140 Protein-based

Vaccines in Rhesus Monkeys
Frank Wegmann (Crucell Holland B.V., a Janssen pharmaceutical company of Johnson & Johnson,
Netherlands)
Poster
P25 Product Acceptability and Adherence

P25.02 Assessing the Uptake and Acceptability of PrEP Among Sex Workers One Year After Scale-
up in Nairobi, Kenya
Hellen Babu (Partners for Health and Development in Africa, Kenya)
P25.04 Understanding the Acceptability of Removable Implanted Medication Delivery Devices

(RIMDDs) as a Possible New HIV Prevention Method
Christine Tagliaferri Rael (Columbia University, United States)
P25.06 Empowering Trial Participants to Use the Dapivirine Vaginal Ring: Experience from an Open
Label Extension Trial in South Western Uganda
Irene Nassuuna (MRC/UVRI & LSHTM Uganda Research Unit, Uganda)
P25.08 Sharing Residual Drug Levels With Trial Participants: Experience From an Open Label
Extension Microbicide Trial in South Western Uganda
Anita Kabarambi (MRC/UVRI and LSHTM, Uganda Research Unit, Uganda)
P25.10 Challenges to Collecting PrEP Adherence Data in the New York City (NYC) Site of the HPTN
067 Study
Sharon Mannheimer (Columbia University/Mailman School of Public Health/ICAP, United States)
P25.12 Feasibility and Effect of Integrated Next Step Counseling on Subjects’ Adherence to HIV Pre-
exposure Prophylaxis in the Senegal Demonstration Project
Eric Tousset (Aardex Group, Belgium)
P25.14 Comparison of Accuracy of MEMs, Missed Dosages and Pill Count Against Tenofovir Blood
Level Tests, for PrEP Adherence Among Key Population in Kenya
Christian Ochieng (LVCT Health, Kenya)
P25.16 Post-use Ring Weight, Residual Drug Content and Drug Depletion Zone Thickness as
Objective Measures of Vaginal Ring Adherence
P25.18 Retention and Persistance on PrEP for MSM and TGW: 96-week Results of the PrEP Brazil
Demonstration Study
Valdilea Veloso (Fundação Oswaldo Cruz, Brazil)
Page 79 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
P25.20LB There Is No Difference in Usability and Performance of Oral and Blood Based HIV Self
Screening Tests in South Africa
Mohammed Majam (University of the Witwatersrand, South Africa)
P25.22LB Delivering PrEP: Lessons From Early Demonstration Projects

Poster
P26 Systems Immunobiology Approaches & Sequencing Technologies

P26.02 miRNAs Profile of PBMCs Show Higher Disruption of TFG-beta Signaling Pathway in HIV/HCV
Patients
Óscar Brochado-Kith (Institute of Health Carlos III, National Center of Microbiology, Spain)
Poster
P27 Therapeutic Vaccine, Viral Latency and Cure

P27.02 Development of Human Follicular Dendritic Cells and B Cell Follicles Supports Enhanced HIV
Replication in BLT Humanized Mice
Todd Allen (Ragon Institute of MGH, MIT and Harvard, United States)
P27.04 CD4-mimetic Compounds Sensitize Simian-human Immunodeficiency Viruses Infected Cells

to ADCC
P27.06 Fully MHC-matched Allogeneic Hematopoietic Stem Cell Transplantation in cART-suppressed

Macaques Indicates GVHD as a Reservoir Clearance Mechanism
Helen L Wu (Oregon Health and Science University, United States)
P27.08 Nef HLA-I Downregulation Function in Early HIV Infection Correlates With Latent Reservoir
Size on cART
Fredrick Omondi (Simon Fraser University, Canada)
P27.10 In-situ Detection of HIV Latency via Super-resolution Imaging

Rhonda M. Brand (University of Pittsburgh School of Medicine, United States)
P27.12 Autologous HIV-1 Isolation Under GMP Conditions by Co-culturing Macrophages Derived
From Monocytes and CD8- T Cells
Sonsoles Sánchez-Palomino (IDIBAPS, Spain)
P27.16LB HIV Cure Means “I Wake Up in the Morning and My Shadow Is Not There:” Cure Research
Findings Every HIV Prevention Researcher Should Know
George Greene (Northwestern University, United States)
Page 80 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Poster
P29 Treatment as Prevention

P29.02 HIV-specific Antibody Mediated Targeting of ENV+ Tissues by Exosomes
Xue Zou (Nanjing University, China)
P29.04 From “Treatment as Prevention” to Undetectable=Untransmittable: Advancing the

Research and Policy Agenda to Ensure Relevance for All Women
Judith Auerbach (University of California, San Francisco, United States)
P29.06 Increases Over Time in HIV Testing Among MSM in Africa: A Systematic Review and Meta-
analysis
Kate M. Mitchell (Imperial College London, United Kingdom)
P29.08 Sub-optimal Engagement of African MSM in the HIV Treatment Cascade: A Systematic
Review and Meta-analysis
James Stannah (Imperial College London, United Kingdom)
P29.10 The Mechanism of Action of the Potential HIV-1 Microbicide Hydroxytyrosol Involves Viral
Integration and Transcription
Luis Miguel Bedoya (Universidad Complutense de Madrid, Spain)
P29.12 Improving ART Programs for Prevention Impact in Ukraine

Kostyantyn Dumchev (Ukrainian Institute on Public Health Policy, Ukraine)
Poster
Poster Session 02
Odd-numbered abstracts will be presented in Poster Session 01 on Tuesday, 23 October. Even-numbered abstracts
will be presented in Poster Session 02 on Wednesday, 24 October.
Page 81 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Thursday, 25 October 2018
Oral
08:30 - 10:00 Londres
OA16 Tickling the Germline

Chairs:
Ian Wilson (The Scripps Research Institute, United States)
OA16.01 Targeted Selection of an Improbable HIV-1 Antibody Mutation Critical for 08:30 - 08:48
Broadly Neutralizing Reactivity With a Designed Immunogen
Kevin Wiehe (Duke University, United States)
OA16.02 Carbohydrate Mimicry for Eliciting Oligomannose-targeting Neutralizing 08:48 - 09:06

Antibodies to HIV-1
Ralph Pantophlet (Simon Fraser University, Canada)
OA16.03 Vaccine Induction of VRC01-class Neutralizing Antibodies in a Knock-in 09:06 - 09:24

Mouse Model
Xuejun Chen (Vaccine Research Center/NIAID/NIH, United States)
OA16.05 Phenotypic Deficits in the HIV-1 Envelope Are Associated With the 09:24 - 09:42
Maturation of a V2-directed Broadly Neutralizing Antibody Lineage
Lucia Reh (University of Zurich, Switzerland)
OA16.06 Chimpanzee SIV Envelope-derived Trimer Guides an Immunofocused HIV 09:42 - 10:00
Cross-neutralizing Ab Response in V2-apex bnAb UCA Expressing Knock-
in Mice
Raiees Andrabi (The Scripps Research Institute, United States)
Oral
08:30 - 10:00 Bristol
OA17 Factors Influencing Viral Transmission and Spread

Chairs:
Jason Brenchley (Niaid, United States)
Nabila Seddiki (Inserm U955, Team 16, France)
OA17.01 HLA Pre-adaptation in Gag Influences Viral Evolution in the New Host 08:30 - 08:45
Daniela Monaco (Emory University, United States)
OA17.02LB Treatment of Schistosoma mansoni Infection in Ugandan Women Reduces 08:45 - 09:00
HIV Entry Into Cervical CD4 T Cells and Induces Type I Interferon
Pathways
Rupert Kaul (University of Toronto, Canada)
OA17.03 The Eclipse Phase Lasted a Week in HIV-1-infected Adults in East Africa 09:00 - 09:15
and Thailand
Morgane Rolland (MHRP | HJF, United States)
Page 82 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA17.04 Infection With Multiple Transmitted/Founder (TF) HIV-1 Viruses Impacts 09:15 - 09:30
Peak VL and HIV-1 Pathogenesis
Gladys Macharia (IAVI Human immunology Lab, Imperial College London, United
Kingdom)
OA17.05 Localization of Infection in Neonatal Rhesus Macaques After Oral Viral 09:30 - 09:45
Challenge
Roslyn A. Taylor (Northwestern University, United States)
OA17.06 Gp41 Ectodomain-specific IgG is Associated with Increased Vertical HIV-1 09:45 - 10:00
Transmission
Nicole Naiman (Fred Hutchinson Cancer Research Center, United States)
Oral
08:30 - 10:00 Oxford
OA18 Opinion 360: Meaningful Engagement From Research to Roll Out

Chairs:
Manju Chatani-Gada (AVAC, United States)
Kundai Chinyenze (International AIDS Vaccine Initiative, Kenya)
OA18.01 Beneficial Impacts Related to Participating in an International HIV 08:30 - 08:45

Prevention Trial Involving People Who Inject Drugs
Jeremy Sugarman (John Hopkins, United States)
OA18.02 Standardized Metrics Can Reveal Region-specific Opportunities in 08:45 - 09:00

Community Engagement to Aid Recruitment in HIV Prevention Trials
Gail Broder (Fred Hutchinson Cancer Research Center, United States)
OA18.03 Ethical Considerations for Involving Adolescents Aged 16-17 in HIV 09:00 - 09:15
Prevention Clinical Trials: Community Perspectives from Uganda
Rita Nakalega (Makerere University - Johns Hopkins University (MU-JHU) Research
Collaboration, Uganda)
OA18.04 The Luxuriant Future of Microbicides: Planning for Success 09:15 - 09:30
Marc-André LeBlanc (HIV Prevention Advocate, Canada)
OA18.05 Planning for PrEP: Facilitating Collaborative Cross-country Learning 09:30 - 09:45
Neeraja Bhavaraju (FSG, United States)
OA18.06 Princess PrEP Program: A Successful Key Population-led PrEP Model in 09:45 - 10:00
Thailand Forming Through Meaningful Participation of Key Populations
Oral
OA19 Stay With Me: Retention on PrEP

Chairs:
Alex Carballo-Diéguez (Columbia University, HIV Center for Clinical and Behavioral Studies at New York State
Psychiatric Institute and Columbia University, United States)
Ferran Pujol Roca (Projecte dels NOMS-Hispanosida, Spain)
Page 83 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA19.01 PrEP Uptake and Retention Among Men and Women Receiving PrEP 08:30 - 08:45
Integrated in Public Health HIV Care Clinic Settings
OA19.02 Examining PrEP Interruptions in a Safety-net Primary Care Network: 08:45 - 09:00
Missed Opportunities to Re-engage PrEP Users Accessing non-PrEP
Services
Matthew Spinelli (University of California, San Francisco, United States)
OA19.03 Early Persistence of HIV Pre-exposure Prophylaxis (PrEP) in African 09:00 - 09:15
Adolescent Girls and Young Women (AGYW) from Kenya and South Africa
Elzette Rousseau-Jemwa (Desmond Tutu HIV Foundation, South Africa)
OA19.04 Intimate Partner Violence and Early PrEP Adherence Among Adolescent 09:15 - 09:30
Girls and Young Women in Cape Town, South Africa: A Longitudinal
Analysis
OA19.05 Early Antiretroviral Therapy and Daily Pre-exposure Prophylaxis for HIV 09:30 - 09:45
Prevention Among Female Sex Workers in Cotonou, Benin: A
Demonstration Study
Michel Alary (CHU de Québec, Canada)
OA19.06 Trends in Engagement in the HIV Prevention and the Care Cascade 09:45 - 10:00
among Young Women who Sell Sex in Zimbabwe
Sue Napierala (RTI International, United States)
Oral
10:30 - 12:00 Londres
OA20 Into the Future With Delivery Technologies

Chairs:
Charles Lacey (University of York, United Kingdom)
Zeda Rosenberg (IPM, United States)
OA20.01 Nanoparticles-in-thermosensitive Enemas as Potential Vehicles for 10:30 - 10:45

Microbicide Development
Mélanie Melo (i3S - Instituto de Investigação e Inovação em Saúde & INEB -
Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal,
Portugal)
OA20.02LB Development of an End-user Informed Tenofovir Alafenamide (TAF) 10:45 - 11:00

Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP)
Ariane van der Straten (RTI International, United States)
OA20.03 Tenofovir Douche for PrEP: On-demand, Behaviorally-congruent Douche 11:00 - 11:15
Rapidly Achieves Colon Tissue Concentration Targets (DREAM 01 Study)
Ethel Weld (Johns Hopkins University, United States)
OA20.04 Self-administered Griffithsin and Carrageenan Containing Microbicide 11:15 - 11:30

Fast-dissolving Insert as Pre-exposure Prophylaxis Against HIV and HPV
Infections
Thomas Zydowsky (Population Council, United States)
Page 84 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA20.05 Innovative 3D Printed Intravaginal Rings: Reengineering Multipurpose 11:30 - 11:45

Intravaginal Rings for Prevention of HIV and Unintended Pregnancy
S. Rahima Benhabbour (University of North Carolina, Chapel Hill, United States)
OA20.06 The Dapivirine and Levonorgestrel MPT Ring: Understanding the 11:45 - 12:00
Levonorgestrel Binding Reaction with Silicone Elastomer
Karl Malcolm (Queen's University Belfast, United Kingdom)
Oral
10:30 - 12:00 Bristol
OA21 Linking Arms in Defense: Innate, Cellular and Humoral

Chairs:
Francesca Chiodi (Karolinska Institutet, Sweden)
Montserrat Plana (Institut d''Investigacions Biomèdiques August Pi i Sunyer, Spain)
OA21.01 Vaccine-induced Activation of Inflammasome in Classical Monocytes and 10:30 - 10:45

Th2 Cell Responses Correlates With Decreased Risk of
SIVmac251 Acquisition
Monica Vaccari (NCI, NIH, United States)
OA21.02 Soluble Immune Activation Biomarkers Predict Accelerated Viral Rebound 10:45 - 11:00
During Treatment Interruption in Fiebig I-treated Individuals
Bonnie M. Slike (US Military HIV Research Program/WRAIR, United States)
OA21.03 Recombinant MVA Prime Elicits Neutralizing Antibody Responses by 11:00 - 11:15
Inducing Antigen-specific B Cells in the Germinal Center
Sampa Santra (Beth Israel Deaconess Medical Center, Harvard Medical School,
United States)
OA21.04 Targeting HIV gp140 Env to Human Langerhans Cells Drives Tfh 11:15 - 11:30
Differentiation and Antibody Responses
Jérôme Kervevan (Inserm U955 - Institut Mondor de Recherche Biomédicale, UPEC,
France)
OA21.05 Broadly Neutralizing Antibodies in Children Correlate With Increased HIV- 11:30 - 11:45
specific T-follicular Helper and Regulatory Cells Within Germinal Centers
Julia Roider (Ludwig-Maximilians-University, Germany)
OA21.06LB The Impact of Vaccination on SIV Evolution Following Break-through 11:45 - 12:00
Infection
Kathryn Foulds (VRC/NIAID/NIH, United States)
Oral
10:30 - 12:00 Oxford
OA22 Antibody Virus Tango

Chairs:
Katie Doores (King's College London, United Kingdom)
Feng Gao (Duke University, United States)
Page 85 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
OA22.01 Targeted Viral Selection Is Associated With the Development of HIV 10:30 - 10:45
Broadly Neutralizing Antibodies
Batsirai Mabvakure (Center for HIV and STIs, National Institute for Communicable
Diseases, National Health Laboratory Service, Johannesburg, South Africa)
OA22.02 Next-generation Sequencing Delineates the Developmental Pathway of 10:45 - 11:00

Fusion Peptide-directed Broadly Neutralizing Antibody N123-VRC34.01
Chen-Hsiang Shen (Vaccine Research Center, NIAID, NIH, United States)
OA22.03 Early Antibodies Against the Transmitted/Founder HIV-1 Envelope gp120 11:00 - 11:15
Are Dominated by the Immunoglobulin Heavy Chain Germline VH1-69
S. Abigail Smith (Emory University, United States)
OA22.04 “Designer” SHIVs Elicit V2 bNAbs in Rhesus Macaques 11:15 - 11:30

Ryan S. Roark (University of Pennsylvania, United States)
OA22.05 eCD4-Ig Is More Difficult to Escape Than Broadly Neutralizing Antibodies 11:30 - 11:45
Christoph H. Fellinger (The Scripps Research Institute, United States)
OA22.06 Defining and Characterizing the ‘Escapability’ of Potent Broadly 11:45 - 12:00
Neutralizing Antibodies Against HIV in Humanized Mice
Cailin Deal (The Ragon Institute of MGH, MIT and Harvard, United States)
Oral
OA23 Great Expectations: The Impact of PrEP

Chairs:
Ume Abbas (Baylor College of Medicine, United States)
Hong-Ha M. Truong (University of California, San Francisco, United States)
OA23.01 HIV Incidence in Persons Using Truvada (FTC/TDF) for HIV Pre-exposure 10:30 - 10:45
Prophylaxis (PrEP): Worldwide Experience From 46 Studies
Jared Baeten (University of Washington, United States)
OA23.02 Sensitive Next-generation Sequencing of HIV-1 From Seroconverters in 10:45 - 11:00

the MTN-020/ASPIRE Dapivirine Vaginal Ring Study
Urvi Parikh (University of Pittsburgh, United States)
OA23.03 Transgender Women on Estrogen Have Significantly Lower 11:00 - 11:15

Tenofovir/Emtricitabine Concentrations During Directly Observed Dosing
When Compared to Cis Men
OA23.04LB Decreased HIV Incidence Among PrEP Users Compared to Non-users in a 11:15 - 11:30
Boston Community Health Center, 2012-2017
OA23.05 Mathematical Modeling to Evaluate the Impact and Cost-effectiveness of 11:30 - 11:45
Oral Pre-exposure Prophylaxis for HIV Prevention in Uganda
OA23.06 Potential Impact of Increased ART and PrEP Coverage on the HIV 11:45 - 12:00
Epidemic Among MSM in Atlanta: Mathematical Modelling for HPTN 078
Kate M. Mitchell (Imperial College London, United Kingdom)
Page 86 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018


Chairs:
John Brooks (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States)
Connie Celum (University of Washington, United States)
Genoveffa Franchini (National Cancer Institute, United States)
Michael Gale (University of Washington, United States)
Jessica Haberer (Massachusetts General Hospital/Harvard Medical School, United States)
Diane Havlir (University of California at San Francisco, United States)
Heather Jaspan (University of Cape Town/ Seattle Children's Research Institute, South Africa)
Sudhir Kasturi (Emory University, United States)
Maureen Luba (Centre for the Development of People (CEDEP), Malawi)
John Mascola (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, United States)
Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya)
Wanjiru Mukoma (LVCT Health, Kenya)
Ram Prasad (Final Mile, United States)
Robert H. Remien (NY State Psychiatric Institute and Columbia University, United States)
Bruce Richman (U=U, United States)
Lena Serghides (University Health Network and University of Toronto, Canada)
Monica Vaccari (NCI, NIH, United States)
Cara Wilson (University of Colorado, United States)
Symposium
13:00 - 14:30 Londres
SY08 Translating Vaccine Concepts to the Clinic: What We Need to Know

Based on current vaccine concepts, we will do a deep dive into immune mechanisms of protection. Using appropriate
animal models, we will evaluate the crosstalk between adaptive and innate immunity, and signatures of protection.
Finally, we will examine the role of susceptibility and how to modulate responses.
Chairs:
Nathalie Dereuddre-Bosquet (CEA, France)
Sandhya Vasan (Military HIV Research Program, Henry M. Jackson Foundation, Thailand)
SY08.03 Antibody Interference and Durable Monocyte Innate Memory Decrease 13:00 - 13:18
SIVmac251 Acquisition Risk Following Immunization with the
DNA/ALVAC/gp120 Regimen
Genoveffa Franchini (National Cancer Institute, United States)
SY08.02 Influence of Vaccine Composition on Envelope Recognition by HIV-1 13:18 - 13:36

Vaccine-induced Antibody-dependent Cellular-mediated Cytotoxic
Responses
SY08.01 Insights Into NK Cell Suppressor Activity in Secondary Lymphoid Organs 13:36 - 13:54
Revealed by Animal Models
Michaela Muller-Trutwin (Institut Pasteur, France)
Page 87 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
SY08.04 Protective Gene Expression Signature of the RhCMV/SIV Vaccine: Lessons 13:54 - 14:12
for Human Studies
Michael Gale (University of Washington, United States)
SY08.05 Modulating Durability of HIV-1 Env Specific Humoral Immunity With 14:12 - 14:30
3M-052, a TLR7/8 Targeted Adjuvant
Sudhir Kasturi (Emory University, United States)
Symposium
13:00 - 14:30 Bristol
SY09 Choosing to Use: What People Want from HIV Prevention

HIV prevention products currently in use were introduced after successful clinical trials for efficacy with little
consideration of user preference. Results from completed efficacy trials consistently show evidence of low product
use among adolescent and young women. This session will explore strategies for adherence support, risk perception,
social marketing and end-user engagement strategies during product development.
Chairs:
Andrew Mujugira (Infectious Diseases Institute, Uganda)
SY09.01 Defining and Supporting Prevention Adherence 13:00 - 13:22

Jessica Haberer (Massachusetts General Hospital/Harvard Medical School, United
States)
SY09.02 Risk Perception and End-users' Perspective: Insights From Research of 13:22 - 13:44
MPTs and HIV Prevention Products
SY09.03 Creating Demand for HIV Prevention Products, Programs and Services 13:44 - 14:06
Wanjiru Mukoma (LVCT Health, Kenya)
SY09.04 Preference and Habits: How Do Users Decide and How Do We Find Out? 14:06 - 14:28
Ram Prasad (Final Mile, United States)
Symposium
13:00 - 14:30 Oxford
SY10 Mucosal Environment: Barriers and Facilitators of Transmission

This session will review how mucosal environments influence the likelihood that HIV transmission occurs following
viral exposure. This includes a review of mucosal factors such as microbes and host responses that influence sexual
transmission, and immunological mechanisms that dictate the integrity of the mucosal barrier and availability of HIV
target cells.
Chairs:
Lyle McKinnon (University of Manitoba, Canada)
SY10.01 Microbiota and HIV Transmission 13:00 - 13:22

Heather Jaspan (University of Cape Town/ Seattle Children's Research Institute,
South Africa)
Page 88 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
SY10.02 High Prevalence of Bacterial STIs in HIV-positive Persons: Transmission 13:22 - 13:44
Implications & Potential Interventions
Connie Celum (University of Washington, United States)
SY10.03 The Rectal Mucosa in At-risk Men who Have Sex With Men: HIV Target 13:44 - 14:06
Cells and the Inflammatory Response to Condomless Receptive Anal
Intercourse
SY10.04 How Do Different Components of the Mucosal Microenvironment Interact 14:06 - 14:28
to Influence HIV Susceptibility?
Cara Wilson (University of Colorado, United States)
Roundtable
RT02 Getting to U: Undetectable = Untransmittable

People living with HIV who are durably virally suppressed are not able to transmit sexually. This roundtable will
explore the psychological and behavioral components in deciding to start and stay on treatment, evaluate population
impact of viral suppression, explore whether U=U holds for breastfeeding, describe what is known about clinical
cohorts of persons being treated and their level of viral suppression, and discuss how to get the word out about U=U
within communities.
Chairs:
Judith Auerbach (University of California, San Francisco, United States)
Ntando Yola (Desmond Tutu HIV Foundation, South Africa)
RT02.01 Starting and Staying on ARVs 13:00 - 13:10

Robert H. Remien (NY State Psychiatric Institute and Columbia University, United
States)
RT02.02 What Are the Population Level Studies Teaching Us about U=U? 13:10 - 13:20
Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya)
RT02.03 What Does U=U Mean for Breastfeeding? 13:20 - 13:30

Lena Serghides (University Health Network and University of Toronto, Canada)
RT02.04 How Do You Know You're “U”? 13:30 - 13:40

John Brooks (Centers for Disease Control and Prevention, Division of HIV/AIDS
Prevention, United States)
RT02.05 U=U: Unpacking the Message and the Movement 13:40 - 13:50
Bruce Richman (U=U, United States)
Panel Discussion 13:50 - 14:30
Page 89 / 90
HIVR4P 2018,
Madrid, Spain,
21 - 25 October 2018
Closing Plenary
PL04 Putting It Together: Strategies to End the Epidemic

Plenary 4 looks ahead to the potential impact of implementing multiple prevention strategies, and challenges
researchers and advocates from every community and prevention field to pool our knowledge, share our experiences
and move forward together to help end the epidemic.
Chairs:
PL04.01 Multi-disease Approaches to Combination Prevention - Insights from 15:00 - 15:20

Rural East Africa
Diane Havlir (University of California at San Francisco, United States)
PL04.02 Implementing a Multi-disciplinary Prevention Revolution 15:20 - 15:35

Maureen Luba (Centre for the Development of People (CEDEP), Malawi)
PL04.03 The Impact of Prevention Strategies on HIV Incidence in a Community 15:35 - 15:50
Center
PL04.04 A Path Forward for HIV Vaccines 15:50 - 16:10

John Mascola (Vaccine Research Center, National Institute of Allergy and Infectious
Diseases, NIH, United States)
Panel Discussion with Closing Plenary Speakers 16:10 - 16:25
Closing Remarks and Handover to 2020 16:25 - 16:30

Page 90 / 90
Powered by TCPDF (www.tcpdf.org)

Program Hivr4p2018

Încărcat de

Informații document

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

Program Hivr4p2018

Încărcat de

Drepturi de autor:

Formate disponibile

HIVR4P 2018,

HIV Research for Prevention 2018,

Download Program (PDF)

Sunday, 21 October 2018

SA01 Advocates' Pre-Conference Workshop

Download Program (PDF)

SA03 Progress in Inducing HIV Broad Neutralizing Antibodies

SA06 Social Sciences in Vaccine Trials: A Booster to Recruit Volunteers

Welcome 12:30 - 12:45

Download Program (PDF)

Volunteers/Participants Recruitment/Enrolment in Africa 12:50 - 13:05

Exceptional Risk: US Healthy Volunteers’ Perceptions of HIV/AIDS Clinical 13:05 - 13:20

Conclusion 14:20 - 14:30

SA05 Planning for Success: Next Steps for Dapivirine Ring

Download Program (PDF)

SA07 Engagement of African MSM in HIV Prevention Research: Effective

•Strategic community engagement

•Sylvia Adebajo, Population Council, Nigeria •Jeffrey Walimbwa, ISHTAR, Kenya

Download Program (PDF)

Monday, 22 October 2018

SA16 Current State of Play: PrEP Implementation Update and Challenges

SA18 A Treasure Trove of Clinical Specimens and Data: Mining Research

Download Program (PDF)

SA08 Catalyzing Translational Research to Advance HIV Vaccine and Immune-based

SA10 Immunological Mechanisms of Inducing HIV Immunity in Infants

Download Program (PDF)

Lunch and Registration 11:30 - 12:00

Welcome 12:00 - 12:10

Opening Remarks 12:10 - 12:20

Download Program (PDF)

Break 13:30 - 13:40

Closing Remarks 14:50 - 15:00

Download Program (PDF)

SA09 Fc-mediated Antibody Functions Impacting HIV Prevention

Welcome and Opening Remarks 12:00 - 12:05

Higher Antibody Fc Effector Functions Significantly Impact HIV‐1 12:05 - 12:20

Impact of HIV‐1 Env Conformation on ADCC 12:35 - 12:50

Knowns and Unknowns: Antibody Fc‐Mediated Anti‐Viral Activity in 12:50 - 13:05

Role of Non‐Neutralizing Effector Mechanisms in Sterilizing Immunity 13:05 - 13:15

Download Program (PDF)

The Link Between Fc Effector Function and Neutralization 13:25 - 13:35

Time‐dependent susceptibility of HIV‐1‐infected cells to ADCC 13:50 - 13:55

Contribution of Fc‐Mediated Antibody Activities to HIV Control 13:55 - 14:00

High Rate of anti‐V1V2 Responses Induced by HIV‐DNA Followed by 14:00 - 14:05

Circulating levels of HIV‐1‐specific IgG differentially affect 14:05 - 14:10

Discussion moderated by Dr. Moog and Dr. Kent 14:15 - 15:00

Download Program (PDF)

SA15 Human Centric Vaccine Discovery

PL01 Planning for Success (and the Challenges Ahead)

Welcome to HIVR4P 2018 16:00 - 16:10

PL01.02 Novel Trial Designs for a Complex Environment 16:47 - 17:17

HIVR4P 2018 Scholars 17:55 - 18:00

Download Program (PDF)

Download Program (PDF)

Tuesday, 23 October 2018

PL02 What Happens First: Understanding Susceptibility, Transmission and Early

PL02.01 Visualizing HIV Transmission and Prevention 08:30 - 09:00

OA01 Location, Location, Location: Mucosal Mediators of Risk

OA01.02 Optical Tissue Imaging and Spectroscopic Measurement of 10:45 - 11:00

Download Program (PDF)

OA01.04 Impact of Vaginal Bacteria Communities on Antiretroviral-based PrEP 11:45 - 12:00

OA02 Immunity in Human Vaccine Trials

OA03 Structure and Maturation of bNAbs

Download Program (PDF)